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Parkinson's disease (PD) is characterised by the dopaminergic cell loss within the substantia 
nigra pars compacta of the basal ganglia. This pathology reduces the concentration of 
dopamine within the striatum and results in the cardinal motor dysfunctions we associate with 
the disease. Currently, therapeutic treatments such as L-DOPA merely act as symptomatic relief 
and do not slow disease progression; new PD therapeutics targeting neurorepair and 
protection are therefore in demand. 
In PD, remaining dopaminergic neurons possess limited capabilities for axonal regrowth and 
rewiring for reasons unknown. In this thesis, we suggest that the chondroitin sulphate 
proteoglycans (CSPGs) of the extracellular matrix may play a role in the inhibition of cellular 
recovery and in the aberrant plasticity associated with L-DOPA-induced dyskinesia. Previous 
studies have identified that the digestion of the CSPGs via the enzyme chondroitinase ABC 
(ChABC) permits axonal regeneration following brain injury. Here, for the first time, we 
investigate the efficacy of ChABC as a therapeutic strategy to aid cellular recovery in PD. 
The results presented in this thesis support the ChABC-mediated digestion of CSPGs within the 
nigrostriatal tract as a strategy of increasing cell survival within the 6-hydroxydopamine 
lesioned mouse. It was discovered that ChABC treatment enhanced dopaminergic cell survival 
in lesioned mice; no behavioural improvements were detected however. In a subsequent study, 
we aimed to further increase ChABC-mediated cell survival and induce behavioural 
improvements by increasing the striatal levels of glial cell line-derived neurotrophic factor and 
brain-derived neurotrophic factor by the administration of the MAO-B inhibitor selegiline. 
Although ChABC alone reproduced a similar degree of cell survival as before, the addition of 
selegiline did not improve cell survival or behavioural outcomes despite increasing 
neurotrophic factor levels during the first two weeks of experimentation. Moreover, selegiline 
decreased the efficacy of ChABC; perhaps a potential conflict between their pathways. 
Additionally, we investigated whether CSPGs and other cellular markers were upregulated in 
the striatum of L-DOPA-induced dyskinetic rats; a region identified to increase in volume within 
the dyskinetic state. Although CSPG expression did not increase, Iba1-positive microglial 
expression did. This suggests a role for microglia in L-DOPA-induced dyskinesia manifestation.  
In conclusion, investigating the CSPGs as therapeutic targets is promising. However, identifying 
ways to enhance cell survival effects to induce detectable behavioural improvements is 
required. In order to do so, further investigations into the mechanism underlying the CSPG’s 
inhibitory nature would be a logical next step.  
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1. General introduction  
1.1. Parkinson’s disease; the ‘Shaking Palsy’ 
In 1817 James Parkinson published the first medical description of paralysis agitans within the 
monograph An Essay on the Shaking Palsy  (Davie, 2008; Parkinson 2002). The condition was 
shown to affect the motor control of six patients in which key dysfunctions characterised the 
disease: bradykinesia, rigidity of the patient’s trunk and a resting tremor. Works by Jean-Martin 
Charcot in the mid-1800s further promoted the understanding of the disease whom thereafter 
adopted the more common name of Parkinson’s disease (PD) (Lees, 2007).  
Since the work of Charcot and Parkinson of the 1800s, great advancements in PD research have 
paved the way for modern understandings and interventions. Despite these advancements, we 
are still unaware of the disease’s cause or cure. 
1.2. Prevalence of Parkinson's disease and its subtypes 
PD is the second most prevalent neurodegenerative disease that affects ~2% of Europeans 
aged 65 to 89 (de Lau et al., 2006; de Rijk et al., 2000). Of these affected people, men are ~2 
times more susceptible than women (Van Den Eeden et al., 2003; Wirdefeldt et al., 2011). The 
incidence is relatively low in the <50 year old demographic but rises sharply to those in the age 
range mentioned above, a significant concern for an ageing population (Dorsey et al., 2007). PD 
can be broken down into two primary subtypes, idiopathic and familial. Idiopathic PD is 
associated with 90% of all cases (Dauer et al., 2003) and arises sporadically without a known 
cause, whereas familial, otherwise known as hereditary PD, is associated with a much lower 
incidence of ~10% and has a collection of mutations associated with its prevalence.   
1.3. Parkinson's disease pathology  
The cardinal motor symptoms associated with PD are a result of cell death within the 
substantia nigra pars compacta (SNc); a significant component of the basal ganglia (BG). This 
nucleus projects to the caudate and putamen nuclei of the striatum via the nigrostriatal tract 
(NS) where it provides a key source of dopamine (DA) which is required for fine motor 
movement. A loss of this dopaminergic input leads to a severe imbalance of the two DA driven 





Alongside the SNc cell loss, neuronal cytosolic inclusion bodies known as Lewy bodies (LBs) 
(Lewy, 1912) begin to accumulate within affected regions and spread in a prion-like manner 
according to Braak staging (Braak et al., 2003; Masuda-Suzukake et al., 2013). This LB-spread 
correlates with PD symptoms. Despite a close relationship with the disease, the role LBs have 
within PD has not yet been elucidated. LBs may be neurotoxic or merely a product of cellular 
degeneration (Goldberg et al., 2000). The main constituents of LBs are ubiquitin, neurofilament 
protein and most prodominantly α-synuclein (α-syn) fibrils; the latter of which is most 
attributed to LB-related toxicity. α-syn is a 140 residue protein encoded by the SNCA gene and 
is abundant within the brain where it is primarily localised to the neuronal presynaptic 
terminals. Due to its location and interaction with membrane proteins and phospholipids 
(Chandra et al., 2003), it is thought to have a role in neurotransmitter (NT) release (Emanuele 
et al., 2015) and the clustering of NT vesicles at the nerve terminal (Diao et al., 2013). Although 
α-syn and LBs are key research areas in PD research, this thesis will not tackle their role within 
the disease, see (Vekrellis et al., 2011) for a more comprehensive review. 
1.4. Symptomatology  
The cardinal motor symptoms associated with PD, such as bradykinesia, trunk rigidity and 
tremor, manifest following a significant loss of SNc cells (~70%). As motor dysfunction occurs 
only once this threshold of cell loss is reached, PD is therefore described as a threshold disease. 
However, this is somewhat misleading as these symptoms only represent a proportion of 
dysfunction experienced. During the years leading to this threshold loss, known as the 
prodromal phase, a wealth of non-motor symptoms (NMS) manifest that lower quality of life. 
Researchers argue that further classification of the aforementioned motor symptoms is 
possible but requires further characterisation. The motor features observed through clinical 
observations indicate two motor subtypes, tremor-dominant and non-tremor dominant. The 
former is associated with a slower onset and milder functional disability to that of the latter 
form, which presents a quick onset with a more severe functional disability (DATATOP, 1989). 
Although the aetiology of the two motor symptoms subtypes is unknown, further investigation 
may lead to better therapies more suited to the specific type of motor disturbance.   
The NMS are commonly experienced well before the date of diagnosis and prolong throughout 
life. These range from constipation, hyposmia and sleep disorders to fatigue, mood alterations, 
pain and psychosis (figure 1). These symptoms manifest before motor onset and during the 
prodromal phase, a time in which severe SNc cell loss has not yet occurred (<70%). Therefore, 
these factors could be potential biomarkers in diagnosing PD well before the manifestation of 
motor dysfunction. The use of NMS as prodromal biomarkers for introducing neuroprotective 
18 
 
agents is promising. For example, a study that analysed rapid-eye movement sleep behaviour 
disorder (RBD) in PD patients correlated its diagnosis with a window 12 to 14 years before 
motor dysfunction and PD diagnosis (Postuma et al., 2012); could this NMS help with 
therapeutic intervention? Studies such as the multicentre ONSET PD Study screened several 
NMS in a cohort of newly diagnosed PD patients and age matched controls (Pont-Sunyer et al., 
2015). It was identified that when present within the prodromal phase, certain NMS (notably, 
hyposmia and constipation) could discriminate PD patients from controls. Although not yet 
consistently predictive, studies like the ONSET PD demonstrate promise in the investigation of 








Figure 1: Symptoms of PD during the course of disease progression. 
Within the prodromal phase (~20 years prior to diagnosis) numerous non-motor symptoms 
(NMS) such as constipation and depression may arise. At the time of diagnosis, typical motor 
dysfunctions (i.e. bradykinesia, tremor) arise and deteriorate throughout the disease. 
Complications involving repeated therapeutic drug use may lead to dyskinesia, psychosis and 




1.5. Aetiology  
PD’s aetiology is not fully understood but it is most likely a combination between several 
environmental and genetic factors. Most cases are considered idiopathic where a cause 
remains unclear. However, the familial form is caused at least in part by nonsense and missense 
mutations of certain genes. The known mutations are often described by their mistranslated 
proteins, these are stated below. 
1.6. Genetic factors involved in PD  
There are two key PD-associated autosomal dominant mutations, those of the PARK1 (SNCA) 
and PARK8 (LRRK2) genes.  
1.6.1. α-synuclein 
 Gene/locus:  SNCA/PARK1; 4q21  
Function: Believed to assist neurotransmitter release, vesicle clustering and 
transmission 
Three common mutations within the α-syn gene SNCA have been associated with the inherited 
form of PD, these are A53T, E46K and A30P (Kruger et al., 1998; Spira et al., 2001; Zarranz et 
al., 2004). Each mutation causes a different manifestation of PD, A53T carriers present early 
onset and a response to anti-PD treatments in their forties whereas both the E46K and A30P 
mutations give rise to a later developing of the disease and associated dementia. Interestingly, 
multiplications of the wild type SNCA gene have shown to induce PD (Singleton et al., 2003). 
Moreover, people with a triplication of the locus present earlier onset to those with a 
duplication of the SNCA gene, indicating a dosage effect of wild type α-syn (Cookson, 2010).  
Evidence suggests that α-syn may act as a chaperone to the soluble NSF attachment protein 
receptor complexes required for vesicle-driven NT exocytosis (Bonini et al., 2005). Therefore, it 





1.6.2. LRRK2 (Leucine-rich repeat kinase 2; a.k.a. Dardarin) 
 Gene/locus: LRRK2/PARK8; 12q12 
 Function: Signalling, kinase (many assumed functions)  
The LRRK2 gene encodes the lrrk2, or dardarin, protein that is a member of the leucine-rich 
repeat family. Lrrk2 is a large 286 kDa protein that has multiple domains and functions (e.g. 
kinase, scaffolding activity and signalling) and is located within the cytoplasm and outer 
mitochondrial membrane. LRRK2 was the second gene associated with the autosomal 
dominant form of PD and has, potentially due to size, the highest mutation frequency of all PD 
associated genes. LRRK2 mutations, namely the G2019S and R1628P, are the most common 
cause of familial PD (Kumari et al., 2009). There are almost forty discovered variants of the 
gene with most of these being missense (Lesage et al., 2009). However, the pathogenicity of a 
large proportion of these mutations is not known due to low penetrance and unidentified 
parental genotypes. But, the vast majority of the pathogenic forms we do know present 




In addition to the autosomal dominant mutations, there are also three autosomal recessive 
forms associated with familial PD. These are encoded by the PARK2 (Parkin), PARK7 (DJ-1) and 
PARK6 (PINK1) genes.  
1.6.3. Parkin 
Gene/locus: PARK2; 6q25.2-q27  
Function:  E3 ligase that aids the ubiquitination of proteins targeted for the 
ubiquitin proteasome system 
Parkin is a mitochondrially localised E3 ligase that targets dysfunctional proteins for ubiquitin 
proteasome system (UPS)-mediated degradation. Under stressed conditions, parkin is recruited 
by PTEN-induced putative kinase 1 (PINK-1) to the dysfunctional mitochondria whereby it 
initiates parkin-driven mitophagy via ubiquitin conjugation (Matsuda et al., 2010). First 
discovered in Japanese patients exhibiting autosomal recessive juvenile parkinsonism (Kitada 
et al., 1998), the mutated parkin was shown to cause dysfunctional mitochondrial mitophagy  
resulting in toxic effects (Rakovic et al., 2011). People with these mutations were found to 
produce similar symptoms to sporadic forms of PD but with an earlier onset of the disease 
(childhood to 50 years old).  
1.6.4. DJ-1 (Daisuke Junko-1) 
Gene/locus: PARK7; 1p36.23  
Function:  Believed to protect against oxidative stress and act as a chaperone to 
nascent proteins 
Mutations within the PARK7 gene, which encodes the Daisuke Junko-1 (DJ-1) protein, leads to a 
rare autosomal recessive form of parkinsonism that exhibits early onset (~40 years old)(Bonifati 
et al., 2003). The DJ-1 protein was discovered to be an oxidative stress sensor that protected 
dopaminergic cells against reactive oxygen species (ROS) toxicity (Lev et al., 2013). Suggestions 
of DJ-1 being integral to the E3 ligase complex are still debated and its true pathogenic effects 
are unknown.  
1.6.5. PINK-1 (PTEN-induced putative kinase 1) 
 Gene/locus: PARK6; 1p36 
 Function: Mitochondrial kinase able to protect against dysfunction 
PINK-1 is involved in the quality control of the mitochondria. Being an active serine/threonine 
kinase, PINK-1 recruits and permits the binding of parkin to damaged mitochondria readying 
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the cell for mitophagy. Missense and nonsense mutations of this gene gives rise to autosomal 
recessive parkinsonism which, as with other autosomal recessive mutations, causes early onset 
parkinsonism (20 to 50 years old) (Valente et al., 2004). 
A close functional relationship seems apparent between the autosomal recessive mutations, 
Parkin, DJ-1 and PINK-1. It is therefore of no surprise that synergistic mutations between these 
three genes may enhance the pathogenic effects. Loss of DJ-1 function in particular may 
further exacerbate oxidative effects caused by poor mitochondrial quality control formed by 
ineffective PINK-1 protein function.   
Other proteins of note are glucocerebrosidase and ubiquitin carboxy-terminal hydrolase L1 
(UCH-L1). Mutations within these proteins' genes appear to not directly cause familial PD but 





1.7. Environmental factors involved in Parkinson's disease 
To explain the vast amount of idiopathic PD cases that, to our knowledge, are not familial, we 
must acknowledge the environmental factors that influence disease risk. These are commonly 
associated with the exposure to chemical compounds such as biocides and heavy metals. 
Biocides (i.e. herbicides, fungicides and pesticides) have long been known to induce 
parkinsonism. Examples such as rotenone, paraquat and dichlorodiphenyltrichloroethane are 
inhibitors of complex I of the electron transport chain (ETC) and so disrupt the production of 
adenosine triphosphate (ATP) and induce oxidative stress (explained more fully in section 
1.11.2.1.). These all mimic the action of the known toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), a compound now used to induce parkinsonisms in preclinical 
models (see section 1.12.2.2.).  
Several studies have correlated an increased risk of parkinsonism with people living rurally; 
people most likely to be who are exposed to biocides from well-water and crops (Ho et al., 
1989; Liou et al., 1997; Morano et al., 1994). However, a large meta analysis study has found 
inconsistencies identifying causal relationships between these factors and PD (Breckenridge et 
al., 2016). Nevertheless, the use of biocides in the preclinical modelling of PD (e.g. rotenone, 
paraquat) have reinforced the belief that environmental toxins increase the risk of idiopathic 
PD (Di Monte, 2003).   
Heavy metals such as manganese (Mn) and iron (Fe) have been well researched as PD risk 
factors (Fukushima et al., 2010; Montgomery, 1995). Mn is present in low concentrations in 
tea, legumes and grains and is essential for a range of bodily functions (Erikson et al., 2003). 
However, occupational exposure to Mn (e.g. mining, welding) has shown to be a significant risk 
factor for central nervous system (CNS) disorders, including PD (Gorell et al., 1999). These 
disorders are collectively known as manganisms (Perl et al., 2007). Manganese-induced 
parkinsonism differs from idiopathic PD in which the globus pallidus (GP) is the most affected 
region. This disorder is unresponsive to the DA replacement therapy L-3,4-
dihydroxyphenylalanine (L-DOPA) (Pal et al., 1999) and so is classified as parkinsonian-like 
rather than idiopathic PD.  
Fe has long been known to have high concentrations within the brain of PD patients (Earle, 
1968), particularly in the SNc (Dexter et al., 1990; Dexter et al., 1989b); indicating that Fe may 
have a role in disease progression. To further this theory, brains from PD patients have 
displayed reduced levels of ferritin, the intracellular protein responsible for Fe storage (Dexter 
et al., 1990); an increase that is debated however (Farhoudi et al., 2012). With increased levels 
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and the potentially dysfunctional homeostatic control of Fe within the BG, there may be an 
enhanced risk of Fe-driven toxicity in PD. Fe as a therapeutic target has led to the use of Fe 
chelators in models of disease with success. Desferrioxamine has been shown to increase SNc 
cell survival by 60% in PD toxin models (Ben-Shachar et al., 1991) whereas the 8-
hydroxyquinolines have been tested in the clinic (Ritchie et al., 2003). 
At high concentrations, Mn and Fe induce cellular toxicity through the creation of free radicals. 
Fe is thought to undergo the Fenton reaction when in the presence of H2O2 and ferritin to 
create the hazardous hydroxyl free radical (Levin et al., 2011). Where on the other hand, Mn 
accumulates within the glia and neurones of the GP, striatum and SNc where it is believed to 
inhibit either complex II of the electron transport chain or the glutamate aspartate transporter 
whereby it ultimately disrupts ATP synthesis and induces ROS production (Gunter et al., 2010; 
Milatovic et al., 2009).  
1.8. Why is the basal ganglia susceptible to cell death?  
Multiple sources of cellular insult have been described to promote PD. But why is the SNc more 
vulnerable to degeneration than other regions of the BG? To understand why may allow the 
development of therapies which slow the progression of SNc degeneration. Several theories 
speculate on this susceptibility, below are two of the most discussed. 
1.8.1. Lower expression of calbindin and Ca2+ homeostasis 
Calbindin-D28K (CB) is a calcium (Ca2+) binding protein which regulates and buffers cellular 
Ca2+. It is thought that without CB the cell accumulates toxic levels of Ca2+ and dies. Within the 
non-human primate (NHP) model of PD the midbrain cells most resistant to MPTP were those 
expressing CB (Liang et al., 1996). Studies have correlated, firstly, that different strains of mice 
possess differing sensitivities to MPTP (Muthane et al., 1994) and, secondly, that these 
sensitivities can be somewhat linked to differing numbers of CB-expressing nigral neurones 
(Dopeso-Reyes et al., 2014; Vidyadhara et al., 2016). Despite this, the lower abundance of CB 
exists in other brain regions, so why is the SNc different to those areas? To account for this 
difference we must look at the physiology of the SNc neurone. The SNc A9 subset of DA 
neurones are, unlike the majority of brain cells, autonomous and produce regulated 2 to 4 Hz 
action potentials without stimuli (Chan et al., 2010); a pace-making activity which requires the 
use of a high number of Ca2+ channels. This increased number of channels leaves the A9 DA 
neurones more sensitive to Ca2+ ions. To counter the large influx of Ca2+ ions, Ca2+ is actively 
transported out of the cell consuming a persistently high level of ATP in the process. This 




1.8.2. Region of high dopamine oxidation and metabolism 
The oxidation of DA has been theorised to create toxic metabolites. The hazardous ROS, 
superoxide radicals, H2O2 and dopamine-quinone molecules have all been identified to be by-
products of the catalysed oxidation of DA (Halliwell, 1992; Stokes et al., 1999). Furthermore, 
normal monoamine oxidase (MAO) metabolism has been seen to cause the rise of a toxic 
metabolite known as 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is later converted to 
3,4-dihydroxyphenylacetic acid (DOPAC) (Marchitti et al., 2007) (Figure  2). DOPAL is the main 
contender of the catecholaldehyde hypothesis that suggests that an intrinsic toxin unique to DA 
producing cells (i.e. DOPAL) is the cause of cell susceptibility. Several studies have tried to 
identify the toxic function of DOPAL within the SNc. Firstly, it has been theorised that the 
metabolite enhances α-syn aggregation within glial cells (Werner-Allen et al., 2016). Secondly, 
the catechol group may auto-oxidise into two harmful products, a semiquinone radical and an 
ortho-quinone (Anderson et al., 2011). Finally, DOPAL presents a functional aldehyde group 
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The MAO enzyme has been identified as a therapeutic target in an attempt to reduce 
intracellular production of DOPAL. However, due to the inhibition of the MAO-A subtype 
leading to hypertension (Sathyanarayana Rao et al., 2009), pan-MAO inhibition is not 
conducted within the clinic. To counter this problem a recent study has assessed the use of 
MAO-B inhibitors, rasagiline and selegiline, on DOPAL inhibition. Although the concentration of 
DOPAL was reduced, the authors state that this may be due to non-selective inhibition at high 
doses (Goldstein et al., 2016). Nevertheless, this is a promising start to a new therapeutic 
target. 
Studies have shown that PD patients may possess lowered levels of the DOPAL dehydrogenase 
enzyme Ahd2 (Mandel et al., 2005; Smidt, 2009). Lowered levels of Ahd2 would permit the 
accumulation of DOPAL and the resulting associated toxic effects. However, studies have 
indicated patients receiving L-DOPA treatment do not have advanced PD pathology or severity 
compared to patients not taking L-DOPA. Thus, indicating that an increase in DA does not 
correlate to increased DOPAL-induced toxicity; disproving the aforementioned 
catecholaldehyde hypothesis. Furthermore, the hypothesis does not explain the differing 
sensitivities between the A9 dopaminergic neurones of the SNc and the neighbouring A10 
dopaminergic neurones of the ventral tegmental area (VTA). The mechanism behind intrinsic 
toxicity must therefore be more complex than first thought. 
 
  
Figure 2: The metabolism of dopamine to DOPAL. 
Dopamine is readily converted into the toxic transition metabolite DOPAL via the MAO 
enzyme. The intermediate is then converted into DOPAC but via Ahd2. DOPAL, 3,4-
dihydroxyphenylacetaldehyde; MAO, monoamine oxidase; DOPAC, 3,4-dihydroxyphenylacetic 
acid, Ahd2, aldehyde dehydrogenase 2. 
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1.9. Pathways of the basal ganglia 
The BG houses a network of nuclei found in the midbrain that orchestrates fine motor control. 
This process is maintained through the finely tuned balance of the BG’s direct and indirect 
pathways; pathways primarily mediated by DA, γ-aminobutyric acid (GABA) and glutamate NTs. 
As the degeneration of the SNc leads to diminished striatal DA, an imbalance of these 
regulating NTs is formed causing the cardinal motor symptoms we associate with PD.  
The nuclei which form the BG are the SNc, substantia nigra pars reticulata (SNr), putamen and 
caudate nucleus complex (known as the dorsal striatum within the rodent models of disease), 
globus pallidus externa (GPe), globus pallidus interna (GPi) and subthalamic nucleus (STN). 
Other key regions of the BG are the motor and sensory cortex and the thalamus. To further 
understand PD we must investigate the pathways between these nuclei. These pathways are 
discussed below and visualised in figure 3. 
1.9.1. Corticostriatal pathway 
The corticostriatal pathway links the glutamatergic pyramidal afferents of the cortex to the 
dendritic spines of the striatal GABAergic neurones known as the medium spiny neurones 
(MSNs). These MSNs feed into the downstream pathways involved in motor control. While 
MSNs contribute to 95% of the striatal cell populous, the fast spiking parvalbumin-positive 
GABAergic interneurones and the tonically active cholinergic interneurones contribute to the 
remaining 5%. The fast spiking interneurones receive glutamatergic input from the cortex that 
in turn cause the feed-forward inhibition of neighbouring MSNs cells; a circuit seen to control 
and suppress unwanted MSN activity (Gage et al., 2010). On the other hand, the tonically 
active interneurones possess a burst-pause pattern of activity and are innervated by the 
thalamic glutamatergic afferents. When stimulated these cholinergic cells are believed to 
mediate learning and DA-dependent striatal plasticity (Benhamou et al., 2014; Wang et al., 
2006). 
Corticostriatal neurones can form two classes of cortical neurones, the intratelencephalic type  
which originate in cortical layers 2 to 6 and innervate the striatum via the external capsule and 
corpus callosum, or the pyramidal tract type which project from layer 5B to the thalamus and 




1.9.2. Nigrostriatal pathway 
The NS is the key pathway that regulates the activity of the striatal MSNs. Innervated by the 
dopaminergic SNc neurones, the NS projects to the striatum where the dopaminergic cells 
synapse onto the spines of the MSNs. The striatum possesses all five classes of DA receptor, D1 
and D5 (D1-like subtype; activators of Gs/Golf proteins) and D2, D3 and D4 (D2-like subtype; 
activators of Go/Gi proteins) (Neve et al., 2004); but it is the D1 and D2 receptors which 
dominate the striatum. MSNs cells either exclusively express D1 or D2 receptors. The MSNs 
that express D1 receptors (dMSNs) form the direct pathway whereas the MSNs that express D2 
receptors (iMSNs) form the indirect pathway. 
Following cortical coordination, DA has different downstream effects depending on the 
whether the dMSNs or iMSNs cells are activated. Agonism of D1 receptors causes the 
stimulation of the Gs/Golf  class of G-protein coupled receptors (GPCRs), which in turn, activate 
adenylyl cyclase. This enzyme then catalyses the synthesis of the secondary messenger cyclic 
adenosine monophosphate (cAMP), which in turn, stimulates L-Type Ca2+ channels and the 
resulting activation of the direct pathway. On the other hand, agonism of D2 receptors initiates 
the stimulation of the Go/Gi class of GPCRs that inhibits the production of cAMP. This reduces 
the excitability of the indirect pathway through L-Type Ca2+ channel inhibition (Hernandez-
Lopez et al., 2000). Both pathways induce motor movement. 
1.9.3. Direct, indirect and hyperdirect pathways  
The direct and indirect pathways are the basis of motor control in the BG and are significantly 
altered in the classical model of PD. The direct pathway is a monosynaptic GABAergic link 
between the striatum and the GPi/SNr complex. The direct pathway is primarily driven by SNc-
mediated DA agonism of the dMSN D1 receptors, although dynorphin and substance P are also 
utilised. The main role of the direct pathway is to induce movement through the disinhibition 
of the thalamocortical feedback loop.  
The indirect pathway is a polysynaptic connection between the iMSNs of the striatum to the 
GPi/SNr complex via the GPe and STN. DA agonism of the iMSN D2 receptors causes the 
inactivation of the indirect pathway. Enkephalin is also utilised within this pathway. D2 receptor 
agonism reduces the activity of the STN, thus resulting in the lower glutamatergic activation of 
the GPi/SNr. This causes the disinhibition of the thalamocortical feedback loop, thereby 
promoting movement. In states of low DA, such as PD, the indirect pathway does not disinhibit 
the thalamocortical feedback loop resulting in lowered motor movement. DA is therefore the 
key regulator behind the balance of these two opposing pathways. 
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In addition to the two classical pathways there is a third known as the hyperdirect pathway. 
The hyperdirect pathway exhibits cortical glutamatergic afferents that directly innervate the 
STN. This pathway stimulates the GPi/SNr complex which ultimately deactivates the 
thalamocortical feedback loop; a process which reduces motor activity whilst bypassing the 
striatum altogether. The hyperdirect pathway is seen to control and induce a switch from 
impulsive to controlled movements (Bosch et al., 2012; Obeso et al., 2008). Furthermore, 
ablation of this pathway (e.g. stroke lesioning) causes impairments such as impulsivity and 
ballism (large involuntary movements of the limbs) (Nambu et al., 2002). 
1.9.4. Thalamic pathways 
Thalamic nuclei form the key connections between both the direct and indirect pathways of 
the BG and specific cortical regions that act as the final part of the BG loop. In this region, 
glutamatergic afferents from the ventral anterior and ventral lateral thalamic nuclei innervate 
the cingulate, premotor and primary motor cortical regions to induce controlled motor activity.  
Two glutamatergic thalamostriatal connections are present within the BG. The first links the 
thalamic centromedian and parafascicular nuclei to the striatal MSNs which is thought to aid 
striatal output (Smith et al., 2014). The second is via the aforementioned tonically active 

















Figure 3: Simplified overview of the basal ganglia.  
Glutamatergic (red) cortical neurons innervate the GABAergic (blue) MSNs, fast spiking 
interneurones and the cholinergic (purple) tonically active interneurones of the striatum. 
Dopaminergic (green) SNc cells release DA into the striatum and bind to D1 or D2 specific 
MSNs, dMSNs and iMSNs, respectively. D1 agonism leads to the activation of the direct 
pathway and the resulting disinhibition of the thalamocortical feedback loop. This pathway 
increases the thalamic release of glutamate and induces movement. Conversely, D2 agonism 
inactivates the indirect pathway. This pathway reduces levels of subthalamic glutamate and 
GPi/SNr activity. Thus causing the disinhibition of the thalamocortical pathway and inducing 
movement. CTX; cortex, Str; striatum, D1/2R; DA 1/2 receptors, GPi/GPe; globus pallidus 
interna/externa, STN; subthalamic nucleus, ENK; enkephalin, SP; substance P, DYN; dynorphin.  
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1.9.5. Alterations in the parkinsonian basal ganglia 
To generate movement, the BG undergoes a series of activations and inactivations within its 
two key pathways. However, in PD the regulation of these is dramatically altered. Figure 4 
summarises the key routes affected by the neuronal degeneration of the SNc. 
The pathological loss of SNc cells reduces the DA content within the striatum, this ultimately 
causes aberrant glutamatergic transmission from the corticostriatal pathway (Pisani et al., 
2005). As a knock on effect, striatal MSNs lose both dendritic spines and arborisations in 
response to the plastic remodelling of the corticostriatal projections. Although a loss of MSN 
spines would indicate a lowering of transmission, studies analysing corticostriatal activity find 
the opposite in which glutamatergic receptor presence on MSNs is increased (Betarbet et al., 
2000a; Calabresi et al., 2007). Conversely, this increase may just be a homeostatic rebalancing 
of transmission due to the altered innervation from the cortex (Jenner, 2008a). 
As DA content is low, neither the D1 nor the D2 MSNs (dMSN and iMSN, respectively) are 
activated. As DA mediated activation of the iMSNs normally inhibits the indirect pathway (Gi/Go 
protein activation), a lack of DA results in the disinhibition of cAMP production causing an 
increase in GABA release to the GPe. Furthermore, a lack of DA mediated activation of the 
dMSNs leads to the inability to produce cAMP therefore inhibiting the activation of the direct 
pathway. This joint compounded effect results in the direct pathways lowered GABAergic 
transmission to the GPi/SNr and the indirect pathway’s overstimulation of the STN. Together 
these lead to an underactive thalamocortical feedback loop that causes bradykinesia. Although 
not present in figure 4, the hyperdirect pathway is crucial in regulating erroneous movement 
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Figure 4 presents the key overview of the dysregulated parkinsonian BG, however, the true 
model is far more complex. Dysfunctions in other non-BG regions such as the serotonin (5-HT), 
acetyl choline (ACh) and noradrenaline systems alongside alterations in the BG neuronal firing 
patterns are currently under investigation. By unveiling new insights behind these systems we 
will further our understanding of the dysregulated parkinsonian BG.  
 
  
Figure 4: Comparison of the key BG pathways affected in PD.  
In the normally functioning BG (left), DA from the SNc stimulates dMSNs and inhibits the 
iMSNs. This causes the generation of controlled movement through the disinhibition of the 
thalamocortical feedback loop. In the parkinsonian BG (right), remodelling of the 
corticostriatal pathway (e.g. reduction in MSN spines) alongside the diminished release of DA 
from the SNc leads to the overstimulation of the STN and GPi/SNr through the inactivity of 
dMSNs and activity of iMSNs. These alterations result in the reduced activation of the 
thalamocortical feedback loop which lowers motor output. In the parkinsonian BG, filled and 
faint neurones indicate cells of enhanced and reduced stimulation, respectively. Red; 
glutamatergic neurone, blue; GABAergic neurone, green; dopaminergic neurone. Thicker 




1.10. Current treatments for Parkinson's disease 
A wide array of treatments have been developed to help rebalance the BG either by direct 
manipulation of the BG circuitry or through replacing striatal DA. The sites of action of these 
treatments are presented in figure 5.  
1.10.1. Dopamine replacement therapies 
By far the most common form of PD treatment are the DA replacement therapies. These are a 
broad spectrum of therapeutics that have been developed to raise the diminished level of 
striatal DA. These therapeutics therefore aim to lessen the symptoms associated with reduced 
striatal DA. Success has been found in levodopa (L-DOPA), the precursor to DA, and DA 
agonists, compounds that mimic DA at the molecular level. These are described below. 
 1.10.1.1. Levodopa; L-3,4-dihydroxyphenylalanine 
 Trade name: Madopar, Sinemet (as adjunct with carbidopa or benserazide) 
 Type:  Blood brain barrier penetrable precursor to DA  
 Action:  Metabolises into DA. Increases depleted striatal DA content  
 
Levodopa, otherwise known as L-DOPA, is the gold standard of DA replacement therapies. It is 
the blood brain barrier (BBB) penetrable precursor to DA that, upon uptake into nerve 
terminals, becomes metabolised into DA by DOPA decarboxylase (DDC). As it is administered 
peripherally, L-DOPA exists as an adjunct therapy with the DDC inhibitors carbidopa or 
benserazide; compounds that enhance the bioavailability of L-DOPA by reducing its peripheral 
metabolism. These inhibitors do not cross the BBB and so do not interfere with intrastriatal DA 
synthesis. The presence of these inhibitors lowers the effective dose required for symptom 
relief and, whilst doing so, delays the onset of L-DOPA associated disturbances such as L-DOPA-
induced dyskinesia (LID) which shall be discussed later in section 1.11.1.  
Although being the most efficacious of all treatments L-DOPA can induce substantial side 
effects. As a result, alternative compounds are frequently prescribed to delay the use of L-







 1.10.1.2. Catechol-O-methyl transferase inhibitors 
 Examples: Entacapone (Comtan), Tolcapone (Tasmar) 
 Type:  Selective inhibitor of the L-DOPA metabolising enzyme, COMT  
 Action:  Increases bioavailability of L-DOPA  
To enhance the effectiveness of L-DOPA, the administration of catechol-O-methyltransferase 
(COMT) inhibitors can be prescribed. As an adjunct to the L-DOPA/carbidopa cocktail, COMT 
inhibitors have been successful in increasing the on time patients experience by increasing the 
plasma concentration of L-DOPA. Although administering COMT inhibitors alongside L-DOPA 
has shown to increase severity of LID, it also enhances the bioavailability of the DA precursor. 
This has shown to lower the effective dose by up to 25% (Jankovic et al., 2008). COMT 
inhibitors therefore allow for L-DOPA-sparing. 
Two COMT inhibitors that have been developed for clinical use are entacapone and tolcapone. 
Entacapone provides minor well-tolerated side effects (e.g. nausea) and is taken with great 
effect (Schrag, 2005). Unlike entacapone, tolcapone has been reported to induce acute liver 
failure which has led to questions being raised over its use (Olanow, 2000). 
 1.10.1.3. Monoamine oxidase B inhibitors 
 Examples: Rasagiline (Azilect), selegiline (L-Deprenyl), safinamide 
 Type:  Irreversible inhibitor of the enzyme MAO-B  
 Action:  Increases bioavailability of DA  
Similar to the COMT inhibitors, MAO-B inhibitors are taken commonly as an adjunct therapy 
with L-DOPA in order to promote the bioavailability of DA. The MAO enzyme is bound to the 
outer membrane of the mitochondria within the presynaptic terminal where it catalyses the 
oxidation of monoamines such as DA. Its inhibition therefore leads to the increase in L-DOPA-
metabolised DA present within the synaptic terminal, thus amplifying post-synaptic receptor 







1.10.1.4. Dopamine receptor agonists 
 Examples: Ergot derived:   Bromocriptine, pergolide, cabergoline 
   Non-ergot derived:  Ropinirole, pramipexole 
 
 Type:  Agonists of the D2-like, and to a lesser extent the D1-like, receptor  
 Action:  Mimics endogenous DA at the postsynaptic terminal  
 
DA agonists cover a wide group of compounds that activate both the D1- and D2-like DA 
receptors in an attempt to restore normal BG function (Quinn, 1995). These compounds are 
typically favoured by newly diagnosed patients as monotherapies (Rascol et al., 2000) but are 
also successfully used as adjunct therapies alongside L-DOPA in an act of L-DOPA-sparing (Fox 
et al., 2011).  
As DA agonists are not metabolised by the typical DA pathways, the production of DA's toxic 
metabolites (e.g. DOPAL) are therefore avoided. Dyskinetic motor dysfunction is also less 
frequent with DA agonists when compared to L-DOPA. This is thought to be due to the longer 
half-life these compounds possess over L-DOPA.   
DA agonists are categorised into two groups, the older ergot-derived and the newer non-ergot 
derived compounds. Derivative compounds of the ergot fungus bind to the D2-like receptors 
almost selectively (many possess a weak affinity for the D1-like and 5-HT receptors). Examples 
of these compounds are bromocriptine, pergolide and cabergoline. The non-ergot compounds 
such as pramipexole and ropinirole suggest a higher affinity to the D2-like family than that of 
the ergoline compounds (Molho et al., 1995).  
Despite the significant benefits of using DA agonists, the side effects they induce can be 
debilitating. Typical side effects caused by both subtypes, are hallucinations, hypotension, 
nausea and the potential exacerbation of LID if used alongside L-DOPA (Factor et al., 1995; 
Micieli et al., 1996). Non-ergoline agonists appear to have lesser side effects than those of the 
ergolides (Lees et al., 1997). Ergot-related erythromelalgia, retroperitoneal and 
pleuropulmonary fibrosis and vasospasm, although rare, have been documented as well as 
several behavioural dysfunctions (Reichmann et al., 2006). Issues with impulse control 
disorders such as compulsive buying, gambling and sexual behaviour have all been related to 
ergot-derived DA agonists (Kaplan et al., 2013). Studies have reported a 2 to 3.5 fold increase in 
odds of having an impulse control disorder whilst undergoing DA agonist treatment (Weintraub 




1.10.1.5. Non-dopamine replacement therapies 
 Examples: Benzatropine (anti-cholinergic), amantadine (anti-glutamategic) 
 Type:  Anti-cholinergics/anti-glutamatergic 
 Action:  Reduces levels of cholinergic and glutamatergic activity  
The anticholinergics were the first therapeutics available for PD. Despite their age, the 
mechanism behind these drugs remains undetermined. It is believed that they counter the 
increased striatal cholinergic activity caused by depleted striatal DA (Katzenschlager et al., 
2003). Being competitive antagonists of muscarinic receptors, anticholinergics are believed to 
reduce the activity of the tonically active interneurones; cells that are suggested to promote 
this hypercholinergic activity in the parkinsonian brain (Sanchez et al., 2011). Drugs like 
benztropine and biperiden although successful in alleviating symptoms of tremor have proven 
to present significant side effects such as blurred vision, anxiety, dry mouth and cognitive 
impairment.  
The non-selective N-methyl-D-aspartate (NMDA) antagonist amantadine has also been 
successful in alleviating PD symptoms (Uitti et al., 1996). Similarly, amantadine's methylated 
analogue, memantine has also shown benefits to patients in clinical trialling (Moreau et al., 
2013). Currently, NMDA antagonists are being used as therapies targeting LID rather than the 
disease itself. This shall later be discussed in detail. 
1.10.1.6. Invasive methods of therapy  
Surgical intervention has long been practiced in the field of PD. During the 1950s people 
experiencing severe symptoms such as tremor and bradykinesia often received a thalamotomy 
or pallidotomy to reduce the experienced symptoms. However, after the discovery of L-DOPA 
the invasive and high-risk strategy was shelved for the oral therapeutic. Coincidentally, it was 
later discovered that pallidotomy was successful in reducing the severity of LID; an effect of 
long term L-DOPA use. As a result, there was a resurgence in investigating the inhibition of BG 
nuclei; a venture that led to the use of deep-brain stimulation (DBS). 
DBS utilises brain-implanted electrodes to induce high frequency stimulation that reversibly 
inhibits select nuclei of interest. In effect, this is a reversible alternative to the aforementioned 
surgical lesioning. DBS is seen to counter the abnormal neuronal firing found within the 
parkinsonian BG, but why this positively affects motor control is not fully known. Electrical 
stimulation from DBS is thought to interrupt the aberrant anti-kinetic beta-oscillations (13-
30Hz) found within key regions of the parkinsonian BG, such as the STN. These oscillations can 
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therapies and DBS itself (Eusebio et al., 2011; Kuhn et al., 2006; Levy et al., 2002). Conversely, 
higher frequency oscillations (200-500Hz) are present during DA-dependent movement and so 
are associated with pro-kinesia (Foffani et al., 2003). 
Although the GPi, pedunculopontine nucleus and STN can be selected for DBS, the latter is 
most commonly chosen in reducing the rigidity, tremor and bradykinesia. Although very 
successful in improving quality of life, the greatest issue regarding DBS is in the eligibility of its 
candidates. Tight regulations prohibit people with cognitive impairment, depression or of 
significant age (>75) to receive DBS. This is due to the procedure possibly worsening pre-
existing ailments. Younger patients who are responsive to L-DOPA and have had symptoms for 
at least 5 years are typically chosen for DBS (Moro et al., 2006).   
  
Figure 5: Sites of action of Parkinson’s disease treatments at the dopaminergic synapse 
Green arrows indicate promotion whereas red arrows indicate inhibition. Green circles are 
dopamine. Orange circles are dopamine agonists. TH: tyrosine hydroxylase, DDC: 
dopadecarboxylase, DAT: dopamine transporter, MAO: monoamine oxidase, VMAT2: vesicular 
monoamine transporter 2, DOPAL: 3,4-dihydroxyphenylacetaldehyde, DOPAC: 3,4-
dihydroxyphenylacetic acid, Adh: aldehyde dehydrogenase, COMT: catechol-O-




1.11. Unmet clinical needs 
There are two clear unmet clinical needs in the field of PD research.  
1. Understanding the mechanisms underlying LID to discover new and improved anti-
dyskinetic agents.  
2. Discovering novel therapeutic strategies to halt disease progression and increase SNc 
cell survival.  
This thesis aimed to target these two clinical needs. 
1.11.1. L-DOPA-induced dyskinesia 
LID is a hyperkinetic phenomenon that affects a large proportion of PD patients globally. As its 
name suggests, it is caused by the aforementioned gold standard PD drug L-DOPA, which when 
administered chronically over 5-10 years (Jenner, 2008b) to a DA depleted system, induces 
aberrant involuntary movements.  
LID can manifest in a variety of abnormal involuntary movements (AIMs), including dystonia 
(abnormal muscle tone), ballism (large ballistic involuntary movements of the limbs), 
myoclonus (jerky contraction of the muscles), and chorea (dance-like unpredictable 
movements), which vary upon the individual and type of LID. Depending on the manifestation 
of these characteristics in relation to L-DOPA dosing, the LID can be diagnosed as one of three 





1.11.1.1. Off-period dystonia  
Off-period dystonia is a state of abnormal muscle tone (i.e. frequent spasms and irregular 
postures) which manifest because of low L-DOPA plasma content within the patient. Off-peak 
dystonia is known to affect young-onset PD patients more than the more common idiopathic 
form (Mehanna et al., 2014), off-period dystonia regularly occurs during the early morning or 
late night when L-DOPA levels are at their lowest. Off-period dystonia commonly gives rise to 
painful foot cramps, toe curling and leg extensions (Vidailhet et al., 1999). 
 1.11.1.2. Diphasic dyskinesia  
Diphasic dyskinesia occurs in response to both high and low plasma levels of L-DOPA. Shortly 
after ingestion of L-DOPA, AIMs manifest primarily within the leg and other limbs of one side of 
the body before subsiding and reappearing several hours later when the level of L-DOPA 
content declines (Encarnacion et al., 2008). 
1.11.1.3. Peak-dose dyskinesia  
Peak-dose dyskinesia, the most common form of LID, occurs when L-DOPA reaches its peak 
concentration within the plasma. Typical AIMs include ballism of the arms and legs and 
writhing and swaying of the trunk and neck/head. Dyskinesia can also progress to the chest 
and cause shortness of breath and difficulties with breathing. The progressive effect of PD 
commonly results in a more severe peak-dose dyskinesia, as higher doses of L-DOPA must be 
administered to counter the motor dysfunction associated with advanced PD. 
The epidemiological profile of LID varies between several large patient studies. A range of 16% 
to 31% of PD patients experienced LID following a year of L-DOPA exposure (CALM-PD Study 
2000; Fahn et al., 2004). This incidence, in another large sample study, rose to 40% following 5 
years of exposure (Ahlskog et al., 2001). Furthermore, 94% of patients had experience with LID 
after 15 years of PD diagnosis (Hely et al., 2005). These data confirm that LID is an almost 































 1.11.1.4. The two requirements for inducing L-DOPA induced dyskinesia 
With most PD patients guaranteed to experience LID sometime in their life, the question 
remains, why are PD patients predisposed to dyskinesias? The answer lies in two key 
prerequisites: dopaminergic cell denervation and exposure to DA replacement therapies such 
as L-DOPA. Despite knowing these prerequisites, the true mechanism underlying the 
manifestation of LID is still unknown. 
Within PD, there is a degeneration of dopaminergic terminals that have key roles in recycling, 
releasing and buffering extrasynaptic DA. It is believed that the diminished capacity to buffer 
and store the acute and intermittent doses of L-DOPA leads to aberrant plasticity; an attempt 
to equilibrate high levels of synaptic DA (Calabresi et al., 2010; Hong et al., 2014). 
Dopaminergic cell expression, activation and tonic firing (5 Hz) is unaltered within the healthy 
brain. However within the DA depleted brain, the administration of L-DOPA gives rise to a 
fluctuating source of DA which upsets this homeostatic balance of activity (Olanow et al., 
2006). Although the initial terminal sprouting found in response to denervation aids in L-DOPA 
buffering, the brain soon becomes overwhelmed and unable to store excess L-DOPA. This 
reduces the experienced effect of L-DOPA and gives rise to the wearing off effect patients 
experience with L-DOPA treatment. This shortening of L-DOPA’s effect becomes acute and then 
more closely replicates the half-life of the drug and brings about the characteristic LID AIMs. As 
a result, this leads to a vicious cycle of requiring increasingly higher doses of L-DOPA to counter 
motor dysfunction whilst, unfortunately, reducing its therapeutic efficacy and promoting more 
severe LIDs 
 
Figure 6: Three types of dyskinesia in relation to L-DOPA plasma concentration. 
Peak dose dyskinesia manifests at the highest doses of L-DOPA whereas off-period dystonia 
occurs at low levels. Diphasic dyskinesia is a combination of the two. 
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Although it is almost certain that a PD patient receiving L-DOPA is guaranteed LID, individuals 
may have it manifest at varied rates and severity. These differences may be associated with 
individual factors that alter the risk for LID.  
 1.11.1.5. Risk factors for L-DOPA induced dyskinesia 
Two key risk factors in LID manifestation are L-DOPA dosage and duration of its exposure, both 
have been found to correlate with LID severity. The DATATOP placebo-controlled clinlical trial 
indicated that a L-DOPA dose of 338 mg did not induce LID whereas an increase to 387 mg saw 
the disorder arise (DATATOP, 1989). It is also well understood that longer peak-dose dyskinesias 
can be seen as a result of higher L-DOPA doses (Nutt et al., 1992). The duration of exposure, as 
previously explained in reference to LID’s epidemiological profile, is directly correlated with LID 
susceptibility. It is because of these two factors that L-DOPA-sparing is an important strategy in 
tackling LID, whereby drug dosage is kept to a minimum to delay LID onset.   
It is important to note that, although not L-DOPA driven, dyskinesia can be caused by other DA 
replacement therapies as well. However, these prove to have lower incidence when compared 
to L-DOPA (Nutt, 1990). DA replacement therapies are often prescribed to target motor 
dysfunction without a significant increase in LID risk. 
There is an inverse relationship between LID and PD onset. Early onset PD (< 40 years old) sees 
the highest prevalence of LID, where 94% of young patients experience the disorder following 5 
years of L-DOPA treatment (Quinn et al., 1987). This is a dramatic increase over the 40% 
described for idiopathic patients. Other studies have indicated a decreased correlation with 
age, in which 16% of people diagnosed after 70 years old manifested LID (Kumar et al., 2005). 
However, we must realise that the genetic factors found associated with early onset PD may 
play a role in LID manifestation, therefore explaining why older idiopathic PD patients may 
experience lower LID prevalence. 
Alongside age, the gender of the patient may influence the risk of LID manifestation. It is 
thought that female sufferers of PD present a higher risk for LID as the lower body weight may 
give rise to a higher dose of L-DOPA in the plasma per kilogram. Studies have suggested that 
this increased plasma concentration of L-DOPA boosts the bioavailability of the L-DOPA and its 
dyskinetic properties (Zappia et al., 2005). However, this does not incorporate other gender or 
hormonal factors that may differ between the sexes.  
Genetic mutations other than the previously described familial factors may have a significant 
say in LID. Individuals possessing polymorphisms of the D2 DA receptor gene have shown a 
reduced risk in the induction of peak-dose dyskinesia (Oliveri et al., 1999; Rieck et al., 2012). 
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Interest in the adenosine A2 A receptor as a LID therapeutic target has led to allele 
discrimination assays. These assays have discovered an association between adenosine A2 A 
receptor polymorphisms and LID. This highlights a potentially new target for anti-dyskinetic 
agents (Rieck et al., 2015). 
 1.11.1.6. Current L-DOPA induced dyskinesia therapeutic interventions 
Established LID can be difficult to treat and so the prevention of the disorder is of high priority. 
A range of strategies can be employed to either delay LID onset, such as L-DOPA-sparing 
through the use of DA agonists, or to reduce severity of existing LID by administering 
pharmacological agents or conducting neurosurgery. As with all diseases, the approach used to 
treat LID should be an personalised strategy based on the patient’s LID type and lifestyle. 
In order to delay LID onset, a favoured approach is to reduce the intake of L-DOPA through the 
aforementioned L-DOPA-sparing method. By administering alternative therapies such as DA 
agonists and/or MAO-B inhibitors, the overall daily dose of L-DOPA can be reduced by up to 
25% (Jankovic, 2008). This is certainly favourable to early-onset PD patients who not only will 
require far more L-DOPA over a lifetime, but also are also far more susceptible to LID than 
typical idiopathic patients. However, the caveat to certain DA agonists is that they provide 
unwanted side-effects and are less successful than L-DOPA in bettering quality of life, albeit 
with the development of LID (CALM-PD, 2000).  
In attempts to reduce LID risk, controlled release formulations of L-DOPA (Sinemet CR) that 
have a longer half-life than that of the standard compound (t1/2: 1.5 hrs) have been developed 
to counter the pulsatile nature associated with the standard medication. However, these have 
proven unsuccessful in reducing LID compared to a standard formulation of L-DOPA in a 5 year 
follow up study (Block et al., 1997; Fox et al., 2011). Nevertheless, this theory of overcoming L-
DOPA's short half-life was furthered. More effective slow release strategies have now been 
developed, such as the intestinal extended release gel, known as L-DOPA/carbidopa intestinal 
gel. Randomised controlled trails found that L-DOPA/carbidopa intestinal gel applications 
reduced off time and increased on time without troublesome LID (Olanow et al., 2014; 
Wirdefeldt et al., 2016). Although promising, the complications associated with the surgical 
procedure required for the L-DOPA/carbidopa intestinal gel implantation in elderly patients has 
been seen as too risky; this approach is a last resort for many patients.  
Amantadine is a low affinity non-selective NMDA antagonist that is commonly prescribed as an 
anti-dyskinetic treatment for LID. Its anti-dyskinetic effect has been proven in trials whereby 
double blind placebo controlled studies indicated a dramatic decrease in the duration of LID 
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following amantadine treatment (da Silva-Junior et al., 2005; Snow et al., 2000). But issues 
have been raised with the long term efficacy of the drug and its associated side-effects 
(Vijverman et al., 2014). This has led researchers to assess the extended release formulation of 
amantadine, ADS-5102, as an improved therapeutic. Phase III clinical trials have shown promise 
in its anti-dyskinetic effects in which Unified Parkinson's disease rating scale (UPDRS) scores 
were decreased (higher scores indicate higher disease severity) whilst there was an increase in 
on time without troublesome LID (reviewed in (Lotia et al., 2016; Pahwa et al., 2015).  
Current anti-dyskinetic approaches have proven successful in providing symptomatic relief of 
LID. Despite this, no current therapeutic has stopped LID from manifesting in PD patients 
receiving chronic L-DOPA treatment. As such, we must further investigate the mechanisms 
behind LID in order to discover new prophylactic therapies. Theories underlying the 




1.11.2. Mechanisms underlying SNc cell degeneration 
In order to discover novel ways to halt disease progression and promote SNc cell survival we 
must further understand the processes in which cells of the NS degenerate. Key mechanisms 
that lead to cell death are described below. 
 1.11.2.1. The electron transport chain and oxidative stress  
The ETC is an important process that takes place on the inner mitochondrial membrane. Its 
purpose is to generate ATP by a series of redox reactions involving several membrane bound 
electron transporters known as complexes I, II, III and IV. This process sees the sequential 
shuttling of electrons from complex I to complex IV by molecular donors obtained from the 
Kreb's cycle (e.g. nicotinamide adenine dinucleotide [NADH]). The ultimate aim of this process 
is to drive the transfer of protons across the membrane causing an electrochemical gradient. 
Once this gradient has formed, free protons drive the formation of ATP from ADP and 
phosphate via the ATP synthase enzyme. This is the key energy producing process in the cell. 
Although essential for cell survival, the mitochondria can also trigger cell death. 
Disrupted ETC function through damage or mutation causes not only the cessation of ATP 
production but also the creation of ROS. Cells possess several biological antioxidants which 
buffer manageable levels of ROS (e.g. superoxide dismutase, glutathione), but continued cell 
stress leads to an accumulation of ROS that is beyond the cell's defence capacity. This state is 
known as oxidative stress. In a stressed state, ROS trigger the release of cytochrome C from the 
mitochondria which then facilitate the caspase cascade and finally apoptosis (Kannan et al., 
2000). Degenerating SNc neurones in PD brains exhibit signs of oxidative stress, such as the 
oxidation of proteins and cytoplasmic nucleic acid, alterations in biological antioxidants and 
also lipid peroxidation (Dexter et al., 1989a; Riederer et al., 1989; Zhang et al., 1999). These 
pathological hallmarks all point towards the dysfunctional mitochondrion as a key component 
in the pathogenesis of PD (Jenner, 1996). 
 1.11.2.2. Glutamate driven excitotoxicity 
A large unmanageable concentration of glutamate gives rise to excitotoxicity; a state which 
induces cell apoptosis (Olney et al., 1971). Unfortunately for the BG, glutamate is a key 
regulator of its function which is greatly affected in PD. The two main sources of glutamatergic 
transmission in the BG are from corticostriatal afferents and the subthalamic projections to the 
GPi/SNr complex. But it is the overactivity of the subthalamic pathway which has previously 
been identified as a correlate for disease progression and a source of excitotoxicity (Remple et 
al., 2011). Additionally, this excitotoxicity can be exacerbated by poor glutamate buffering. 
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Glutamate reuptake from the synaptic cleft has suggested to be inhibited in PD due to the 
dysfunctional expression of glutamate transporters in PD models (Chung et al., 2008; Salvatore 
et al., 2012).  
When glutamate is in excess, it floods the synaptic cleft and overstimulates NMDA receptors on 
the post-synaptic membrane. Stimulation and depolarisation of these neurones leads to the 
influx of large quantities of Ca2+ that then cause the activation of several pro-apoptotic 
pathways. Ca2+ is known to accumulate in the mitochondria causing the depolarisation of the 
membrane and the opening of the permeability transition pore. In doing so, apoptotic proteins 
such as cytochrome C are released causing cell death (Orrenius et al., 2003). Intracellular Ca2+ 
can also activate the nitric oxide synthase (NOS) isozymes present in neuronal cells (nNOS) and 
endothelial cells (eNOS), resulting in the production of nitric oxide (NO). The highly reactive 
peroxynitrite (ONOO-) is then formed from the reaction between NO and superoxide radicals. 
Both NO and ONOO- have shown to be significantly higher in PD patients and are thought to 
worsen disease progression (Kouti et al., 2013).  
 1.11.2.3. Dysfunction of the proteasome 
The ubiquitin-proteasome system (UPS) is an intracellular complex which ubiquitinates and 
degrades proteins that are destined for recycling. The aim of the UPS is to remove the 
hazardous build up of damaging or non-functioning proteins that may inhibit the processes 
within the cell. Dysfunction of the UPS underlies one of the key theories behind α-syn presence 
within SNc cells. Furthermore, particular forms of familial PD are associated with the mutation 
in UPS related proteins, such as the E3 ubiquitin ligase Parkin and the enzyme UCH-L1 (Leroy et 
al., 1998; Um et al., 2010). In idiopathic post mortem tissue, reduced expression of the core 
20S proteasomal subunit has been discovered, highlighting the possible decrease in UPS 
activity (McNaught et al., 2003). The cause of an impaired proteasome in sporadic PD is 
unknown. 
 1.11.2.4. Neuroinflammation 
 
Neuroinflammation has been identified as a likely contributor to idiopathic PD pathology. 
Several inflammatory hallmarks have shown to be increased within the patient brain and 
various toxin models, such as activated microglia (CNS-resident macrophages) within the SNc 
(Hirsch et al., 2009) and increases in several cytokines (IL-1, -2, -6 and tumour necrosis factor-
α) within the SNc and cerebral spinal fluid (Liu et al., 2003).  
It has been suggested that the neuromelanin, which accumulates within the SNc cells and gives 
it its blackened hue, is a target for autoimmune responses (Graham, 1979). The presence of 
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neuromelanin was found to cause dendritic cell maturation and phagocytosis (Oberlander et 
al., 2011). Other studies suggest autoantibodies (antibodies that target the body's own cells 
rather than foreign ones) are the cause of SNc cell death. In further support of this theory, 
injecting immunoglobulin samples from PD patients into the rat SNc induces the activation of 
microglia and the degeneration of dopaminergic cells (Armando et al., 2016; He et al., 2002).  
1.11.3. Neurotrophic factors as therapeutics for SNc cell survival 
The delivery of specific neurotrophic trophic factors (NTFs) has generated therapeutic interest 
in PD. NTFs are a group of neuro-active molecules that have specific neuroprotective, pro-
growth or modulatory roles when interacting with neuronal cells. Several NTFs have shown 
promise in models of PD and even human clinical trials. NTFs, such as brain-derived 
neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), are seen as 
interesting alternatives to current symptomatic relief therapeutics due to their interaction with 
dopaminergic cells (Allen et al., 2013; Howells et al., 2000). 
BDNF has been used in preclinical settings as a potential neuroprotective agent. Interest was 
first raised when its reduced concentration was detected within the SNc and VTA of PD patients 
(Howells et al., 2000; Scalzo et al., 2010). It was later discovered that an increased expression 
of BDNF was caused by wild-type α-syn presence but not by mutant α-syn (products of the 
gene point mutations A53T and A30P). This indicates a relationship between SNCA gene 
mutants and the abnormal expression of BDNF (Kohno et al., 2004). Despite the lack of trials in 
humans, preclinical studies have shown positive results concerning the efficacy of BDNF. It was 
discovered that BDNF treatment prevented MPTP-induced (Frim et al., 1994) and 6-OHDA-
induced SNc degeneration (Spina et al., 1992). These toxin models of PD are explained in full in 
section 1.12.2. 
GDNF has a close relationship with dopaminergic cells, where it has shown to induce 
differentiation and survival of the cells from embryonic midbrain cultures (Lin et al., 1993). 
Several GDNF delivery studies have been conducted using rodent and NHP models with great 
symptomatic effect but with mixed cell survival results (Martin et al., 1996; Winkler et al., 
1996). It was the interest and promise raised from these studies that led to the investigation of 
GDNF administration in clinical trials.  
In 2003 a phase 1 open-label clinical trial was conducted analysing the effects of 
intraputamenal administration of GDNF (Gill et al., 2003). The study stereotaxically 
administered GDNF continually for 12 months to the posterodorsal putamen of five idiopathic 
patients via abdominal pumps. The posterodorsal putamen was selected as it was theorised 
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that the GDNF would be retrogradely transported back to the cell bodies, via the NS, to aid in 
cell survival. Patients showed a significant improvement in activities of daily living and off-
medication UPDRS scores when analysed with the UPDRS. However, with a low sample size and 
open-label approach, the study had a significant flaw in its design. Despite this, a 12 month 
follow up study saw further improvements in UPDRS scores (Patel et al., 2005). Later, a second 
open-label intraputamenal study with differing methods proved also to be successful (Slevin et 
al., 2006). These results led the field to conduct a controlled trial. Unfortunately due to 
insignificant alterations in UPDRS scores, the placebo-controlled trial, which had a more robust 
design than that of the previous trail, was a failure (Lang et al., 2006). Follow up investigations 
in NHPs discovered that the method of GDNF administration may have caused the low 
availability of GDNF to the putamen. The method was criticised for having issues with reflux 
and not allowing maximal spread of the NTF throughout the putamen (Salvatore et al., 2006).  
More recently, pre-clinical trials have been conducted to identify optimum ways of NTF 
delivery. Viral vector based deliveries (Wang et al., 2002) and nanoparticle technology (Fletcher 
et al., 2011) have been adopted to promote long-term expression of NTFs. In addition, 
approaches to promote intrinsic NTF levels within the brain have also been investigated. 
Enzymatically removing certain components of the extracellular matrix (ECM; regions of space 
in between the cells of the CNS) is thought to liberate trapped NTFs and create a more 
favourable milieu for synaptic plasticity and regrowth. This ECM-manipulation strategy is based 
on a well-described spinal cord injury model that digests the chondroitin sulphate 
proteoglycans (CSPGs) of the ECM to promote neuronal regrowth following injury (Bradbury et 
al., 2002). Although not fully investigated within PD, this approach could repair and protect 
degenerating neurones of the SNc. Utilising the ECM as a therapeutic target for SNc cell 




1.11.4. The extracellular matrix 
The ECM occupies the surrounding spaces between all glia and neurones of the CNS (i.e. the 
interstitial space and the basement membrane) and consists of a wide array of cell-secreted 
molecules. The ECM is vital to the neighbouring cells of the adult and of the developing brain. 
In an injured state, the ECM undergoes composition alterations that are seen to be detrimental 
to normal cellular function. As a result, it has been a key target for cell survival therapies of the 
CNS.  
 1.11.4.1. Chondroitin sulphate proteoglycans 
The ECM consists of a wide array of multifunctional molecules (see Table 1). However, it is the 
CSPGs that are of most interest due to their axonal repair capabilities (Bartus et al., 2012; Kwok 
et al., 2008). There are several types of CSPGs, such as phosphacan, NG2, and the lecticans; the 
lecticans form the largest proportion of the CSPGs. These lecticans consist of aggrecan, 
versican, neurocan and brevican (two smaller lecticans exist, biglycan and decorin, but these 
are not significant to this thesis). CSPGs consist of several constituent components, at their 
centre resides the structural core protein that determines the flavour of the CSPG (e.g. 
neurocan, versican). These core proteins are then bound to highly sulphated 
glycosaminoglycan (GAG) disaccharide chains. The degree of core protein glycosylation 
depends on the particular CSPG subtype; aggrecan possesses the most GAG side-chains and 
brevican with the least (figure 6A). Several GAG types are known, such as, keratan sulphate, 
heparin sulphate, dermatan sulphate and chondroitin sulphate (CS); the latter being the most 
abundant within neural tissue (Hascall et al., 1983; Lander, 1993; Ruoslahti, 1988). The GAG 
disaccharide chains are formed by the alternating glucaronic acid (GlcA) and N-acetyl 















  Glycoproteins which interact with fibronectin and aid with cell signalling   
  Join CSPG core proteins to the hyaluronan scaffolding, required for PNN formation
  Collection of structures comprised of a core protein and sulphated CS-GAG side-chains
Function
  Essential for the basement membrane, required for cell adhesion
  Roles associated with cell adhesion, migration and proliferation
  Structural support by providing tensile strength and scaffolding
  Anionic, unsulphated GAG which provides a scaffold to CSPGs and ECM integrity
  Pericullular lattice structures which are comprised of CSPGs and help define developmental critical periods  
 
All lecticans, aside from phosphacan, possess two key domains. Firstly, the N-terminal G1 
domain which has a hyaluronan and link protein binding domain. This G1 region allows the 
complexing of CSPGs with the hyaluronan scaffolds. Secondly, the C-terminal G3 domain which 
contains a lectin binding region required for ECM interactions. The G3 domain permits the 
binding of CSPGs to tenascin which allows the cross linking of CSPGs. In addition to these 
common domains, aggrecan possesses the unique G2 domain that is homologous to the G1 
domain. G2’s function is not fully clear, although it is known not to bind to the link protein as 
found with the G1 domain (Kiani et al., 2002).  
Two atypical CSPGs exist as membrane bound glycoproteins, NG2 and phosphacan. NG2 is 
found on oligodendrocyte progenitor cells whereas phopshacan is the cleaved extracellular 
portion of the protein tyrosine phosphatase β receptor (figure 6A). Furthermore, unlike the 
rest of the CSPGs, phosphacan possesses a carbonic anhydrase (CAH)-like domain that binds to 

















Table 1: Extracellular matrix components.  
Chondroitin sulphate proteoglycans are one of many extracellular matrix molecules. The table 
below summarises the key function of many other components. PNNs; perineuronal nets, 














Within the CNS, CSPGs have a significant role in the development and plasticity of neural 
systems during postnatal development (Pizzorusso et al., 2002). However, within the adult 
brain their role is not known (Rhodes et al., 2004). Evidence suggests that CSPGs are potentially 
neuroprotective in the adult brain, in which their highly sulphated-negative charge is thought 
to buffer divalent cations, such as Ca2+ (Moos, 2002). An increase in Ca2+ gives rise to ROS, so 
Ca2+ buffering would therefore reduce ROS and cell death (Suttkus et al., 2012). Moreover, 
studies examining amyloid related degeneration in Alzheimer’s disease have presented a 
correlation between cells devoid of CSPG formations and increased AD-related neurofibrillary 
aggregates (Bruckner et al., 1999). This reinforces the theory of CSPGs being beneficial to cell 
survival. However, extensive research into the upregulation of CSPGs during astroglial scar 
formation following spinal cord injury still suggests that CSPGs are inhibitory to neuronal 
growth and that their enzymatic degradation permits neuronal cell sprouting (Bradbury et al., 
2002). The case may be that CSPGs fulfil both roles of being a Ca2+ buffer and a neuronal 
growth inhibitor within the adult CNS. It may be that the buffering effect is negligible after 
significant CNS damage and so CSPGs just perceive to be purely inhibitory (Rhodes et al., 2004).  
  
Figure 7: Structure of the CSPGs within the extracellular matrix. 
(A) The six major CSPGs include the four lecticans, which are aggrecan, versican, neurocan and 
brevican, and also the transmembrane glycoproteins, NG2 and phosphacan. CSPGs bind to 
hyaluronan via link proteins to form the interstitial ECM structure. (B) Further cross-linking via 
tenascin helps form perineuronal nets that form around the cell soma and proximal dentrites. 
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1.11.4.2. The perineuronal net 
CSPGs exist in a few forms within the ECM. A small number exist as non-aggregated units 
within the diffuse matrix, whereas a large majority are present in large pericellular structures 
known as perineuronal nets (PNNs). The PNNs are large lattice-like structures, comprised 
mainly of CSPGs (i.e. aggrecan) and cross-linking proteins such as tenascin that form a 
significant part of the ECM. Being pericellular formations, PNNs surround the neuronal cell 
body and extend down proximal dendrites of neuronal cells (Wang et al., 2012b). The role this 
structure possesses differs throughout the mammalian lifecycle. 
PNNs are significant to neuronal plasticity and the maturation of the CNS (Carulli et al., 2006; 
Galtrey et al., 2008), suggesting that their presence is led by neuronal activity and network 
development. Many regions have shown to possess PNNs, such as, the visual cortex, 
cerebellum, amygdala, hippocampus, spinal cord and the basal ganglia (Bruckner et al., 2008; 
Dityatev et al., 2007; Galtrey et al., 2007). The plastic nature of the PNN is classically described 
within the developing visual system where the formation is said to close the critical period, a 
timeframe where stimulus driven neuronal activity causes the organisation of neuronal 
networks (Pizzorusso et al., 2002; Wang et al., 2011). Depleting the sensory input to these 
motor neurones is said to end the critical period as PNNs form and plasticity ceases (Kalb et al., 
1994).  
Although the role of the PNN is largely associated with developmental plasticity, it is believed 
to still retain significance within the adult CNS, albeit an inhibitory one. Due to the high CSPG 
content, the PNN possesses an inhibitory role within the adult that is reversed by its removal. 
PNN digestion reactivates plasticity that leads to axon sprouting and repair within the CNS 
(Massey et al., 2006). Although the exact mechanism behind this reactivation of plasticity is 
unclear, one theory states that as the ECM acts as a repository for many NTFs such as fibroblast 
growth factor-2, pleiotrophin and others (Mi et al., 2007; Penc et al., 1998). Its digestion 
therefore liberates an array of pro-growth agents creating a favourable milieu for increased cell 
plasticity and sprouting. It is feasible that such digestion may offer an alternative means of 




1.12. Preclinical mammalian modelling of Parkinson's disease  
Although a lot of biomarker and immunohistochemical work can be conducted on human post 
mortem tissue or with in silico modelling, the lack of behavioural and in vivo data can be 
critical. As a result, animal models of disease have been developed in order to replicate PD. 
Two types of validity mark the successfulness of a model of PD these are construct and face 
validity (as described in (Chesselet et al., 2011; Duty et al., 2011). Construct validity describes 
how well the model replicates the pathogenesis of the disease (e.g. SNc denervation, 
inflammation), face validity on the other hand is a mark of how well symptomatology is 
represented in the model (e.g. rigidity, tremor, akinesia). No one model is considered perfect 
but some are seen as more applicable to certain studies than others. Both the pharmacological 
and toxin induced models are described below.   
1.12.1. Pharmacological models of Parkinson's disease 
Normally favoured for shorter and less invasive studies, the pharmacological models are 
typically transient and have far more face validity than construct. Nevertheless, the quick and 
cheap nature makes these models still used to this day.  
1.12.1.1. Reserpine  
 Trade name: Raudixin, Serpasil, Serpalan 
 Type:  alkaloid, antipsychotic, antihypertensive 
 Action:  depletes catecholamines from nerve terminals 
Reserpine irreversibly inhibits the monoamine transporter, VMAT2, the protein responsible for 
the transport of monoamines into vesicles at the presynaptic bulb. Inhibition of VMAT2 
therefore halts the exocytosis of monoamines and the excitation of the postsynaptic neurone. 
Monoamines remaining in the cytoplasm of inhibited neurones are usually metabolised by 
COMT and MAO enzymes. A subcutaneous dose of 5 mg/kg reserpine reduces DA content in 
the rat striatum by 95% and the SNc by 85% within 2 hours of administration, this monoamine 
deprived state is maintained for ~24 hours before basal levels return (Duty et al., 2011).   
Reserpine reproduces good face validity in which the overall effect of DA depletion is evident 
by akinesia. However, the model has low construct validity as PD pathology is not present (e.g. 
cell loss). One of the major problems found with the model is the non-selective nature of the 
compound. As VMAT2 is a monoamine transporter, its inhibition affects the release of other 
monoamines, such as 5-HT. Despite this, some argue that this replicates the biochemistry 
found in PD patients whereby monamine deficiency also occurs (Duty et al., 2011).  
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 1.12.1.2. Haloperidol 
Trade name: Haldol 
 Type:   antipsychotic, antiemetic 
 Action:  high affinity D2 receptor antagonist 
As with reserpine, the overall construct validity of haloperidol is low (e.g. no SNc cell loss or 
other pathologies). On the other hand, face validity is replicated well with both catalepsy and 
rigidity exhibited. As a D2 receptor antagonist, and a D1 antagonist to a degree (Sanberg, 
1980), haloperidol blocks the DA transmission in the striatum leading to aberrant firing 
patterns within the BG. This provides the aforementioned symptoms of catalepsy and rigidity. 
The behavioural phenotype of the model is short lasting and is maintained only a few hours 




1.12.2. Toxin models of Parkinson's disease 
Unlike the easier pharmacological models, toxin models require a more invasive and skilled 
approach to induce and reproduce. These usually present high construct and good face validity 
that is permanently maintained. As a result, these models are favoured for longer studies that 
require consistent phenotypes for the analysis of behavioural recovery over longer periods. 
1.12.2.1. 6-OHDA 
 A.k.a.:  6-hydroxydopamine, oxidopamine 
 Type:  Toxic DA analogue 
Action: Reactive oxygen species generator; full mechanism not fully 
understood 
 
The 6-hydroxydopamine (6-OHDA) animal model has been one of the most commonly used in 
PD research since its discovery in the late sixties (Ungerstedt, 1968). As 6-OHDA does not cross 
the BBB, the toxin must be administered directly into the NS. Although requiring more skill to 
administer (i.e. stereotaxic surgical technique), this lack of BBB penetrance allows 
experimenters to induce hemiparkinsonian models. These animal models exhibit one lesioned 
hemisphere whilst the other is left unlesioned to act as an internal control. This model has 
been favoured by researchers assessing the functional recovery of animals following treatment 
by a reparative or protective agent over a long course. Any pathological improvements (e.g. cell 
survival, better behavioural outcomes) can then be observed in the lesioned hemisphere in 
comparison to the internal control. Phenotypic improvements are typically assessed by 
behavioural tests that distinguish the injured (a.k.a. parkinsonian) from the uninjured (a.k.a. 
control) sides of the body. A standard behavioural test that benefits from this unilateral model 
is the forelimb asymmetry test; this will be explained in detail in Chapter 3 section 3.3.4.6. 
Another benefit of utilising 6-OHDA is its ability to be administered in one of three places 
within the NS for varying degrees of SNc denervation (Francardo et al., 2011). The striatum is 
commonly selected to induce a partial lesion which replicates early-stage PD (~50-60% SNc cell 
loss) and is relatively progressive (taking several weeks to stabilise). This progression is due to 
the toxin being retrogradely transported back to the cell soma where toxicity is induced. Unlike 
the striatum, injections into the medial forebrain bundle (MFB) and SNc induce a full lesion; a 
model that more replicates late stage PD. Although lower doses may cause a lower cell loss, 
these routes are routinely used for consistent SNc ablation (>90% cell loss) and the swiftness at 
which they develop (<7 days). Although 6-OHDA is commonly used to induce hemiparkinsonian 
models, it can also be injected bilaterally for further effects (e.g. adipsia, severe akinesia). 
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However, mortality rates are drastically higher in these animals and therefore require much 
stricter post-operative care.   
Upon administration, 6-OHDA is transported into the dopaminergic nerve terminals by the DA 
transporter (DAT). Due to the structural similarity to other catacholamines, 6-OHDA has a low 
affinity for other transporters such as the noradrenaline transporter which can result in off-
target cell loss (Luthman et al., 1989). To counter this, a noradrenaline transporter inhibitor 
such as desipramine can be co-administered with 6-OHDA to increase selectivity for DAT. This 
limits 6-OHDA’s toxicity to the dopaminergic A9 and A10 neurones of the SNc and VTA, 
respectively. As the A10 neurones are not part of the motor circuit involved in PD, the A9 
neurones are specifically targeted by stereotaxic injection to minimise A10 cell death. 
Pargyline, an irreversible MAO-B inhibitor, may also be administered to reduce the breakdown 
of 6-OHDA by MAO. This thereby lowers the required dose of 6-OHDA administered. 
The mechanism of 6-OHDA's toxicity is multifaceted when compared to other toxins such as 
MPTP. Once 6-OHDA enters the neurone, cellular degeneration occurs through a few means. 
Firstly, the generation of ROS through auto-oxidation is thought to be the main cause of 
toxicity. Under physiological conditions, 6-OHDA can form H2O2 and the hazardous quinone 
molecules that, in the presence of Fe, can form harmful hydroxyl free radicals (Rodriguez-
Pallares et al., 2007; Soto-Otero et al., 2000). Secondly, 6-OHDA has been found to directly 
interact and interrupt both complex I and complex IV of the ETC (Glinka et al., 1997). This 
reduces ATP production within the cell and causes cell death. Finally, evidence suggests that 6-
OHDA decreases the mRNA levels of the antioxidant enzyme SOD in the SNc (Kunikowska et al., 
2001).  
The 6-OHDA rodent model has been a mainstay in PD research for nearly 50 years. The model, 
available in both the rodent and NHP, recapitulates the pathology of SNc degeneration, 
reduction in striatal DA, mitochondrial dysfunction and ROS production. However, it does lack 
key features such as LB-like inclusions or the dysfunction of other brain circuits outside of the 
BG. Construct validity is adequate as several factors such as ROS production and complex I 
inhibition are present. Face validity is high in which DA loss is significant and the resulting 
parkinsonian motor dysfunction is apparent. Despite some weaknesses, this toxin model is 
highly effective at predicting disease state (i.e. severity of lesion correlating with parkinsonism 





 A.k.a.:  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
Type:  BBB penetrative proform of the 1-methyl-4-phenylpyridinium (MPP+) 
toxin  
 Action:  Inhibitor of Complex I of the electron transport chain 
MPTP was initially discovered in the 1980s when heroin users accidentally formulated MPTP 
instead of the desired 1-methyl-4-phenyl-4-propionoxypiperidine opioid. Upon systemic 
administration to users, the damaging effects of MPTP closely resembled PD (Langston et al., 
1983). It was later found that MPTP's toxic metabolite MPP+ specifically targeted SNc cells and 
resulted in the reduction of striatal DA. Since this discovery, both rodent and NHP models have 
been developed to reproduce parkinsonism through MPTP toxicity.    
Being lipophilic, MPTP readily crosses the BBB and is therefore systemically active (Riachi et al., 
1989). Once within the brain MPTP is taken up by glia, namely astrocytes, and metabolised into 
the aforementioned toxic metabolite MPP+ by MAO-B. This toxic by-product is then released 
from the glia into the intracellular space, before being transported into the neighbouring 
neurones via DAT. Once it has entered the cytosol, MPP+ gathers within mitochondria and 
inhibits complex I of the ETC. This leads to two toxic results, the interruption of ATP synthesis 
and the production of ROS (Zawada et al., 2011). These two factors are the primary cause of 
cell death. As these pathologies are present within PD this toxin model presents good construct 
validity. 
Due to its BBB penetrative nature, systemic MPTP administration is far easier to administer 
than 6-OHDA which requires skilled stereotaxic surgery. The caveat to this being the inability to 
create a hemiparkinsonian model; removing the convenience of an internal control limb when 
conducting behavioural analyses. However, this bilateral denervation of the BG replicates the 
state of parkinsonism far better than 6-OHDA, especially within the NHP.  
Although both mice and NHP are used, it is the NHP (e.g. macaque monkey), which is 
commonly used as the gold-standard MPTP PD model. This is because the NHP model 
recapitulates all of the main behaviours associated with PD, such as rigidity, bradykinesia and 
abnormal postural positioning (Bezard et al., 2011) plus NMS such as sleep disturbances, 
cognitive impairment and LID (Barraud et al., 2009; Bezard et al., 2003; Schneider, 1990). The 





However, due to the expensive upkeep of the NHPs, this model is frequently exchanged for the 
MPTP mouse. This rodent model is considered a trade-off between model validity (e.g. lack of 
typical PD-like symptoms) and expense. Interestingly due to an innate insensitivity to MPTP, 
the rat model is not used. Although not fully understood, this is thought to be in part due to 
the higher level of VMAT2 present within rat striatal vesicles (Staal et al., 2000). Recent work 
theorises that VMAT2 sequesters toxins into vesicles as a method of toxin removal (Lohr et al., 
2016). Like the rat, the mouse does retain some insensitivity to MPTP and, as a result, 
subchronic administrations of MPTP lead to transient phenotypes (Colotla et al., 1990). These 
transient phenotypes are deemed of little use in testing drug efficacies, therefore to maintain 
a more testable phenotype a chronic dosing schedule is enforced. A common practice is to co-
administer probenecid (a drug which promotes uric acid excretion) with MPTP to enhance the 
effects of the toxin via inhibition of urinary clearance (Lau et al., 1990). In recent years the 
development of continuous MPTP administration through osmotic pumps has been developed. 
Models with a continuous delivery of MPTP present typical pathologies of PD, such as even α-
syn- and ubiquitin-positive inclusions (Fornai et al., 2005; Meredith et al., 2008). However, this 
model exhibits issues with its predictive nature whereby lesion size does not always correlate 
with behavioural outcomes (Duty et al., 2011; Gibrat et al., 2009). 
1.12.2.3. Rotenone 
 Trade name: Tubatoxin, Paraderil 
 Type:  Pesticide  
 Action:  Inhibitor of Complex I of the electron transport chain 
Rotenone, as with MPTP, is an inhibitor of the ETC and is systemically active. Rotenone is a 
pesticide that was investigated in 2000 as a potential model of PD. When intravenously 
administered via osmotic mini pumps the neurochemical, neuropathological (including LB-like 
inclusions) and behavioural features of idiopathic PD were replicated (Betarbet et al., 2000b). 
Although the model presents good face validity, the consistency of the model has been a 
significant issue with its use. Toxin resistance has been shown by some animals, whereby only 
~50% of treated animals display PD-like symptoms seen in the original Betarbet paper.  
Other ETC inhibitors of note are paraquat and maneb, both of which produce similar effects to 





Trade name: n/a 
 Type:  Bacterial (Streptomyces genus) toxin 
 Action:  Inhibitor of the proteasome 
  
Reduced activity of the UPS has been identified within the SNc of PD idiopathic patients 
(McNaught et al., 2001). Alongside this observation, ubiquinated α-syn has been located within 
surviving SNc neurones indicating a UPS response to α-syn accumulation. This lowered ability 
to metabolise damaged, misfolded or accumulated proteins within cells is believed to lead to 
apoptosis. However, the role the dysfunctional UPS plays in the pathogenesis or manifestation 
of the neurodegeneration seen in PD is not certain. 
In view of this finding, the lactacystin animal model of PD was established in an attempt to 
replicate both the proteasomal dysfunction and SNc cell death associated with PD. The 
bacterial toxin lactacystin was found to induce not only cell death but also the accumulation 
and aggregation of α-syn-positive inclusion bodies within the rodent. Similarly, administration 
of other proteasome inhibitors such as PSI and epoximycin induce typical parkinsonian effects 
(McNaught et al., 2002; Xie et al., 2010). In the rodent this model induces bradykinesia and 
rigidity which is reversed by L-DOPA administration (McNaught et al., 2004). Due to the SNc cell 
loss, inclusion presence and motor dysfunction, this model retains good construct and face 
validity. Despite robust validity, the use of this model has been limited. This is in part due to the 
inconsistent reproduction of the model, whereby several labs were not able to recreate the 
motor dysfunction or cell loss first described (Kadoguchi et al., 2008; Kordower et al., 2006; 




1.12.3. Genetic models of Parkinson's disease 
Identifying the genes responsible for familial PD has led to the creation of transgenic models of 
disease.   
1.12.3.1. α-synuclein 
 Action:  A30P and A53T mutations in drosophila and mouse; A53T in rat   
The identification of the autosomal-dominant α-syn mutation led to the generation of the α-
syn transgenic model (Chesselet et al., 2011). This model has been developed in mouse, rat 
and drosophila, each with varying results. Mouse models have shown, quite surprisingly, no 
loss in DA and no responsiveness to L-DOPA. An opposite result to the rat which has L-DOPA 
responsiveness whilst displaying LB-like inclusions. Furthermore, drosophila models possess 
not only DA loss and LB-like inclusions but are responsive to L-DOPA despite having no 
mitochondrial dysfunction (Dawson et al., 2010). These models report inconsistency in SNc cell 
loss and as a result have not established a significant role in PD modelling as of yet.  
1.12.3.2. MitoPark 
 Action:  Cre-loxP conditional knockout of TFAM; DA cell targeted   
 
The MitoPark mouse is a dopaminergic conditional knockout model of the mitochondrial 
transcription factor TFAM. It was first established to replicate the many familial forms of PD 
which present mitochondrial dysfunction. The knockout is generated by crossing knock-in Cre 
recombinase (DAT promoter driven) mice with mice expressing a loxP flanked TFAM gene. This 
allows the conditional deletion of the TFAM gene in cells expressing DAT, resulting in the 
inhibition of the respiratory chain (Ekstrand et al., 2009). The phenotype presents a slow 
progressive loss of BG dopaminergic neurones resulting in reduced striatal DA content and 
typical motor impairments. Intraneuronal LB-like inclusions can also be found. Moreover, a 
recent study found MitoPark mice recapitulating typical MRI alterations found within the PD 
patient, such as ventricular volume and Fe accumulation (Cong et al., 2016). The construct and 
face validity of the model is significant as both PD pathogenesis and symptomatology are well 
represented. Despite this model not being widely available yet, it shows promise as a genetic 




1.13. General aims of this thesis  
As previously described there are two key unmet clinical needs in PD research, these are: 
facilitating the neurorepair and/or protection of the vulnerable SNc cells and understanding 
the mechanisms behind the LID phenomenon.  
This thesis has attempted to, firstly, investigate novel ways of providing neuroprotection and 
repair of the degenenerating SNc cells and, secondly, further identify the mechanism 
underlying LID. The broad aims and their reasoning are described below.  
1.13.1. Aims 
The CSPGs and PNNs have been considered inhibitory to cellular plasticity and regrowth 
following injury for many years in the spinal cord injury field. Since the early 2000’s, 
investigators in the field have utilised the ECM as a therapeutic target to induce motor 
recovery. Here we suggest that the CSPGs and PPNs may have significance in PD. 
Aim of Chapter 2: Examine the expression of CSPGs in the NS 
CSPGs may play a role in the NS and may therefore be responsible for the inhibition of 
axonal repair. However, little is known about these molecules in context of PD. In Chapter 2 
of this thesis, we aimed to perform preliminary studies to examine the expression of CSPGs 
in the NS in order to establish whether these molecules are likely to be useful targets in the 
treatment of PD. 
Aim of Chapter 3: Investigate the potential of ECM manipulation in the repair or protection 
of the SNc cells in a rodent model of PD 
Having confirmed their presence in relevant mouse brain regions, we aimed to investigate 
whether enzymatic digestion of the CSPGs and PNNs can induce restoration of the injured 
NS. A venture explored in the spinal cord injury field but not extensively within PD research. 
It would be of great interest to determine the efficacy of the strategy in both late stage (full) 




Aim of Chapter 4: Identify a method of enhancing NTF levels within the BG, and also 
whether enhanced NTF levels could induce repair or protection of the SNc cells in a rodent 
model of PD 
As described in 1.11.3., increasing the level and/or expression of NTFs, such as GDNF, in 
patients with PD has been of significant interest. Be it in animal or Man, no method has 
attempted to increase endogenous release of NTF within the damaged NS without the use 
of viral vector delivery; a technique which provides many safety considerations. We 
therefore aimed to identify whether the treatment of systemic NTF-release agents in the 
unilateral lesion 6-OHDA model increases cell survival. 
Aim of Chapter 5: Investigate the mechanism behind LID by identifying any cellular changes 
which occur within the dyskinetic striatum 
The mechanism behind LID has not yet been identified. Current theories indicate aberrant 
plastic changes that occur in the striatum and the corticostriatal pathway. In order to 
attempt to counter the effects of LID, further investigations into its manifestation are 
required. We therefore aimed to identify any gross striatal changes via neuroimaging and 












2. Investigating the distribution of chondroitin sulphate 
proteoglycans in the mouse basal ganglia 
2.1. Introduction 
2.1.1. Chondroitin sulphate proteoglycans as therapeutic targets 
The chondroitin sulphate proteoglycans (CSPGs) are a key focus of this thesis. As these 
extracellular matrix (ECM) molecules have been described as modulators of plasticity, we 
wished to target the CSPGs for cellular repair and protection strategies.  
As briefly described in the general introduction, CSPGs are considered inhibitory to axonal 
growth through means not fully known (see Chapter 3 for two main theories). Despite this, 
their removal is well established as being beneficial to growth following injury to the CNS 
(Bradbury et al., 2002). These CSPGs can crosslink around the cell soma to form perineuronal 
nets (PNNs); pericellular formations which have been described as key regulators of plasticity 
within the neonate and developing systems (Wang et al., 2012a). CNS injury has been 
identified to induce CSPG deposition in an attempt to, presumably, limit damage to the 
surrounding tissues. This process has been seen to inhibit any recovery in the long term (Fitch 
et al., 1997; Moon et al., 2002).  
CSPGs are interesting targets for novel PD therapeutic strategies, as they are considered 
inhibitory to growth as well as regulators of plasticity. However, before assessing the efficacy of 
CSPG removal in a model of PD, we must first characterise the CSPGs within the mouse through 
immunohistochemical means. This will help identify which CSPGs may have relevance to PD 










Both GAGα and GAGβ in core; the largest versican isoform
Only the smaller GAGα in core
Only the larger GAGβ in core
Neither in core; smallest versican isoform
2.1.2. The distribution of CSPGs in the mammalian CNS 
Certain CSPGs have been identified as being localised to particular CNS tissues in the past. 
Although not specific to the mouse BG, these studies have aided our understanding of CSPGs 
within the brain. The distribution and characteristics of several CSPGs in the mammalian CNS 
are described below. 
 Aggrecan 
Aggrecan is the most glycosylated member of the lectican family. It is expressed within both 
connective and neural tissues whilst also being an essential component in cartilage. However, 
its most interesting role in the ECM is within the PNN where it is required for the formation and 
function of its structure; aggrecan is required more than other CSPGs (Morawski et al., 2012). 
Aggrecan and the PNN are therefore in concert in controlling neuronal plasticity. As with the 
PNN, it is likely that aggrecan manipulation would be required for the reopening of the critical 
period (i.e. the period where stimulus driven neuronal plasticity causes the organisation of 
neuronal networks) to induce neuronal rewiring and growth. 
 Versican 
Versican remains a unique lectican as it has several core protein splice variants. Versican’s GAG 
binding region is encoded by two genes, GAGα and GAGβ. With these, versican can form four 











Versican is expressed in both the CNS and other regions, with the V2 variant being the most 
plentiful in neuronal tissues (Paulus et al., 1996). Interestingly, V2 versican has been found 
expressed by immature oligodendrocytes during development (Asher et al., 2002). This 
presents an interesting link between the inhibitory nature of both CSPGs and oligodendrocytes 
(which are recruited to CNS injury).  
Table 2: Isoforms of versican.  
Differential splicing of the two GAG region genes dictate the final isoform of 





Brevican is the smallest and least glycosylated lectican CSPG and is widely prevalent 
throughout the adult CNS. Brevican is expressed by immature oligodendrocytes and by 
astrocytic cells (Yamada et al., 1997a). Once again, this links the CSPGs to the glial cells of the 
CNS. 
Neurocan 
Neurocan is another lectican CSPG that is brain specific in its expression. Produced by 
oligodendrocyte progenitors, astrocytes and neurones (Asher et al., 2000; Meyer-Puttlitz et al., 
1996; Oohira et al., 1994), neurocan appears to have a relationship with glial and neuronal cells 
alike. 
 NG2 
Although not a member of the lectican family as the others before, NG2 is of interest due to its 
close relationship with the immune system. As described in the General Introduction (section 
1.11.4.1.), NG2 are transmembrane CSPGs which are predominantly expressed on the surface 
of oligodendrocyte progenitor cells. Interestingly, NG2 has been suggested to also associate 
with microglia whereby the colocalisation of microglial-specific markers and NG2 has been 
identified (Pouly et al., 1999). However, this is debated as a distinct difference in localisation 
has also been found (Levine, 1994). 
2.1.3. The ECM and the lectican CSPGs following birth 
It has been previously discussed that CSPGs and PNNs have significance in early development. 
However, their role in later life has not been fully identified. As idiopathic PD is an age-related 
disease, we must not forget that the distribution of CSPGs in the elderly may be different to the 
young adult used in many of these experiments. Therefore, it is of importance to understand 
the nature of CSPG expression (namely the lecticans) at this stage.  
In the days following birth, the ECM undergoes several changes in which CSPGs that are high in 
the neonate are slowly exchanged for an array of CSPGs found in the adult CNS. CSPGs in high 
expression during the neonate period are neurocan and the V0/V1 versican isoforms. These are 
then replaced by more typical adult CSPGs such as V2 versican, aggrecan and brevican (Milev et 
al., 1998). V2 versican and brevican presence is mostly found in white matter due to their 
association with oligodendrocytes and myelinated axons (Ogawa et al., 2001) and aggrecan 
presence is mostly associated with PNNs (Morawski et al., 2012). 







Aggrecan V0/V1and V2 versican
Brevican Neurocan























periods and the reduction in axonal plasticity as an attempt to lock down neuronal pathways. 
To further understand this switch, Milev et al. took whole brain extracts of rats of varying ages 
ranging from neonate (day 0) to adult (day 250) in order to assess the levels of lectican CSPGs 
present. Figure 7 adapts the data from that study to clearly show the changes occurring at 




















With these data clearly presenting alterations in ECM composition in the postnatal versus adult 
rodent brain it may be of benefit to look beyond 250 days. As PD is age-related, investigations 
of CSPG distributions in aged animals may reveal new insights in ECM-targeted therapies; novel 
agents may work differently in young adult and aged brains. Such differences would then need 
to be taken into account when either designing or interpreting the studies aimed towards the 
investigation of the therapeutic target potential of CSPGs in PD rodent models. 
 
 
Figure 8: Time course of CSPG expression in the rat from birth to adult.  
Neurocan and V0/V1 versican are both expressed to a high degree in neonatal rats. These levels 
start to decline as other lecticans are expressed more highly in the brain, such as aggrecan, V2 
versican and brevican. Pink regions highlight postnatal day 56 (8 weeks old); the common age 
of young adult animals used throughout this thesis. Plots are estimations based on data from 
(Milev et al., 1998). 
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2.1.4. Study rationale 
Although aggrecan-associated PNN expression has been previously mapped in the human BG 
(Bruckner et al., 2008), there has been no characterisation of PNNs and CSPGs within the 
mouse BG, specifically the SNc and striatum. Therefore, before proceeding with large 
investigative studies that manipulate the ECM, we first set out to confirm the presence of at 
least one type of CSPG within the mouse BG. In particular, we were keen to identify which 
CSPGs were present in the mouse SNc. Preliminary investigations saw very weak staining for 
both brevican and neurocan in the adult mouse BG (which was not possible to image in thin 
paraffin embedded sections), for these reasons, these two CSPGs were not investigated further. 
However, the expression of aggrecan, versican and NG2 were examined. 
In addition to identifying specific CSPGs, we wished to investigate the localisation of PNNs 
within the mouse SNc. PNN expression has been shown to be devoid in the dopaminergic 
systems of the human BG (Bruckner et al., 2008). We wished to investigate whether this was 
also the case within the naive mouse. If so, a lack of PNNs within the SNc region may explain 
the enhanced neuronal susceptibility the cells possess to ROS and other means of 
degeneration. 
Finally, as PD is an age-related disease we wished to investigate the expression of certain CSPGs 
within the young adult and aged mouse brain. Such comparisons may explain the 
pathophysiology of ageing. It would also determine whether CSPGs are appropriate targets in 





2.2. Aims and Hypotheses  
This chapter presents two brief investigations into the distribution of CSPGs within the naive 
mouse BG. The first study was a qualitative investigation of aggrecan, versican (all isotypes due 
to selectivity of the antibody used), NG2 and PNN expression within the naive mouse SNc.  
The final study, investigated the expression of aggrecan, CS56 (pan intact CS-GAG antibody) 
and tyrosine hydroxylase (TH) in the young adult (8 weeks old) compared to the aged mouse 
(18 months old). The aims and hypotheses for these studies are described below. 
Study aims: 
1. Investigate whether there is expression of aggrecan, versican and NG2 in the adult 
mouse SNc and surrounding regions. Which CSPGs may be worthwhile investigating in 
later studies? 
 
2. Determine whether PNNs are found associated with the dopaminergic cells of the 
mouse SNc 
 
3. Investigate whether age is a factor in the expression of aggrecan, CS56 and/or TH in the 
naive aged (18 months old) and young adult (8 weeks old) mouse 
Study hypotheses: 
1. The adult mouse expresses aggrecan, versican and NG2 in the SNc and surrounding 
regions. All three CSPGs are worth investigating in later investigations.   
 
2. PNNs are found not to be associated with the dopaminergic cells of the SNc 
 
3. The expression of aggrecan, CS56 and TH is not different in the naive aged (18 months 






2.3. Materials and Methods 
2.3.1. Investigative study 1: Identifying CSPGs and perineuronal nets within 
the naive mouse SNc 
 2.3.1.1. Naive mouse tissue used  
6 formalin perfused fixed brains from eight-week-old male C57Bl/6 mice (Harlan, UK) were 
used in this study; courtesy of Dr Martin Broadstock. 
3 formalin perfused fixed brains were used for CSPG identification, these were previously 
embedded in paraffin wax and ready to be sectioned. The remaining 3 perfused fixed brains 
were to be embedded in gelatin and sectioned for PNN identification. Gelatin embedding was 
conducted on these 3 brains to obtain thicker sections which were required to identify the 
diffuse PNN structure. 
 2.3.1.2. Sectioning of the paraffin embedded brains 
The 3 paraffin embedded brains containing the SNc were sectioned (7 µm thick sections) with a 
microtome (Thermo Scientific) at three rostrocaudal levels of the SNc (rostral: -2.92 mm, 
medial: -3.16 mm and caudal: -3.52 anteroposterior [AP] mm; relative to bregma). Sections 
were then mounted on Poly-L-lysine coated slides (VWR Int.; 4 sections per slide) before being 
stored at 60°C over night.   
2.3.1.3. CSPG staining in paraffin embedded naive SNc sections 
Coronal sections were deparaffinised (2x 5 minutes in xylene before 4x 2 minutes in 100% 
methanol immersions). 3% H2O2 (10 minutes) immersion allowed the quenching of endogenous 
peroxidases before sections were boiled within a 1 mM citric acid antigen retrieval solution (pH 
6) for 10 minutes. Blocking solution (1% bovine serum albumin [BSA] in 0.05M Tris buffered 
saline (TBS) with 1% sodium azide, pH 7.6) was applied to the sections (10 minutes) prior to the 
24 hour incubation with either aggrecan, NG2 or versican primary antibody (see Table 3 for 
dilutions). A biotinylated anti-rabbit IgG secondary antibody (see Table 3) was applied before a 
final incubation with the streptavidin-biotinylated horseradish peroxidase conjugate 
(VectorLabs PK6100 Vectastain Elite ABC kit) for 30 minutes at room temperature. Slides were 
immersed in diaminobenzidine tetrachloride (DAB) developing buffer (10% DAB in 200 ml 0.1M 
TBS with 0.03% H2O2, pH 7.6) for 10 minutes. Finally, sections were rinsed thoroughly in 
distilled H2O for 10 minutes to remove any traces of DAB, dehydrated in 100% methanol (4x 2 
minutes immersions) and cleared in xylene (2x 5 minute immersions). Sections were mounted 




Type Antigen Host Dilution Supplier
Primary CSPG core protein Rabbit; polyclonal 1 in 200 ab36861; Abcam
Primary CSPG core protein Rabbit; monoclonal 1 in 200 ab177480; Abcam
Primary Tyrosine hydroxylase Rabbit; polyclonal 1 in 500 AB152; Millipore
Primary CSPG core protein Rabbit; polyclonal 1 in 200 ab5320; Abcam
biotinylated Wisteria floribunda  agglutinin Primary PNNs Plant agglutinin 1 in 500 L1516; Sigma Aldrich
Alexa Fluor 546 Secondary rabbit primary ABs Goat IgG (H + L) 1 in 200 A-11035; Invitrogen
ExtrAvidin-FITC Secondary conjugates with biotin Egg white avidin 1 in 200 E2761; Sigma Aldrich








 2.3.1.4. Gelatin embedding  
 
The 3 remaining perfused fixed brains were submerged within cryoprotectant (30% sucrose, 
0.01% Sodium Azide in PBS) until sunk. Tissue was then set within gelatin (10% porcine skin 
type A gelatin in 0.1 M PBS) then further post fixed in 10% buffered (pH 7.4) formalin for 8 
hours. The set gelatin block was trimmed and frozen on a freezing sledge microtome. A series 
of 40 μm parasagittal sections of the SNc were then taken and stored as free-floating sections 
within PBS at 4°C.  
 2.3.1.5. bWFA and TH fluorescence staining of PNNs and SNc cells on free 
 floating sections  
Parasaggital sections (which contained the SNc: +0.96 mm mediolateral [ML]; relative to 
bregma) were washed in TBS (3x 5 minutes) before a blocking solution (3% normal goat serum 
(NGS)) was added for 1 hour at room temperature. The TH primary antibody and biotinylated 
WFA (see Table 3) were left to incubate with the sections overnight at room temperature. 
After TBS washes (3x 5 minutes) Alexa Fluor 546 (see Table 3) was applied for 3 hours at room 
temperature. ExtrAvidin-FITC (see Table 3) was then administered with DAPI (1 μg/ml) for 2 
hours. Vectorshield (VectorLabs) was then used to mount coverslips onto the sections; nail 
polish was used around the edges of the slide to stop the section from drying out.  
 
2.3.1.6. Image analysis 
CSPG expression images of the SNc were imaged at 5X magnification (Axioskop, light-field 
compact microscope). TH and bWFA fluorescently labelled parasaggital SNc sections were 
imaged using a wide field fluorescence microscope (Zeiss) and Axiovision software at 20X 
magnification. 
Digital TIFF format images were equilibrated in Adobe Photoshop CS5 in order to create the 
background uniform in terms of brightness and contrast.  
No analysis was performed in the first investigative study, as this was purely a qualitative 
venture to identify whether particular CSPGs were present in the mouse SNc.  
Table 3: Investigative Study 1: Antibodies used for immunohistochemistry.  
The following antibodies were used at their described dilutions and according to the histology 




2.3.2. Investigative study 2: Comparing TH and CSPG distribution within the 
young and aged mouse 
 2.3.2.1. Naive young adult and aged mouse tissue  
5 perfused fixed brains from eight-week-old and 5 perfused fixed brains from eighteen-month-
old male C57Bl/6 mice (Harlan, UK) were used; courtesy of Dr Martin Broadstock.  
The perfused fixed brains were previously embedded in paraffin wax and were ready to be 
sectioned. Sectioning was conducted as described in section 2.3.1.2. Sections of the three 
rostrocaudal levels of the SNc (rostral: -2.92 mm, medial: -3.16 mm and caudal: -3.52 AP mm; 
relative to bregma) and the striatum (rostral: +1.0 mm, medial: +0.5 mm and caudal: -0.22 AP 
mm; relative to bregma) were taken. 
2.3.2.2. Tyrosine hydroxylase and CSPG staining in the young adult and 
aged mouse SNc and striatum 
Coronal sections were deparaffinised (2x 5 minutes in xylene before 4x 2 minutes in 100% 
methanol immersions). 3% H2O2 (10 minutes) immersion allowed the quenching of endogenous 
peroxidises before sections were boiled within a 1 mM citric acid antigen retrieval solution (pH 
6) for 10 minutes. Blocking solution (1% bovine serum albumin [BSA] in 0.05M Tris buffered 
saline (TBS) with 1% sodium azide, pH 7.6) was applied to the sections (10 minutes) prior to the 
24 hour incubation with either aggrecan, CS56 or TH primary antibody (see Table 4 for 
dilutions). A biotinylated anti-rabbit IgG or biotinylated anti-mouse IgG secondary antibody 
(see Table 4) was applied (depending on the host of the primary antibody) before a final 
incubation with the streptavidin-biotinylated horseradish peroxidase conjugate (VectorLabs 
PK6100 Vectastain Elite ABC kit) for 30 minutes at room temperature. Slides were immersed in 
diaminobenzidine tetrachloride (DAB) developing buffer (10% DAB in 200 ml 0.1M TBS with 
0.03% H2O2, pH 7.6) for 10 minutes. Finally, sections were rinsed thoroughly in distilled H2O for 
10 minutes to remove any traces of DAB, dehydrated in 100% methanol (4x 2 minutes 
immersions) and cleared in xylene (2x 5 minute immersions). Sections were mounted with 




Type Antigen Host Dilution Supplier
Primary Protein core protein Rabbit; polyclonal 1 in 200 ab36861; Sigma Aldrich
Primary Intact CS-GAGs Mouse; monoclonal 1 in 1000 ab11570; Sigma Aldrich
Primary Tyrosine hydroxylase Rabbit; polyclonal 1 in 500 AB152; Millipore
Secondary rabbit primary ABs Goat IgG (H + L) 1 in 200 BA1000; Vector Labs








2.3.2.3. Image analysis of CSPG and TH presence in young adult and 
aged striatum 
Densitometry images for the immunohistochemistry markers were acquired with a Canon DSLR 
camera with a macro lens. Digital TIFF format images from all treatment groups were 
equilibrated in Adobe Photoshop CS5 in order to create the background uniform in terms of 
brightness and contrast. ImageJ (publically available: National Institutes of Health) was used to 
measure the optical densities of CSPG and TH stain within the striatum.  
6 sections per marker were used across the rostrocaudal axis per animal (two caudal, two 
medial and two rostral striatum). Using the freehand tool in ImageJ, the dorsal or ventral 
striata were selected and their optical densities obtained (both the left and right hemispheres 
were analysed and averaged). Each optical density at each rostrocaudal level was then 
averaged to create a representative degree of expression throughout either the dorsal or the 
ventral striatum. These results were then averaged across all animals in their respective groups. 
This gave a representative optical density for the marker in either the dorsal or ventral striatum 
of either the young adult or aged mice. 
2.3.2.4. Image analysis of CSPG presence in young adult and aged SNc 
SNc densitometry images for the immunohistochemistry markers were obtained as described 
above in section 2.3.2.3. 
6 sections per marker were used across the rostrocaudal axis per animal (two caudal, two 
medial and two rostral SNc). Using the freehand tool in ImageJ, the SNc was selected and its 
optical density obtained (both the left and right hemispheres were analysed and averaged). 
Each optical density at each rostrocaudal level was then averaged to create a representative 
degree of expression throughout the SNc. These results were then averaged across all animals 
in their respective groups. This gave a representative optical density for the marker in the SNc 
of either the young adult or aged mice. 
  
Table 4: Investigative Study 2: Antibodies used for immunohistochemistry.  
The following antibodies were used at their described dilutions and according to the histology 




2.3.2.5. Assessment of the number of TH-positive SNc cells within the 
aged and young adult naive mouse brain 
TH-positive cells were imaged at 10X magnification (Axioskop, light-field compact microscope). 
Digital TIFF format images from all treatment groups were equilibrated in Adobe Photoshop 
CS5 in order to create the background uniform in terms of brightness and contrast. ImageJ 
(publically available: National Institutes of Health) was used to count the TH-positive cells. 
Triplicate sections (three sequential sections) were taken at each of three different levels of the 
SNc (rostral: -2.92 mm, medial: -3.16 mm and caudal: -3.52 mm; AP axis relative to bregma) for 
each animal. SNc cell counts from the two hemispheres were then averaged. Only TH-positive 
cells from the SNc were counted, VTA TH-positive cells were omitted as these do not form part 
of the basal ganglia motor circuitry. Counts for the triplicate sections were further averaged to 
give an average count of SNc cells within a hemisphere for each SNc level. A final mean for 
each animal was obtained by averaging the values of the three levels. Mean SNc counts for the 
aged and young adult mice were then calculated. 
2.3.3. Statistical analyses 
All statistical analyses within this chapter were conducted with the SigmaPlot 12 package; 
statistical tests used are displayed within the figure legends. Graphpad Prism 5 was used to plot 
all graphs. GPower 3.1 was utilised for power calculations. 
For all immunohistochemical density comparisons within the striatum the Two-way ANOVA and 
Bonferroni post hoc test was used. For all immunohistochemical density comparisons within 






2.4.1. CSPGs are expressed within the mouse SNc 
To investigate the expression of CSPGs within the mouse SNc, we immunohistochemically 
stained for the CSPG core proteins aggrecan, NG2 and versican. Analyses were those of a 
qualitative nature, therefore, we only wished to confirm the presence of these CSPGs whilst 
observing regions of high expression. No statistical testing was conducted. All patterns found 
were consistent across all three animals. 
Aggrecan presented high levels of expression in the SNc when compared to the expression of 
NG2 (figure 8A). The stain represented the disperse nature of CSPGs within the diffuse matrix. 
No distinct PNN formations can be seen (the PNN structure will be explained more fully in 
figure 9). Expression seems uniform across the section with a slight increase in the ventral 
midbrain and cortical regions (i.e. visual cortex [V1]) and lowered expression in white matter 
regions such as the cingulate cortex (Cg). 
NG2 presented very little expression within the SNc and surrounding areas (figure 8B). Imaging 
for this CSPG core protein proved very difficult to image due to the highly diffuse staining. 
Although higher expression can be found in the medial mammillary nucleus (MM), NG2 is not 
greatly expressed in the naive mouse BG. 
Versican, as with aggrecan, presented high levels of expression within the mouse SNc (figure 
8C). Regions of most positivity were in the cortex, such as the visual and the neighbouring 
retrosplenial granular cortex (RSG), and the ventral midbrain regions, such as the SNc and SNr. 


















   
Figure 9: CSPG expression within the naive mouse SNc.  
Images taken at 5X magnification from coronal sections of the mouse SNc indicate the 
presence of aggrecan, NG2 and versican. Images are representative of all three animals. 20X 
magnification insert images focus on the region of the SNc itself (black dashed line)(A) 
Aggrecan expression within the SNc is high. (B) NG2 is not highly expressed within the mouse 
SNc. (C) Versican expresses highly within the mouse SNc. Cg = cingulate cortex, MM = medial 
mammillary nucleus, RSG = retrosplenial granular cortex, SNc = substantia nigra pars 




2.4.2. Perineuronal nets do not surround cells of the mouse SNc 
Although previous investigations have confirmed the absence of PNNs within the human SNc, 
we wished to use immunofluorescent techniques to determine whether this was conserved in 
the mouse as well. A similar result would support the translatability from the mouse ECM to 
the human. Representative images of the PNN distributions in the SNc are shown below. These 
patterns were seen across all three mice.  
Parasaggital sections, containing the SNc of naive mice, were stained for TH and PNN presence 
using the anti-TH antibody and biotinylated Wisteria floribunda agglutinin (bWFA; a classical 
marker for PNNs). bWFA staining alone indicated a channel of PNN absence within the SNc 
(figure 9A). PNNs, as depicted by the higher magnification inset image in Panel A, can be clearly 
found in the regions surrounding the SNc such as the SNr (ventral to the SNc) and the VTA 
(dorsal to the SNc). The channel of PNN absence can be found to house the dopaminergic TH-
positive cells of the SNc (figure 9B) 
 
Figure 10: PNNs are absent within the SNc.  
(A) Representative fluorescent images taken from parasagittal sections of the mouse SNc 
indicate the absence of PNNs (green; biotinylated Wisteria floribunda agglutinin antibody 
[bWFA]) in the SNc (red; tyrosine hydroxylase). Inset image displays the typical structure of a 
PNN; inset scale bar = 25 μm. (B) TH clearly marks the SNc that resides within the PNN-absent 









2.4.3. Aggrecan and CS56 distribution is enhanced within the SNc and 
striatum of the aged mouse 
To examine whether young adult mice (8 weeks old) possessed different CSPG expressions to 
that of the aged mice (18 months old), we stained for aggrecan and the pan-marker for CS-
GAGs, CS56. All images below are taken from the medial SNc (-3.16 mm AP; relative to bregma) 
or medial striatum (+0.5 mm AP; relative to bregma). Quantification is shown for all 
rostrocaudal levels combined as there were no differences in expression patterns at the three 
rostrocaudal levels. 
Overall, aggrecan had a diffuse staining pattern throughout regions of the rostrocaudal axis. In 
particular, the SNc appeared to have higher staining in the aged animals compared to the 
young adults, as evident in figure 10A + B. Quantification confirmed this difference as 
significant. Aggrecan had a higher degree of optical density within the aged SNc (0.184 ± 





















































































































































































































































Figure 11: Aggrecan expression within the aged and young adult mouse SNc. 
(A + B) Representative coronal medial SNc sections stained for aggrecan from an aged and 
young adult mouse, respectively. Dashed line corresponds to the area of SNc taken for optical 
density readings. Scale bar = 1 mm. (C) Data represent the averaged optical densities of the 
SNc across all three levels. Student's t-test; *** denotes p<0.001. Scale bar = 1 mm. Young 







































































































































































































































































































As with the previous SNc stain, the diffuse staining of aggrecan was apparent throughout the 
rostrocaudal axis of the striatum. Although difficult to see by eye in figure 11A + B below, 
aggrecan was also found to be significantly higher in the dorsal striatum of the aged mouse 
(0.18 ± 0.0003) when compared to the equivalent striatal hemisphere in the young adult 
mouse (0.172 ± 0.004; p<0.05; Two-way ANOVA with Bonferroni post hoc; figure 11C). There 





Figure 12: Aggrecan expression within the aged and young adult mouse striatum.  
(A + B) Representative coronal medial striatal sections stained for aggrecan from an aged and 
young adult mouse, respectively. Dashed line corresponds to the striatum taken for optical 
density readings. The top region of the striatum is the dorsal striatum whereas the bottom 
region of the striatum is the ventral striatum. Scale bar = 1 mm. (C) Data represent the 
averaged optical densities of the dorsal and ventral striatum across all three levels. Two-way 
ANOVA with Bonferroni post hoc test; * denotes p<0.05 between the dorsal striata of the aged 




















































































































































































































The pan-marker for intact CS-GAGs, CS56, was diffusely stained throughout the rostrocaudal 
axis. However, unlike aggrecan, CS56 expression was topographical. Darker staining was 
apparent in regions of white matter and the ventral midbrain. It was apparent that CS56 
expression was enhanced in the retrosplenial granular cortex (RSG) in the aged animals when 
visually compared to the young adult (no statistical testing was conducted; figure 12A + B). 
CS56 was expressed at a significantly higher level in the aged mouse SNc (0.226 ± 0.002) to that 





Figure 13: CS56 expression within the aged and young adult mouse SNc. 
(A + B) Representative coronal medial SNc sections stained for CS56 from an aged and young 
adult mouse, respectively. Dashed line corresponds to the area of SNc taken for optical density 
readings. RSG = retrosplenial granular cortex. (C) Data represent the averaged optical densities 
of the SNc across all three levels. Student's t-test; * denotes p<0.05. Scale bar = 1 mm. Young 
adult: n=5, aged: n=5. Data are mean ± S.E.M. AU = arbitrary units. 
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Striatal expression of CS56 was topographical, with some regions of the rostrocaudal striatum 
being more stained than others. CS56 was specific to striosomes and white matter tracts within 
the sections (no statistical testing was conducted). CS56 expression within the cortex appeared 
to be raised in the aged mouse when compared to the young adult (no statistical testing was 
conducted) (figure 13A + B).  
The degree of CS56 expression was not significantly different within either the dorsal or ventral 
striatum of the aged (dorsal: 0.203 ± 0.004, ventral: 0.199 ± 0.004) or young adult mice (dorsal: 
































































































































































































































Figure 14: CS56 expression within the aged and young adult mouse striatum. 
(A + B) Representative coronal medial striatal sections stained for CS56 from an aged and 
young adult mouse, respectively. Dashed line corresponds to the striatum taken for optical 
density readings. The top region of the striatum is the dorsal striatum whereas the bottom 
region of the striatum is the ventral striatum. (C) Data represent the averaged optical densities 
of the dorsal and ventral striatum across all three levels. Scale bar = 1 mm.  Young adult: n=5, 


















































































































































































2.4.4. TH-positive SNc cells were seen to decrease whereas striatal TH-
positive fibres were found to increase 
TH staining was found to mark the cells of both the SNc and the VTA. Only the TH-positive SNc 
cells were counted, these cells are ringed in figure 14A + B. Data in figure 14C display the 
average count of TH-positive cells in one hemisphere of SNc across all rostrocaudal levels.  
The average number of TH-positive cells in one hemisphere of the aged mouse SNc (57 ± 4.5 
cells; figure 14C) was significantly lower to that found in the young adult (92.5 ± 4.6 cells; 





Figure 15: TH-positive SNc cells in the aged and young adult mouse. 
(A + B) Representative coronal medial SNc sections stained for TH from an aged and young 
adult mouse, respectively. Dashed line corresponds to the SNc in which only the A9 
dopaminergic cells were counted. (C) Data represent the averaged number of TH-positive cells 
within one hemisphere of SNc across all three levels. Student's t-test; *** denotes p<0.001. 




TH density was significantly elavated within the aged striatum compared to the young adult in 
both the dorsal (young adult: 0.024 ± 0.0001 and aged: 0.032 ± 0.0001; p<0.001; Two-way 
ANOVA with Bonferroni post hoc test) and ventral (young adult: 0.024 ± 0.0001 and aged: 
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Figure 16: TH-positive striatal fibres within the aged and young adult mouse striatum.  
(A + B) Representative coronal medial striatal sections stained for TH from an aged and young 
adult mouse, respectively. Dashed line corresponds to the striatum taken for optical density 
readings. The top region of the striatum is the dorsal striatum whereas the bottom region of 
the striatum is the ventral striatum. (C) Data represent the averaged optical densities of the 
dorsal and ventral striatum across all three levels. Two-way ANOVA with Bonferroni post hoc 
test; *** denotes p<0.001 Scale bar = 1 mm.  Young adult: n=5, aged: n=5. Data are mean ± 




2.5.1. Aggrecan and versican were found expressed highly in the naive mouse 
SNc 
The purpose of this small investigative study was to determine whether the naive mouse would 
express particular CSPGs within the SNc. Unfortunately, due to the availability of certain brain 
sections, only the SNc was tested and not other PD relevant regions such as the striatum.  
Aggrecan and versican were both found to have high positivity within the ventral regions of the 
midbrain where the SNc could be found. When comparing the expression of these lecticans to 
the data by Milev et al (Milev et al., 1998) (see figure 7 for graphical representations), we see a 
close relationship with aggrecan and versican expression increasing 8 weeks postnatally. It is 
likely that our versican stain depicts the increase in V2 versican and not the neonatal V1 and V0, 
as depicted by the aforemention plots in figure 7. We cannot distinguish between isoforms as 
the antibody used was a pan-versican marker. 
Unfortunately, unlike aggrecan and versican, NG2 did not express highly in any region of these 
sections; the MM being the only exception. Nevertheless, there is some global diffuse staining 
within the mouse brain. As the CSPG NG2 is strongly associated with resident glia of the brain 
(i.e. oligodendrocyte progenitors and potentially microglia), this CSPG is most likely at a low 
level of expression due to no local injury or region of neuroinflammation. Perhaps NG2 optical 
density would increase significantly if it were investigated in tissue from toxin mouse models 
(possessing regions of inflammation and injury). However, NG2 has been described as transient 
even in these injured states (Morgenstern et al., 2002). This transient nature may be due to the 
expression of NG2 correlating with the oligodendrocyte progenitors recruited to the site of 
injury and not with the glia they eventually mature into. 
Since we could not detect any notable staining of neurocan or brevican positivity within the 
adult mouse, these two lecticans were not included in this chapter. The absence of neurocan 
positivity can be explained by the decreased presence of this CSPG following birth (figure 7). 
However the absence of brevican does not follow the work by Milev et al. According to the 
study, brevican expression should increase following birth. This may be a fault of the antibodies 
used or, more likely, it is because brevican is closely associated with oligodendrocytes 




As only aggrecan and versican were detected within the SNc in high levels, only these two 
CSPGs shall be used in the future to detect levels of CSPG expression within the mouse BG. 
However, this does not support our initial hypotheses as these were the only CSPGs robustly 
expressed within the SNc. 
2.5.2. Perineuronal nets were not associated with the SNc dopaminergic 
neurones  
The PNN staining indicated that the pericellular formations were specific to particular cell types 
and that no association between PNN and TH-positive SNc cells were found; supporting our 
hypothesis. The presence of PNNs in anatomically neighbouring regions to the SNc, such as the 
GABAergic SNr, suggests that, as found by Bruckner et al., 2008, PNNs may exclusively associate 
with GABAergic regions. Furthermore, according to that study’s data, PNNs were not found 
associated with glutamatergic cells of the pedunculopontine nucleus or the ventral lateral 
nucleus. This indicated that PNNs might only associate with the inhibitory nuclei of the BG. 
The absence of PNNs in the SNc raises the question of whether these pericellular formations 
are actually protective. It has been suggested that alterations in the ECM may help protect 
neurones against oxidative stress, environmental stress and ageing (Cabungcal et al., 2013; 
Morawski et al., 2004; Suttkus et al., 2014). Furthermore, there is evidence suggesting that 
regions of numerous PNN-associated neurones present low/no tau pathology in tissue from 
patients with Alzheimer’s disease (Bruckner et al., 1999), furthering this theory that CSPGs 
enforce a protective state. However, the obvious question arises - If CSPGs are protective, why 
does their digestion give rise to axonal sprouting and growth? This conflict between the pro-
growth versus inhibitory argument is not yet understood. Perhaps their absence in the SNc is a 
contributor to cell vulnerability. On the other hand, it is possible that as PNNs are in 
neighbouring regions they are still able to protect and secrete beneficial molecules to the SNc 
cells. 
2.5.3. Age may be a significant factor of CSPG distribution in the naive mouse 
As aggrecan was detected within the human BG (Bruckner et al., 2008), it was of interest to 
investigate whether age was a factor to its distribution. Additionally, to understand the degree 
of CS-GAG expression within these tissues, the CS56 marker was also used. We were also 
interested to analyse any alterations in TH-positive SNc cell or striatal fibre presence between 
the different ages of these animals.   
Our results suggest that the aged mouse presented higher levels of aggrecan in both the SNc 
and striatum to that of the young adult mouse. This correlated to an increase in CS56 
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expression in the aged SNc but not the striatum. Although thought to stabilise following birth, 
both aggrecan and CS-GAG presence is enhanced beyond the level seen in the young adult. But 
this increase is predictable when taking the work of Milev et al. into account. As the degree of 
aggrecan expression in the young adult mouse (see figure 7; pink region) is found on the 
exponential rise of the sigmoidal curve, the final stabilised expression of the CSPG is likely to be 
higher in the aged animals. Although not investigated by Milev et al., CS56 would likely follow 
the same expression to aggrecan as the CS-GAGs would be expressed most prevalently on the 
aggrecan core proteins (aggrecan is the most glycosylated lectican). 
This indicates a potential issue with many models used in ECM-targeted therapies for age-
related diseases. As many studies utilise animals that are young adults, the results obtained 
may not translate well to the elderly patient, as age may be a factor in the success of that 
therapy. Thus, using an aged model of disease may produce results that reflect those found in 
an aged ECM environment, such as those in age-related diseases. Despite this, these changes in 
expression were still considerably small and would likely not affect ECM-targeted therapies. In 
fact, these data show that CSPG expression is still present to a similar, albeit slightly higher, 
degree to those of the young adult. This result is positive and validates the use of the younger 
mice. If CSPGs were not expressed within the aged tissue then their use as a therapeutic target 
in an age-related disease would be lost.  
2.5.4. In the aged naive mouse the number of TH-positive SNc cells declined 
but TH-positive fibre density in the striatum increased 
It was also of interest to investigate whether age was a factor in total SNc cell number and total 
TH-positive fibres in the striatum; these are both factors suggested to decrease with age.  
Perhaps a loss in cells or fibres could correlate to CSPG upregulation. 
Within our small sample it was apparent that the number of cells drastically declined with age, 
with the young adult revealing a similar count of SNc cells (80 – 100 cells per hemisphere) to 
previously published data (Heuer et al., 2012). This result followed previous beliefs that age 
reduced SNc cell numbers within mammalian models (Surmeier et al., 2010). Age-related cell 
loss is thought to be due to several factors, reduced UPS activity (Tai et al., 2008), toxin 
susceptibility (McCormack et al., 2004) and ROS accumulation from the enhanced metabolic 
rate of the SNc cell (Wallace, 2005). Perhaps in subsequent studies investigating markers of 
these age-related factors in the aged mouse would be of interest. 
On the other hand, TH-positive fibre optical densities were found to be significantly higher in 
the age mouse striatum to that of the young adult. This result was somewhat surprising, as a 
decrease in SNc cell counts would usually be predictive of a loss in striatal TH-positive 
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terminals; a similar pattern to what is found in PD itself and its related toxin models. This 
phenomenon has not been documented before and is possibly a false positive due to a low 
sample size. However if true, this suggests that the remaining cells in the aged SNc are inducing 
compensatory TH-positive terminal sprouting. This plasticity could be an attempt to output a 
similar concentration of striatal DA to that of a young adult. Perhaps this is a form of repair 
countering the effects of natural SNc cell loss in aged mice. This deserves future investigation, 
whereby an increased sample size alongside assessments of DAT expression would be required. 
However, the effects of ageing are outwith the main aims of this thesis.  
2.5.5. Chapter conclusions 
Overall, the investigative studies in this chapter have answered several important questions. 
The mouse BG does express aggrecan and versican but other CSPGs such as NG2, brevican and 
neurocan display little to no positivity. With brevican as the only exception, these expressions 
were expected when taking the work of Milev et al. into consideration.   
As described within the human BG, PNNs are not associated with the SNc. This raises more 
questions about the function of the PNN. Is their absence an additional reason to the SNc's 
susceptibility of cell degeneration? 
Finally, age may be a significant factor in the expression of aggrecan and therefore potentially 
the rest of the lectican family. Although it is well known that CSPGs express differently in the 
neonate and during development to the adult, it was not clear whether this was found within 
the aged animal as well. We discovered that both aggrecan and CS56 were expressed within 
the aged mouse striatum and that they were slightly raised above the levels detected in the 
young adult. This ultimately justified the use of young adult mice in future studies as similar 





3. Investigating the effect of CSPG digestion within the 
nigrostriatal tract of the partial and fully lesioned 
hemiparkinsonian mouse model 
3.1. Introduction 
3.1.1. CSPGs and perineuronal nets within the human basal ganglia  
CSPGs are conserved in the mammalian CNS where they reside in the PNN and diffuse ECM 
surrounding a range of varying neuronal networks, one of which being the BG (Bruckner et al., 
2008; Deepa et al., 2006). In Chapter 2, we showed how CSPGs are expressed in key mouse 
brain regions affected in PD and how in aged tissue certain CSPGs were not only present but 
also increased beyond what was found in the young adult mice. ECM-related therapies have 
been investigated as methods of neuronal repair, primarily in the spinal cord injury field. This 
chapter investigates whether an ECM-related therapy can be developed for PD. 
The aforementioned Bruckner et al., 2008 paper analysed ECM components within various 
areas of the BG. It was found that PNNs, key regulators of neuronal plasticity, surrounded the 
GABAergic projection neurons of the GPi/SNr and the GABAergic fast spiking interneurones of 
the striatum but not of the dopaminergic cells of the SNc. This finding was confirmed in the 
histological studies of Chapter 2. This cell selectivity raised several questions in regards to the 
PNN’s true function within the BG. Firstly, are PNNs beneficial for cation buffering? If so, does 
their absence in the SNc increase cell vulnerability? Secondly, are PNNs, which are in close 
proximity to the SNc, somehow inhibitory towards intrinsic recovery methods in PD? It is 
interesting to note that only healthy human brains have been analysed for PNN presence, 
therefore it is possible that PD patients possess altered PNN and CSPG distributions or 
structures that could affect disease state. Although we tried to investigate this in Chapter 2, the 
quality of tissue led to inadequate staining therefore this shall remain unclear. 
Although there is evidence indicating the presence of CSPGs in the human BG, there is little 
data to suggest that CSPGs have a role in the disease. Only one study suggests that CSPGs may 
have a function within PD. Utilising an antibody for CS-GAGs it was discovered that CSPGs were 
retained in high concentrations within LBs (DeWitt et al., 1994). The specific role of these LB-




3.1.2. The inhibitory nature of CSPGs and perineuronal nets 
CSPGs within the PNN have been widely accepted as inhibitory to axon growth and neuronal 
repair; as of yet there is no agreed upon mechanism of inhibition. Multiple theories have 
attempted to explain the inhibitory nature of the PNN and to why its digestion leads to axon 
sprouting within injured models. Two of the most significant theories have been described 
below (see (Wang et al., 2012a) for a comprehensive review): 
 The PNN may simply act as a physical barrier to growth, in which new cellular 
contacts and advancing filopodia are inhibited (Asher et al., 2000; Oohira et al., 
1991). Being a dense ECM lattice, the digestion of the CS-GAGs may enable the 
forming of new cell contacts and reduce inhibitory CSPG-receptor interactions. To 
date, three receptors have been discovered to interact with CSPGs, these are: 
receptor protein tyrosine phosphatase sigma (Shen et al., 2009), contactin-1 (Mikami 
et al., 2009) and leukocyte common antigen-related phophatase (Fisher et al., 2011). 
Genetic and pharmacological inhibition of the Rho/ROCK and PKC signalling pathways 
have overturned the inhibitory nature of the CSPGs, indicating the role these 
cascades may have in blocking axonal regeneration (Monnier et al., 2003) 
(Sivasankaran et al., 2004). Genetic knockouts of these receptors have led to neuronal 
regeneration following spinal cord injury, indicating an inhibitory function. Despite 
this, the role these receptors may play in PNN-related plasticity is still not known.  
 
 The PNN may be a source of molecules that affect neuronal plasticity. Molecules such 
as the semaphorin 3A have shown to bind to the PNN (de Winter et al., 2016; De Wit 
et al., 2005). Semaphorin 3A is a known growth cone collapser which inhibits 
lamellapodia in advancing cells. Their presence in the PNN is thought to cause 
inhibition towards lamellapodia through chemorepulsion. Moreover, PNNs are 
thought to harbour pro-growth molecules such as NTFs which are liberated when 
digested. NTFs such as fibroblast growth factor 2, vascular endothelial growth factor, 
hepatocyte growth factor and BDNF have all shown affinity for GAG side-chains 
(Karumbaiah et al., 2015; Takada et al., 2013). Therefore, PNNs potentially trap NTFs 




3.1.3. Removing the perineuronal nets 
The enabling of axonal regrowth by the removal or digestion of CSPGs has been frequently 
mentioned in previous sections. Removing CSPGs can be done in one of a few ways. 
The most prominent method of removing CSPGs is via the administration of the Proteus 
vulgaris bacterial enzyme known as chondroitinase ABC (ChABC). ChABC is a lyase with the 
capability to degrade CS-GAG chains via the hydrolysis of the GlcA/GalNAc glycosidic bond. This 
in effect prunes the GAG side-chains off the attached CSPG core protein. Pruned side chains 
reveal residual stub epitopes attached to the core protein which are then effective binding sites 
for the chondroitin-4-sulphate (C4S) antibody; a common marker used to visualise tissue 
digested by ChABC (see figure 16). Digested CSPGs lose their inhibitory nature and permit 
repair to occur. As CSPGs are removed, PNNs lose their dense lattice structure, their inhibitory 
mechanisms and their potential trapping of NTFs. The administration of ChABC in vivo has been 
the basis of the ChABC spinal cord injury recovery model, a paradigm model that promotes 
functional recovery post injury (Barritt et al., 2006; Bradbury et al., 2002).  
Although sometimes used interchangeably in terms of plasticity and therapeutic target, the 
diffuse matrix CSPGs and PNNs are different structures. These two locations of CSPG are 
impossible to individually target when using ChABC. As a result, any beneficial plastic effects 
caused by CS-GAG digestion cannot be attributed to PNN removal alone. However, a genetic 
approach has been developed to knockout the formation of the PNN. The Crtl1 gene has been 
identified as one of the most important genes required for effective PNN formation (Carulli et 
al., 2006; Wang et al., 2011). Crtl1 encodes the link protein that binds the core protein to the 
CS-GAG side chains. Disruption of this gene leads to the inability to form normal PNNs and, as a 
result, leaves the brain open for plasticity. Animals with this genotype have presented 
significant motor recovery following spinal cord injury, which has been comparable to that of 
ChABC-mediated recovery (Carulli et al., 2010). This genetic approach has proven that the 
recovery seen with ChABC administration can be largely, if not solely, caused by the digestion 
of the PNN in spinal cord injury models. This does not rule out the possibility of the CSPGs of 
the diffuse matrix being inhibitory, rather PNNs are most likely more inhibitory due to their 
sheer number of CSPG components.  
Methods of CSPG removal have not been investigated extensively in other areas of 
neurodegeneration such as PD. As the degeneration of SNc cells and their inability for repair 












3.1.4. ChABC administration as a Parkinson's disease therapeutic venture  
To date, ChABC has been utilised in few studies regarding PD. One relevant study administered 
ChABC to rats bearing a damaged nigrostriatal pathway (NS) whereby an axotomy was made to 
the MFB by a Scouten wire-knife incision (AP: -3.0 mm, ML: ± 2.5 mm and DV: -7.5 mm; relative 
to bregma and dura mater surface) (Moon et al., 2001). These injured rats were administered 
ChABC perilesionally via implanted cannulae on days 0, 3, 7 and 10 and later killed on days 11, 
18 or 100 post-axotomy. ChABC administration elicited the regrowth of TH-positive NS fibres 
when compared to those of the control group; no significance was found between any of the 
days post-lesion in the number TH-positive processes. Unfortunately, no behaviour was 
conducted so determining whether functional recovery was induced by ChABC is impossible. 
This study suggests that ChABC administration induces plasticity and repair in the rodent BG as 
seen in ChABC spinal cord injury recovery model. As the axotomy model does not replicate the 
mechanism or pathology associated with the disease, construct validity is nonexistent. 
Nonetheless, this proof-of-concept investigation suggests that applying ChABC in a more 
conventional model of PD could give rise to a novel repair approach.  
Homotopic grafting has proven difficult in restoring the dopaminergic function of the BG due to 
Figure 17: PNNs in naive and ChABC-treated tissue. 
As shown in Chapter 1, the CSPGs of the PNN are bound to the scaffolding protein hyaluronan 
by link proteins. The net-like structure is formed by the complexing of several CSPGs via the 
binding to tenascin. CSPGs in the naive tissue (left cartoon) possess many CS-GAG side-chains 
that are believed to cause axonal inhibition. However, ChABC administration induces the 
digestion of the CS-GAGs (right cartoon) and the unveiling of chondroitin-4-sulphate (C4S) 
epitopes. These sites allow the binding of C4S antibodies to the digested CSPGs and highlight 




issues with long distance rewiring and potentially the CSPG-rich inhibitory environment. CSPGs 
have been found to proliferate significantly in the glial scar surrounding graft sites and so 
therefore can been seen as a barrier to growth (Barker et al., 1996). With this in mind, studies 
investigated the effect of ChABC administration on graft success rate and discovered CSPG 
digestion aided graft growth (Diaz-Martinez et al., 2013; Kauhausen et al., 2015). This further 
confirms the inhibitory nature of CSPGs within the BG and their potential as a therapeutic 
target in PD.  
3.1.5. Study rationale  
The brief use of ChABC in the injured rodent BG has provided the proof-of-concept for ECM-
targeted therapeutics in PD. So far, there has been no investigation into the effects of ChABC on 
either SNc cell protection/repair or behavioural recovery in a face-and-construct-valid toxin 
model of disease. In this chapter, we investigate for the first time the potential of ChABC 
administration as a method of recovery in the injured BG of the 6-OHDA mouse model. The 
unilateral 6-OHDA model was chosen, as each animal possessed its own control hemisphere to 
which it could compare lesion severity. These data then permitted the comparison of SNc cell 
survival between the saline- and ChABC-treated animals. Additionally, this toxin model was 
used as it could recreate both early and late stage pathology of PD through either a full or a 
partial lesion, respectively. Both the early and late stage models were of interest, as it would 
indicate whether digestion of the CSPGs could help protect susceptible SNc cells in the early 
stages or repair dying SNc cells in the late stages of disease. As this mouse model was new to 





3.2. Aims and Hypotheses  
A wealth of data supports the inhibitory role of CSPGs within the mammalian CNS. To date, 
several spinal cord injury models have targeted the CSPGs of the ECM as a method of repair. 
Nonetheless, only one study suggests the possibility of ChABC-mediated axonal repair within 
the BG. Moon et al. presented increased TH-positive fibre sprouting following ChABC 
treatment in the damaged NS, a study that paved way for the possibility of ChABC as a novel 
agent in the treatment of PD. However, the axotomy model used in the Moon et al. 2001 paper 
was not a model of PD, therefore the next step was to administer ChABC within a validated 
model of PD (i.e. the unilateral 6-OHDA mouse). This chapter describes for the first time the 
effects of ChABC in both a full and partial unilateral 6-OHDA lesion model. To assess the effect 
of ChABC, both behaviour and SNc cell survival rates were recorded and analysed. 
This chapter is subdivided into five studies. The initial three are pilot studies that establish the 
full lesion model, the partial lesion model and the method of ChABC administration. The final 
two studies present the effects of ChABC within these full and partial lesion models. The aims 
and hypotheses for the latter two studies are described below. 
Study aims: 
1. Determine whether ChABC has a beneficial effect on cellular and motor recovery in the 
full lesion 6-OHDA hemiparkinsonian mouse model  
 
2. Determine whether ChABC has a beneficial effect on cellular and motor recovery in the 
partial lesion 6-OHDA hemiparkinsonian mouse model  
  
Study hypotheses: 
1. Entire digestion of CSPGs in the NS by ChABC administration will act as a 
neuroprotective/repair strategy in the full hemiparkinsonian mouse model of PD 
 
2. Entire digestion of CSPGs in the NS by ChABC administration will act as a 
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3.3. Materials and Methods 
Several methods have been repeated throughout this experimental chapter. In these cases, the 
method will be described in full in the first instance and then referenced to as section x.x.x. in 
the later instances. 
3.3.1. Pilot study 1: Establishing the 6-OHDA full lesion mouse model 
 3.3.1.1. Animal subjects 
18 eight-week-old male C57Bl/6 mice (Harlan, UK) were maintained on a 12:12 hour light/dark 
cycle (07:00am lights on) with food and water ad libitum. Room temperature and humidity 
were kept at 22 ± 2°C and 55 ± 2% respectively. All surgical, behavioural and histological 
procedures were performed whilst blinded to the experimental groups. 
 3.3.1.2. Experimental design 
The timeline for the study is described below in figure 17. A week prior to lesioning (d-7) a 7 
day habituation period was implemented to ensure animals were non-responsive to non-
biologically relevant stimuli. On day 0, 6-OHDA lesioning was conducted in a randomised block 
design whilst blind to 6-OHDA dose. A recovery period of 19 days was then enforced post-
lesion whereby daily rehydration and health checks were conducted until the animals had 
returned to pre-surgical weight. Necropsy was conducted at midday on day 21. Animals were 






Figure 18: Experimental design: Pilot study 1: Establishing the 6-OHDA full lesion model. 
All procedures of the study were conducted on certain days pre- or post-lesion as described in 




 3.3.1.3. Surgery 
Surgeries conducted were based around a randomised block design to reduce variability 
between the blinded treatment groups. All animal procedures were conducted in accordance 
with the Animal Scientific Procedures Act 1986. Anaesthesia was induced in mice using a 5% 
isofluorane/oxygen mixture within an induction chamber and maintained at 3% 
isofluorane/oxygen. Body temperature was monitored and maintained at 37°C with a 
homeothermic heating blanket (Harvard Apparatus). The surgical site was sterilised with 0.4% 
chlorhexidine (Hibiscrub) and eye-drops (Viscotears) were applied to the animal’s eyes to avoid 
drying out and ulceration during surgery and post-recovery. An incision was made from eye to 
ear level along the AP axis before the surface of the skull was then cleaned and dried. 
 3.3.1.4. 6-OHDA full lesion model 
In this model, varying concentrations of 6-OHDA were injected supranigrally to identify the 
dose which would induce a consistent full lesion.  
Fine-bore holes (Ø 0.5 mm) were drilled at coordinates AP: -3.0 mm and ML: +1.2 mm (relative 
to bregma and skull surface). A blunt-ended 30 gauge needle was then inserted supranigrally to 
dorsovetral [DV]: -4.5 mm (relative to bregma and skull surface) before either saline, 4, 6 or 8 
μg 6-OHDA.HBr (Sigma-Aldrich) in 1 μl ice-cold 0.02% ascorbate/saline (Vehicle: n=4; 4 µg: n=6; 
6 µg: n=4; 8 µg 6-OHDA.HBr: n=4) was administered at a rate of 0.5 μl/min. The injection 
needle was left in place for 5 minutes after toxin administration to ensure the full diffusion of 
the compound.  
 3.3.1.5. Post-operative procedure  
After the suturing and sterilisation of the surgical site, animals were administered 0.1 ml 
buprenorphine (Vetergesic; 0.1 mg/kg; subcutaneous *s.c.+) and 1 ml Hartmann’s solution 
(Aqupharm 11; s.c.) for analgesia and rehydration purposes, respectively. Animals were then 
left to recover for the rest of the surgical day in a clean cage resting on a heat mat set to 37°C 
(Harvard Apparatus) with food and tap water ad libitum. Lesioned mice suffer from extensive 
heat loss and so it was important to ensure all animals had sufficient warmth during recovery. 
Morning and afternoon checks of all the animals were conducted daily to ensure that weight 
was gained in the days following surgery; 1 ml of warmed Hartmann’s solution was 
administered if >10% body weight had been lost from the previous weigh-in. Unwell animals 
were placed back on heat mats in a clean cage to ensure body temperature was stabilised. 
Rigorous post-operative care reduced the mortality rate to ~10%. 
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3.3.1.6. Immunohistochemical assessment of lesion size 
On day 21, animals were killed by an anaesthetic overdose (4 ml/kg IP, sodium pentobarbital, 
Sigma-Aldrich) and perfusion-fixed with PBS, followed by 10% formalin (Sigma-Aldrich) at room 
temperature. Brains were then removed and postfixed within 10% formalin overnight at room 
temperature. 
 3.3.1.7. Paraffin embedding and sectioning 
Post-fixed brains were readied for paraffin wax embedding by firstly removing the cerebellum 
and forebrain in the coronal axis. Tissue was then set in paraffin wax using a Leica TP1020 
processing machine. A 120 min/station protocol was adopted (complete cycle: 20 hours). 
Tissue embedded paraffin wax blocks containing the entire SNc were then sectioned (7 μm 
thick sections) with a microtome (Thermo Scientific) at three rostrocaudal levels of the SNc 
(rostral: -2.92 mm, medial: -3.16 mm and caudal: -3.52 AP mm; relative to bregma). Sections 
were then mounted on poly-L-lysine coated slides (VWR Int.) before being stored at 60°C over 
night. Note, in this initial study the striatum was not analysed. 
 3.3.1.8. Tyrosine hydroxylase staining in paraffin embedded 6-OHDA 
 unilaterally lesioned brain sections 
The same paraffin wax immunohistochemical protocol was used to that found in Chapter 2 
section 2.3.1.3. The key difference was in the primary antibody used (anti-tyrosine hydroxylase; 
1:500 dilution; AB152; rabbit host; Millipore).  
 3.3.1.9. Assessment of lesion severity via percentage SNc cell loss 
Triplicate sections (three sequential sections) were taken at each of three different levels of the 
SNc (rostral: -2.92 mm, medial: -3.16 mm and caudal: -3.52 mm; AP axis relative to bregma) for 
each animal (nine sections in all per animal). To highlight SNc cells, sections were stained for 
TH-positivity, as explained in section 2.3.2.2. Cells of the SNc, in both the lesioned and 
unlesioned hemispheres, were imaged at 10X magnification (Axioskop, light-field compact 
microscope). TH-positive cells from both hemispheres were counted via ImageJ software. Only 
TH-positive cells from the SNc were counted, VTA TH-positive cells were omitted as these do 
not form part of the basal ganglia motor circuitry. 
TH-positive SNc cells in the lesioned and intact SNc were then counted for each triplicate. The 
number of TH-positive cells remaining in the lesion hemisphere as a percentage of the intact 
was then calculated. Triplicate sections were then averaged to give a final value of SNc cells 
remaining for each SNc level (three final values for each animal). A final mean for the SNc cells 
remaining at each level in an experimental group was then obtained by averaging those values 
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from all animals in that group. If no difference was found between the three SNc levels in an 
experimental group then the values for the three levels were averaged. This then gave an 
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3.3.2. Pilot Study 2: Characterising the 6-OHDA partial lesion mouse 
Parkinson's disease model 
 3.3.2.1. Animal subjects 
7 eight-week-old male C57Bl/6 mice (Harlan, UK) were used and treated according to 
conditions in section 3.3.1.1. 
 3.3.2.2. Experimental design 
The timeline for the study is described below in figure 18. A week prior to lesioning (d-7) a 7 
day habituation period was implemented to ensure animals were non-responsive to non-
biologically relevant stimuli. On day 0, 6-OHDA lesioning was conducted in a randomised block 
design whilst blind to 6-OHDA dose. A recovery period of 14 days was then enforced post-
lesion whereby daily rehydration and health checks were conducted until the animals had 
returned to pre-surgical weight. Necropsy was conducted at midday on day 15. Animals were 
killed by anaesthetic overdose and brains were removed for histological analysis. 
 
 3.3.2.3. Surgery 
All surgical (apart from the lesioning protocol) and post-operative care techniques were 
identical to sections 3.3.1.3. and 3.3.1.5., respectively.  
 3.3.2.4. 6-OHDA partial lesion model 
In this model, varying concentrations of 6-OHDA were injected intrastriatally to identify the 
dose which would induce a consistent partial lesion.  
Fine-bore holes (Ø 0.5 mm) were drilled at coordinates AP: +0.5 mm, ML: +2.2 mm (relative to 
bregma and skull surface). A blunt-ended 30 G needle was then inserted intrastriatally at DV: -
3.5 mm (relative to bregma and skull surface) before 4, 8 or 12 μg 6-OHDA.HBr (Sigma-Aldrich) 
in 1 μl ice-cold 0.02% ascorbate/saline (4 μg: n=3; 8 μg: n=2; 12 μg: n=2) was administered at a 
rate of 0.5 μl/min. The injection needle was left in place for 5 minutes after toxin 
administration to ensure the full diffusion of the compound.  
Figure 19: Experimental design: Pilot study 2: Establishing the 6-OHDA partial lesion model. 
All procedures of the study were conducted on certain days pre- or post-lesion as described in 




 3.3.2.5. Assessment of lesion severity via percentage striatal TH-positive 
 fibres remaining and TH-positive SNc cells remaining 
On post-lesion day 15, all animals were killed, perfuse fixed and their brains removed. Brains 
were embedded in paraffin wax, as according to section 3.3.1.7. Immunohistochemical staining 
of TH, as described in Chapter 2 section 2.3.1.3., was conducted on both SNc and striatal 
sections to detect the number of TH-positive cells within the SNc and also TH-positive fibres 
within the striatum. The key difference was in the primary antibody used (anti-tyrosine 
hydroxylase; 1:500 dilution; AB152; rabbit host; Millipore).  
SNc cell counts were conducted according to the protocol in section 3.3.1.9. 
Triplicate sections (three sequential sections) were taken at three different levels of the 
striatum (rostral: + 1.0 mm, medial: + 0.5 mm and caudal: - 0.22mm; AP axis relative to 
bregma) for each animal (nine sections in all per animal). Sections were stained for TH-
positivity to highlight striatal TH-positive dopaminergic terminals. TH-positivity in both the 
lesioned and unlesioned striatal hemispheres, were imaged at 10X magnification (Axioskop, 
light-field compact microscope) and analysed via ImageJ software. Striatal images were divided 
into quadrants, these being the dorsolateral (DL), dorsomedial (DM), ventrolateral (VL) and 
ventromedial (VM) as depicted in figure 28. The TH-positivity in each quadrant was determined 
by grey mean value assessment in ImageJ using the freehand tool.  
The TH-positive fibre optical densities of the four striatal quadrants in the lesioned and intact 
hemispheres were then assessed for each section. The density of TH-positive fibres remaining 
in each quadrant in the lesion hemisphere as a percentage of the respective quadrant in the 
intact was then calculated for all nine sections. Triplicate sections were then averaged to give a 
final TH-positive fibres remaining value for each quadrant at each striatal level (twelve final 
values for each animal). A final mean for TH-positive fibres remaining in each quadrant at each 
level in a experimental group was then obtained by averaging that quadrant's TH-positive fibres 








Supranigral + intrastriatal (n=5) or
Rostral SNc + caudal striatum (n=5)
d-7 - d-1 d1 - d6
Habituation period Recovery period
8 week old; n = 10 Daily rehydration; 
health checks
3.3.3. Pilot Study 3: Identifying two coordinates for ChABC administration to 
cause the digestion of CSPGs along the entire nigrostriatal tract 
 3.3.3.1. Animal subjects 
5 eight-week-old male C57Bl/6 mice (Harlan, UK) were used in both the first set of coordinates 
tested and second set. Animals were treated according to conditions in section 3.3.1.1. 
 3.3.3.2. Experimental design  
The timeline for the study is described below in figure 19. A week prior to lesioning (d-7) a 7 
day habituation period was implemented to ensure animals were non-responsive to non-
biologically relevant stimuli. On day 0, ChABC administration was conducted in either the 
rostral SNc and caudal striatum or supranigral and intrastriatal regions. A recovery period of 6 
days was then enforced post-lesion whereby daily rehydration and health checks were 
conducted until the animals had returned to pre-surgical weight. Necropsy was conducted at 




 3.3.3.3. Surgery 
All surgical and post-operative care techniques were identical to sections 3.3.1.3. and 3.3.1.5., 
respectively. 
 3.3.3.4. Stereotaxic injections of ChABC into the SNc and striatum 
Fine-bore holes (Ø 0.5 mm) were drilled at AP: +0.5 mm and ML: ±2.0 mm (relative to bregma 
and skull surface; intrastriatal site) and AP: -3.0 mm and ML: ±1.2 mm (relative to bregma and 
skull surface; supranigral site). All five animals received two single 1 μl intracerebral injections 
of ChABC (10 U/ml; Seikagaku) into the left hemisphere. One dose was administered 
intrastriatally (DV: -3.5 mm; relative to bregma and skull surface) and the other supranigrally 
(DV: -3.5 mm; relative to bregma and skull surface) (as determined by Paxinos and Watson 
Mouse Brain Atlas). The injection needle was left in place for a further 5 minutes to avoid 
reflux. 
  
Figure 20: Experimental design: Pilot Study 3: Identifying the sites for ChABC administration. 
All procedures of the study were conducted on certain days pre- or post-lesion as described in 
the figure. Further details are found either below the time line or in subsequent sections. 
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3.3.3.5. Stereotaxic injections of ChABC into the rostral SNc and caudal 
 striatum 
Fine-bore holes (Ø 0.5 mm) were drilled at AP: -2.3 mm and ML: ± 1.0 mm (relative to bregma 
and skull surface; rostral SNc site) and AP: +0.02 mm; ML: ±2.2 mm (relative to bregma and 
skull surface; caudal striatum site). All five animals received two single 1 μl intracerebral 
injections of ChABC (10 U/ml; Seikagaku) into the left hemisphere. One dose was administered 
into the rostral SNc (DV: -4.2 mm; relative to bregma and skull surface) and the caudal striatum 
(DV: -3.5 mm; relative to bregma and skull surface) (as determined by Paxinos and Watson 
Mouse Brain Atlas). The injection needle was left in place for a further 5 minutes to avoid 
reflux. 
 3.3.3.6. C4S staining of digested CS-GAG stub epitopes in paraffin 
 embedded mouse brain sections 
Apart from the use of the C4S primary antibody (mouse monoclonal; 1:500; MPBio #636511), 
the immunohistochemical procedures for detecting C4S immunoreactivity were otherwise 
identical to those described in Chapter 2 section 2.3.1.3.   
C4S staining was visualised and imaged at 10X magnification (Axioskop, light-field compact 
microscope). No quantification was conducted. Sections were instead used to confirm the 
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ChABC and 8 μg 6-OHDA Amphetamine Apomorphine Necropsy
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Cylinder baseline: d-4 and d-1 Cylinder testing: d3, d10, d17, d24 and d31
3.3.4. Investigating the effect of ChABC administration on cellular and 
behavioural recovery in a full 6-OHDA lesion mouse model  
 3.3.4.1. Animal subjects 
27 eight-week-old male C57Bl/6 mice (Harlan, UK) were used and treated according to 
conditions in section 3.3.1.1. 
 3.3.4.2. Experimental design 
The timeline for the study is described below in figure 20. A week prior to lesioning (d-7) a 7 
day habituation period was implemented to ensure animals were non-responsive to non-
biologically relevant stimuli. During this period, baseline recordings for the cylinder test (see 
section 3.3.4.6.) were conducted (days -4 and -1). 6-OHDA and ChABC administration was 
conducted on day 0 in a randomised block design whilst blind to the treatment. All animals 
received 8 µg of supranigral 6-OHDA and either ChABC or saline (rostral SNc and caudal 
striatum). A recovery period of 31 days was enforced whereby daily rehydration and health 
checks were conducted until the animals had returned to pre-surgical weight. During this 
period the cylinder test was conducted on all animals at weekly intervals. On day 35 and 38 
animals undertook the amphetamine and apomorphine-induced rotation tests, respectively. 
On day 42 post-lesion animals were killed by anaesthetic overdose and brains were removed 
for histological analysis. 
 
 
 3.3.4.3. 6-OHDA and ChABC administration 
All methods of surgery and post operative care were identical to those previously described in 
sections 3.3.1.3 and 3.3.1.5., respectively. The 6-OHDA lesioning protocol (8 μg 6-OHDA; 
supranigral) was identical to those used in section 3.3.1.4. 
Animals received two 1 μl intracerebral injections of either saline (n=14) or ChABC (n=13; 10 
U/ml; Seikagaku) into the 6-OHDA injected hemisphere. In accordance with data obtained from 
Pilot Study 3 to derive optimum CSPG digestion, one dose was administered into the rostral 
SNc (AP: -2.3 mm; ML: +1.0 mm and DV: -4.2 mm; relative to bregma and skull surface) and the 
other into the caudal striatum (AP: +0.02 mm; ML: + 2.2 mm and DV: -3.5 mm; relative to 
Figure 21: Experimental design: Investigating the effect of ChABC administration on cellular 
and behavioural recovery in a full 6-OHDA lesion mouse model.  
All procedures of the study were conducted on certain days pre- or post-lesion as described in 




bregma and skull surface). The injections of ChABC were administered sequentially 5 minutes 
after the injection of the 6-OHDA and were left in place for a further 5 minutes to avoid toxin 
reflux. 
 3.3.4.4. Quantifying and assessing the effect of ChABC in the full lesion 
 model 
Behavioural, immunohistochemical and analytical methods were similar to those in the pilot 
studies. As the techniques have been previously mentioned, brief descriptions of the methods 
conducting in this study are described below. 
 3.3.4.5. Behavioural assessment of parkinsonian phenotype 
At set time points pre- or post-6-OHDA lesioning (see subsequent tests for specific days), 
behavioural assessments of hemiparkinsonian phenotype was conducted via the cylinder test, 
amphetamine-induced rotation and apomorphine-induced rotation tests. 
 3.3.4.6. Cylinder test 
The cylinder test exploits the natural rearing behaviour rodents exhibit in novel environments 
in order to identify bias in forepaw use following a unilateral lesion (Schallert et al., 2000). As 
the forepaw contralateral-to-the-lesion is weakened, the ipsilateral paw will therefore be 
favoured in the majority of weight-bearing touches. This test, through a calculated asymmetry 
score, can identify whether an animal recovers the mobility of its contralateral forepaw by 
disease modifying pharmacological agents or cell survival strategies. The cylinder test can 
correlate SNc lesion severity to the calculated asymmetry score (Lundblad et al., 2002). 
On days -4, -1, 3, 10, 17, 24 and 31, mice were placed individually within 2 litre glass beakers (Ø 
12 cm) in which the forepaw preference was monitored during rearing behaviour (figure 21). 
Mirrors were placed behind the beakers to ensure a 360° view of the animal during its rears. 5 
minute video recordings of the cylinder test were taken; only cases where the animal had not 
yet made the required 10 touches did the experiment run for additional time. Weight bearing 
touches by only the forepaw ipsilateral-to-the-lesion, contralateral-to-the-lesion or both 
forepaws simultaneously were measured. An asymmetry score was then calculated to indicate 





















Where: Both is the weight-bearing touch of both the ipsi- and contralateral-to-the-lesion 
forepaws simultaneously, Contra is the weight-bearing touch of only the contralateral-to-the-
lesion forepaw and Total is the total number of weight-bearing touches (the sum of Both, 
Contra and the ipsilateral-to-the-lesion touches).  
A score of 50% would indicate no bias whereas a lower score would denote a loss of injured 
(contralateral) forepaw ability. Any behavioural recovery would be represented by a rise in 
asymmetry score back to 50%. A minimum of 10 touches were required before the 
experimental run was judged complete. In order to maintain consistency with activity levels, 
testing was always carried out at midday. Representative images of the cylinder test in progress 
can be seen in figure 21.  
Figure 22: Performance of the cylinder test. 
(A) Mice were individually placed in 2 litre beakers for 10 minutes. Specific forepaws used for 
weight-bearing touches were recorded. (B) A unilaterally lesioned mouse will favour the 
ipsilateral-to-the-lesion paw over the contralateral. Asymmetry scores typically drop to 20-
30%. Red circle highlights the weight-bearing touch of the ipsilateral paw. (C) Saline 
administered animals present no bias in paw preference. Non-lesioned animals typically 
present an asymmetry score of ~50%. Red circles highlight weight-bearing forepaw touches. 
This would be recorded as a Both. 
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 3.3.4.7. Amphetamine and apomorphine-induced rotations 
Lesioned mice were administered with either D-amphetamine hemisulphate (Tocris; 5 mg/kg, 
i.p.) in saline or apomorphine (Sigma-Aldrich; 0.5 mg/kg, s.c.) in saline. Animals were placed 
within cylindrical arenas (Ø 40 cm) immediately after drug administration in which the motion 
tracking tool Ethovision XT6 was used for recording. A custom optimised calibration file was 
loaded, which allowed the recording of full 360° rotations about the animal's midpoint (figure 
22C + D). Ipsiversive and contraversive rotations were then individually measured. The lesioned 
animals expected response to amphetamine and apomorphine is shown in figure 22A + B 
respectively. A 20 minute habituation period prior to drug administration was conducted; 




























































Figure 23: Typical rotational behaviour of amphetamine- and apomorphine-induced 
rotations as measured by Noldus Ethovision XT6 tracking software. 
(A) Amphetamine increases striatal DA by upregulating vesicular DA release. As a result, motor 
output is increased (+++) from the unlesioned hemisphere causing ipsiversive rotations 
towards the lesion. (B) In contrast, as toxin driven denervation upregulates D1/D2 receptor 
expression at the post-synaptic nerve terminal, apomorphine (non-selective DA receptor 
agonist) has a more marked action in the lesioned hemisphere (+++). This therefore causes 
contraversive rotations (away from the lesion) in the hemiparkisonian rodent (C) The Noldus 
Ethovision XT6 apparatus distinguished the animal’s body from the arena via the dynamic 
subtraction method of detection, in which animals placed into the defined arena were 
considered novel when compared to an empty reference arena. A typical arena set up is 
shown in panel C. (D) Nose, midpoint and tail-base markers were assigned (blue, red and 
purple dots, respectively) by the program. 360° rotations about the animal’s midpoint were 




 Immunohistochemical assessments 
On post-lesion day 42, all animals were killed, perfuse fixed and their brains removed. Brains 
were embedded in paraffin wax, as according to section 3.3.1.7. Immunohistochemical staining 
of TH, as described in Chapter 2 section 2.3.2.2., was conducted on both SNc sections (rostral: -
2.92 mm, medial: -3.16 mm and caudal: -3.52 mm AP; relative to bregma) and striatal sections 
(rostral: +1.00 mm, medial: +0.5 mm and caudal: -0.22 mm AP; relative to bregma) to detect 
the number of TH-positive cells within the SNc and TH-positive fibres within the striatum. The 
assessment of lesion severity by the cells remaining in the SNc and TH content within the 
striatum was conducted as per section 3.3.1.9. and 3.3.2.5., respectively. 
As no significance was detected between the two dorsal striatal (between DL and DM) or two 
ventral striatal quadrants (between VL and VM), the striatal optical densities for the DL and DM 
were averaged to form the dorsal striatum and the striatal optical densities for the VL and VM 
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3.3.5. Investigating the effect of ChABC administration on cellular and 
behavioural recovery in a partial 6-OHDA lesion mouse model 
 3.3.5.1. Animal subjects 
34 eight-week-old male C57Bl/6 mice (Harlan, UK) were used and treated according to 
conditions in section 3.3.1.1. 
 3.3.5.2. Experimental design 
The timeline for the study is described below in figure 23. A week prior to lesioning (d-7) a 7 
day habituation period was implemented to ensure animals were non-responsive to non-
biologically relevant stimuli. During this period, baseline recordings for the cylinder test were 
conducted (days -3 and -1). 6-OHDA and ChABC administration was conducted on day 0 in a 
randomised block design whilst blind to the treatment. All animals received 4 µg of intrastriatal 
6-OHDA and either ChABC or saline (rostral SNc and caudal striatum). A recovery period of 35 
days was enforced whereby daily rehydration and health checks were conducted until the 
animals had returned to pre-surgical weight. During this period the cylinder test was 
conducted on all animals at weekly intervals. On day 37 animals undertook the amphetamine-
induced rotation test. This study did not require the apomorphine-induced rotation test as this 
behavioural assay responds only to fully lesioned animals. On day 39 post-lesion animals were 
killed by anaesthetic overdose and brains were removed for histological analysis.  
 
  3.3.5.3. Quantifying and assessing the effect of ChABC in the partial 
 lesion  model 
Behavioural, immunohistochemical and analytical methods were similar to those in the pilot 
studies. As the techniques have been previously mentioned, brief descriptions of the methods 
conducting in this study are described below. 
  
  
Figure 24: Experimental design: Investigating the effect of ChABC administration on cellular 
and behavioural recovery in a partial 6-OHDA lesion mouse model.  
All procedures of the study were conducted on certain days pre- or post-lesion as described in 
the figure. Further details are found either below the time line or in subsequent sections. 
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 Behavioural assessments 
The cylinder test was conducted to assess the degree of forelimb asymmetry as described in 
section 3.3.4.6. Cylinder tests were conducted during the habituation period on days -3 and -1 
and on days 14, 21, 28 and 35 post-lesion. On post-lesion day 37 the amphetamine-induced 
rotation test was conducted as per section 3.3.4.7. 
 Immunohistochemical assessments 
On post-lesion day 39, all animals were killed, perfuse fixed and their brains removed. Brains 
were embedded in paraffin wax, as according to section 3.3.1.7. Immunohistochemical staining 
of TH, as described in Chapter 2 section 2.3.1.3., was conducted on both SNc and striatal 
sections to detect the number of TH-positive cells within the SNc and also TH-positive fibres 
remaining within the striatum. The assessment of lesion severity by the cells remaining in the 
SNc and TH content within the striatum was conducted as per section 3.3.1.9. and 3.3.2.5., 
respectively. 
As no significance was detected between the two dorsal striatal (between DL and DM) or two 
ventral striatal quadrants (between VL and VM), the striatal optical densities for the DL and DM 
were averaged to form the dorsal striatum and the striatal optical densities for the VL and VM 
were averaged to form the ventral striatum.  
3.3.6. Statistical analysis 
All statistical analyses within this chapter were conducted with the SigmaPlot 12 package; 
statistical tests used are displayed within the figure legends. Graphpad Prism 5 was used to plot 





3.4.1. Pilot Study 1: supranigral administration of 8 μg 6-OHDA induced the 
full ablation of the mouse SNc 
To assess the efficacy of ChABC as a PD therapeutic we wished to apply the enzyme to both a 
partial and full unilateral 6-OHDA lesion model. However, due to the novelty of the mouse 
model within the Duty laboratory these models were required to be characterised. 
This dose finding pilot focussed on identifying the correct dose of supranigral 6-OHDA required 
to induce a consistent full lesion in the SNc; a lesion model that attempts to recapitulate the 
pathology of late-stage PD (>85% SNc cell loss). To determine which dose of 6-OHDA was most 
successful in producing the correct lesion size, immunohistological approaches were conducted 
to permit the counting of the remaining cells in both the intact and lesioned SNc. These values 
would then be used to determine the total cells remaining in the lesioned SNc as a percentage 
of the total cells in the intact. Unfortunately, due to damage, no striatal tissue was obtained for 
TH-positive fibre assessment. 
With this full lesion model established, it would then be possible to assess the effects of ChABC 
in a model of late-stage PD. 
  































 TH immunohistochemistry of the SNc 
To gather the relevant data required for correct 6-OHDA dose assessment, images of the SNc 
were first obtained. Photomicrographs (10X magnification), shown below in figure 24, depict 
the increased loss in SNc cells in the parkinsonian hemisphere in a dose dependent manner. 
The A10 dopaminergic cells of the VTA (black dotted line) were avoided when counting the 
SNc’s A9 dopaminergic cells (black dashed line; vehicle section). The medial lemniscus (ml) was 
used as spirit level throughout the SNc as it allowed myself to determine whether the sections 
were perpendicular to the central midline of the brain. 
 
  
Figure 25: Photomicrographs highlighting a 6-OHDA dose dependent increase in SNc 
pathology severity. 
Coronal TH-positive SNc cell sections taken at the medial level (-3.16 mm AP; relative to 
bregma). Top to bottom: vehicle, 4 μg, 6 μg and 8 μg 6-OHDA. The lesioned SNc is shown on 
the left of each section. The SNc (black dashed line) and ventral tegmental area (VTA; black 
dotted line shown) have been highlighted on the vehicle section above. The medial lemniscus 
(ml) acted as a spirit level to aid cutting a perpendicular section for accurate cell counts. Scale 



















































































































































 Assessment of cells remaining in the SNc as a result of 6-OHDA lesioning 
TH-positive cells of the rostral, medial and caudal SNc sections were counted in the lesioned 
and intact hemispheres of each animal. Counts from the three levels were then averaged. Raw 
cell count data is presented in figure 25A. All doses of 6-OHDA induced a significant loss in TH-
positive SNc cells in the lesioned hemisphere (p<0.001 for all groups; Two-Way ANOVA with 
Bonferroni post hoc test). Loss in total cell numbers in the lesioned SNc compared to the intact 
SNc were as follows: 79 to 31, 69 to 20 and 75 to 17 for the 4, 6 and 8 μg 6-OHDA groups, 
respectively. The saline vehicle did not see a significant loss in cell number in the injected 
hemisphere (Lesioned: 68 SNc cells and Intact: 69 SNc cells). The number of SNc cells in the 
uninjured SNc was equivalent to those found in published data (Heuer et al., 2012). 
To help standardise these results with other published lesion models, final means of the TH-
positive cells in the lesioned SNc as a percentage of the intact SNc were calculated. These 
values were an average of the three SNc levels. Intranigral 6-OHDA produced significant SNc 
cell loss across all 6-OHDA doses compared to the vehicle administered animals (p<0.001 for all 
groups; One-Way ANOVA with Bonferroni post hoc test). The mean percentage of TH-positive 
cells remaining in the lesioned SNc (to those of the intact SNc) of animals in the 4, 6 and 8 μg 
groups were 40.6 ± 11.5 %, 27.6 ± 11.9% and 23.6 ± 5% respectively (figure 25B).  
  
Figure 26: Increased concentrations of 6-OHDA induced higher severity in SNc pathology. 
(A) Averaged TH-positive cell counts across the caudal, medial and rostral levels of the intact 
and lesioned SNc. (B) TH-positive cells in the lesioned SNc as a percentage of the intact SNc 
across the caudal, medial and rostral levels. Lesion severity increased with 6-OHDA dose. Panel 
A: Two-way ANOVA with Bonferroni post hoc test; *** denotes p<0.001 between lesioned 
hemisphere and group's intact hemisphere. Panel B: One-way ANOVA with Dunnett's post hoc 
test; *** denotes p<0.001 between 6-OHDA dose and vehicle control. Saline: n=4, 4 μg: n=6, 6 
μg: n=4 and 8 μg: n=4. Data are mean ± S.E.M. 
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3.4.2. Pilot Study 2: Intrastriatal administration of 4 μg 6-OHDA induced the 
partial ablation of the mouse SNc 
This second dose finding pilot study focussed on identifying the correct dose of intrastriatal 6-
OHDA required to induce a consistent partial lesion in the SNc. This lesion model would 
attempt to recapitulate the pathology of early-stage PD (~50-60% SNc cell loss). To determine 
which dose of 6-OHDA was most successful in producing the correct lesion size, 
immunohistological approaches were conducted to permit the counting of the remaining cells 
in both the intact and lesioned SNc. These values were then used to determine the total cells 
remaining in the lesioned SNc as a percentage of the total cells in the intact. Additionally, 
optical densities of the TH-positive fibres in the lesioned striatum were obtained to calculate 
dopaminergic terminal loss as a percentage of the intact.  
 
With this full lesion model established, it would then be possible to assess the effects of ChABC 










































 TH immunohistochemistry of the SNc 
To gather the relevant data required for correct 6-OHDA dose assessment, images of the SNc 
were first obtained. Photomicrographs, shown in figure 26, depict the increased loss in SNc 








Figure 27: Photomicrographs highlighting a 6-OHDA dose dependent increase in SNc 
pathology severity.  
Photomicrographs of coronal TH-positive SNc cell sections taken at 10X magnification. Top to 
bottom: Vehicle, 4 μg, 8 μg and 12 μg 6-OHDA. The unilaterally lesioned SNc is shown on the 
left of each section. All sections were cut at the medial level (-3.16 mm AP; relative to bregma). 

















































































































































 Assessment of cells remaining in the SNc as a result of 6-OHDA lesioning 
TH-positive cells of the SNc were counted in the lesioned and intact hemispheres of each 
animal. Raw data is presented below in figure 27A. Only the 12 μg dose of 6-OHDA induced a 
significant loss in TH-positive SNc cells in the lesioned hemisphere (p<0.05; Two-Way ANOVA 
with Bonferroni post hoc test). Loss in total cell numbers in the lesioned SNc compared to the 
intact SNc were as follows: 58 to 37, 69 to 34 and 85 to 36 for the 4, 8 and 12 μg 6-OHDA 
groups, respectively. The saline vehicle did not see a significant loss in cell number in the 
injected hemisphere (Lesioned: 69 SNc cells and Intact: 65 SNc cells). The number of SNc cells 
in the uninjured SNc was equivalent to those found in published data (Heuer et al., 2012). 
To help standardise these results with other published lesion models, final means of the TH-
positive cells in the lesioned SNc as a percentage of the intact SNc were calculated. These 
values were an average of the three SNc levels. Intrastriatal 6-OHDA produced significant SNc 
cell loss across all 6-OHDA doses compared to the vehicle administered animals (4 μg and 8 μg: 
p<0.05 and 12 μg: p<0.01; One-Way ANOVA with Bonferroni post hoc test). The 4 μg 6-OHDA 
group induced a partial lesion which left almost half of the SNc cells alive (56.7 ± 8.9%). The 8 
and 12 μg 6-OHDA groups induce a fuller lesion that left 43.9 ± 20.8% and 36.3 ± 16.1% of the 
lesioned SNc alive, respectively; figure 27B. The 4 μg 6-OHDA dose produced the closest lesion 









Figure 28: Increased concentrations of 6-OHDA induced higher severity in SNc pathology. 
(A) TH-positive cell counts in the intact and lesioned SNc. (B) TH-positive cells in the lesioned 
SNc as a percentage of the intact SNc. Lesion severity increased with 6-OHDA dose. Panel A: 
Two-way ANOVA with Bonferroni post hoc test; * denotes p<0.05 between the group’s 
lesioned hemisphere and intact hemisphere. Panel B: One-Way ANOVA with Dunnett’s post 
hoc test; * denotes p<0.05 and ** denotes p<0.01 between 6-OHDA dose and vehicle control. 




























TH immunohistochemistry of the striatum 
Photomicrographs (10X magnification) of the striatum were taken to assess the degree of 
dopaminergic denervation caused by the varying doses of 6-OHDA (figure 28). The remaining 
levels of TH-positive fibres in the parkinsonian striatum (black line; 4 μg 6-OHDA section) were 
seen to decline with an increasing dosage of 6-OHDA. In figure 29, analysis of TH-positive 
denervation was assessed by optical density measurements of the subdivided quadrants of 





Figure 29: Photomicrographs highlighting a 6-OHDA dose dependent increase in striatal 
pathology severity 
(A) Photomicrographs of the TH-positive dopaminergic terminals in the mouse striatum taken 
at 10X magnification. Top to bottom: 4 μg, 8 μg and 12 μg 6-OHDA. Striata were divided into 
quadrants for analysis, these were dorsomedial (DM), dorsolateral (DL), ventromedial (VM), 
and ventrolateral (VL). All sections were cut at the medial level (+1.00 mm AP; relative to 









































































































































































































Assessment of TH-positive fibres remaining in the striatum as a result of 
6-OHDA lesioning 
Optical densities of the TH-positive fibres within the four quadrants of the lesioned and intact 
striata were obtained. Means representing the TH-positive fibres in the quadrants of the 
lesioned striatum as a percentage of the equivalent quadrants in the intact striatum were then 
calculated. These were calculated for the caudal, medial and rostral levels (figure 29A - C).  
The 4 μg 6-OHDA dose produced the closest lesion size to that of the ideal partial lesion (~50-
60% TH-positive fibre content loss). The 4 μg dose induced the smallest lesion size across all 
four quadrants which left a significant amount of TH-positive fibres within the lesioned 
striatum (Mean TH-positive fibres remaining across all four quadrants - Caudal: 35.0 ± 11.4%, 
Medial: 56.2 ± 6.1%, Rostral: 59.8 ± 4.9). However, the 8 μg and 12 μg doses ablated the 
striatum almost entirely across all quadrants (TH-positive fibres remaining across all four 
quadrants - Caudal: 9.1 ± 4.9%, Medial: 20.0 ± 14.3%, Rostral: 33.1 ± 19.5 and Caudal: 11.7 ± 
6.1%, Medial: 14.5 ± 9.6%, Rostral: 25.5 ± 14.5, respectively). The dashed line at 50% cell loss 
indicates the ideal partial lesion for each quadrant at each level. 
 
No specific statistical tests were performed as the purpose of these data was to qualitatively 
identify the 6-OHDA dose that could provide a consistent partial lesion. The 4 μg 6-OHDA dose 
produced the closest lesion size to that of the ideal partial lesion across the striatum (~50-60% 
TH-positive fibre content loss), whereas the 8 and 12 μg 6-OHDA doses induced a more full 
ablation of the SNc. 
 
  
Figure 30: Increased concentrations of 6-OHDA induced higher severity in striatal pathology. 
(A - C) The three levels of the striatum at which analysis of TH content was taken. Data 
represent the measured optical densities of the TH-positivity in a striatal quadrant within the 
lesioned striatum as a percentage of the equivalent quadrant within the intact striatum. Black 
dashed line denotes an ideal partial lesion size of ~50%. 4 μg: n=3, 8 μg: n=2 and 12 μg: n=2. 







3.4.3. Pilot Study 3: ChABC digests CSPGs along the nigrostriatal tract when 
administered to the caudal striatum and dorsal SNc 
Injecting ChABC both intrastriatally and supranigrally (see methods for coordinates; section 
3.3.3.4.) saw the digestion of the CSPGs along the rostro-caudal axis of the mouse brain (figure 
30). Brown stain indicates immunoreactivity for the C4S CS-GAG stub epitope; an epitope 
highlighting regions of ChABC digestion. Only the left hand hemisphere was injected with 
ChABC, the right hand side was left as a control. Not all regions of the NS, such as the MFB, 
were digested (yellow ovals).   
 
  
Figure 31: C4S immunoreactivity displaying the ChABC digestion pattern following the 
intrastriatal and supranigral administration of ChABC. 
Displayed are 6 consecutive sections of the striatum (top row), rostral and caudal NS (two 
centre rows) and the SNc (bottom row) presenting the pattern of CSPG digestion. ChABC was 
injected into the striatum (injection site: red dot, top row) and the SNc (injection site: red dot, 














Readjusting the location of the striatal ChABC injection site to a more caudal region and the 
SNc injection site to a more rostral region (see methods for coordinates; section 3.3.3.5.) 
compared to the previous pilot enhanced ChABC digestion in the NS. Along the rostro-caudal 
axis the entire NS was found immunoreactive for the C4S stub epitope (figure 31). 
  
Figure 32: C4S immunoreactivity displaying the ChABC digestion pattern following the caudal 
striatal and rostral  SNc administration of ChABC. 
Displayed are 4 representative images of the SNc, MFB, mid striatum and rostral striatum. The 
entire NS was found to have immunoreactivity for the C4S epitope. 
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3.4.4. ChABC administration does not increase SNc cell survival in a full lesion 
6-OHDA model of Parkinson's disease 
This study used the parameters derived in Pilot Study 1 and 3 (i.e. dose of 6-OHDA required for 
a consistent full lesion and the location of ChABC administration for full digestion of the NS) to 
determine the effect of ChABC's digestion of CSPGs within the NS of a full lesion model. 
 Confirmation of CSPG digestion along the nigrostriatal tract 
Using the coordinates determined by Pilot Study 3, unilateral ChABC administration brought 
about the full digestion of the entire NS in the lesioned left hemisphere (figure 32A; bottom 
panel). The ChABC digested the CSPGs surrounding the fully ablated SNc and neighbouring 
regions, whereas vehicle administration presented no C4S-positivity and thus no digestion. At 
other levels of the NS, C4S digestion was also apparent (figure 32). Due to the success of the 
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Figure 33: Two bolus injections of ChABC digests the entire NS in the full lesion model. 
(A) Immunofluorescent photomicrographs of the SNc indicating area of CSPG digestion. The 
ChABC-digestion epitope, C4S (green), was not detected in the saline-treated animals but only 
the ChABC-treated. TH immunoreactivity (red) indicates SNc cells. Full lesioning of the SNc in 
the left hand hemisphere removes any TH-positivity. (B) Three levels of the NS (Caudal and 
medial SNC and striatum) highlighting the regions of C4S-positivity and thus CSPG digestion 
























 TH immunohistochemistry of the SNc and striatum 
To gather the relevant data required for correct 6-OHDA dose assessment, images of the SNc 
and striatum were first obtained. Photomicrographs, shown in figure 33A + B, depict the 




Figure 34: Photomicrographs highlighting ChABC's inability to increase TH-positive cell and 
fibre survival in the full lesion model.  
(A) Photomicrographs of the coronal TH-positive SNc cell sections taken at 10X magnification. 
Top: saline-treated SNc, Bottom: ChABC-treated SNc. The unilaterally lesioned SNc is shown on 
the left of each section. All sections were cut at the medial level (-3.16 mm AP; relative to 
bregma and skull surface) Scale bar represents 250 μm. (B) Photomicrographs of the TH-
positive dopaminergic fibres taken at 5X magnification. All sections were cut at the medial 




Assessment of TH-positive cells remaining in the SNc and TH-positive 
fibres remaining in the striatum as a result of saline and ChABC 
treatment 
TH-positive cells of the SNc were counted in the lesioned and intact hemispheres of each 
animal (data not shown). These data were then used to produce values that represent the TH-
positive cells in the lesioned SNc as a percentage of the intact SNc. There was no significant 
difference between treatment groups in the percentage of SNc cells remaining in the fully 
lesioned hemisphere. Animals that received saline had 6.2 ± 3.1% cells remaining compared to 
animals that received ChABC (6.7 ± 3.7%; Student’s t-test; figure 34A). A similar pattern was 
observed in the levels of striatal TH-positive dopaminergic terminals (figure 34B), whereby 
levels of TH-positivity across the dorsal striatum or ventral striatum in the ChABC group (6.1 ± 
5.4% and 9.5 ± 2.7%, respectively) showed no difference compared to the dorsal striatum or 
ventral striatum in the vehicle control animals (3.4 ± 3.5% and 10.9 ± 4.8%, respectively; Two-




Figure 35: Effects of ChABC on cell and terminal pathology in the full lesion model. 
(A) Percentage number of TH-positive SNc cells remaining in the lesioned hemisphere as a 
percentage of the intact for both the saline- and ChABC-treated groups. Total cell counts were 
averaged across the three levels of SNc analysed. (B) Percentage TH-positive dopaminergic 
fibres in the lesioned striatum for both the saline- and ChABC-treated group. Panel represents 
averaged data for the dorsal quadrants (DL and DM) and ventral quadrants (VL and VM) across 






















































































































































































































 Assessment of behavioural outcomes as a result of saline and ChABC 
 treatment 
In order to determine whether ChABC improved behavioural outcomes, three tests were 
enforced. These were the cylinder and the two drug-induced rotation tests. Two-Way repeat 
measures ANOVA with Bonferroni post hoc tests were used for all three. 
No significant differences between treatment groups were seen in asymmetry score on any day 
(figure 35A). Both groups presented similar average base line asymmetry scores (mean values 
for days -4 and -1; Saline: 48.1 ± 1%; ChABC: 48.8 ± 0.7%). Scores declined from day 3 until the 
end of experimentation for both the groups (values on day 31; Saline: 30.6 ± 3%; ChABC: 33.7 ± 
3.7%).  
Results from the drug-induced rotation tests were not significant. Amphetamine did not induce 
a difference in net ipsiversive rotations between saline- and ChABC-treated animals. Both the 
saline- and ChABC-treated animals peaked at ~60 minutes (51.6 ± 12.6% and 54.9 ± 8.4%, 
respectively) (figure 35B). Similarly, apomorphine did not induce a difference in net 
contraversive rotations between saline- and ChABC-treated animals Both the saline- and 
ChABC-treated animals peaked at ~40 minutes (10.5 ± 3.9% and 8.2 ± 4.1%, respectively) 
(figure 35C). Due to timing complications, both drug-induced rotation tests were limited to 90 
minutes. 
From the three tests used in this study, ChABC did not elicit better behavioural outcomes when 
compared to the vehicle control group.  
Figure 36: Effects of ChABC on behaviour in a full lesion hemiparkinsonian model of PD. 
(A) Asymmetry score of animals in the saline and ChABC-treated group determined by the 
cylinder test. (B) Amphetamine-induced net ipsiversive rotations of animals in the saline- or 
ChABC-treated groups. Mice were tested over 90 minutes. (C) Apomorphine-induced net 
contraversive rotations of animals in the saline- or ChABC-treated groups. Mice were tested 
over 90 minutes.  Saline: n=17 and ChABC: n=17. Data are mean ± S.E.M. 
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3.4.5. ChABC-treatment increases cell survival in the rostral SNc of the partial 
lesion model 
Despite ChABC not producing a beneficial effect in the full lesion model, we believed that it 
could still possess efficacy in the partial lesion model. This study utilised the parameters 
derived in Pilot Study 2 and 3 (i.e. dose of 6-OHDA required for a consistent partial lesion and 
the location of ChABC administration for full digestion of the NS) to determine the effect of 
ChABC's digestion of CSPGs within the NS of a partial lesion model. 
 Confirmation of CSPG digestion along the nigrostriatal 
As with the previous full lesion investigation, this partial lesion study used the coordinates 
determined by Pilot Study 3. As before, unilateral ChABC administration brought about the full 
digestion of the entire NS in the lesioned left hemisphere (figure 36). The ChABC digested the 
CSPGs surrounding the SNc, striatum and NS regions. Although not shown below due to 
difficulty of imaging, vehicle administration presented no C4S-positivity and thus no digestion. 





Figure 37: Two bolus injections of ChABC digest the entire NS in the partial lesion model. 
Photomicrographs of four levels of the NS highlighting the regions of C4S-positivity and thus 
CSPG digestion (brown). ChABC was administered unilaterally into the 6-OHDA lesioned 




































 TH immunohistochemistry of the SNc and striatum 
To gather the relevant data required for the assessment of ChABC's cell survival effects, images 
of the SNc and striatum were obtained. Photomicrographs, shown in figure 37A + B, depict 
increased SNc cell and TH-positive striatal fibre survival in the ChABC group (left hemisphere). 
It is evident that ChABC helps either protect or repair neurones of the NS. 
  
  
Figure 38: Photomicrographs highlighting ChABC's effect of increasing TH-positive cell and 
fibre survival in the partial lesion model. 
(A) Rostral coronal TH-positive SNc cell sections. Top: saline-treated SNc, Bottom: ChABC-
treated SNc. The unilaterally lesioned SNc is shown on the left of each section. All sections 
were cut at the rostral level (-2.92 mm AP; relative to bregma and skull surface) Scale bar 
represents 250 μm. (B) Rostral coronal sections of the TH-positive dopaminergic fibres of the 
mouse striatum. All sections were cut at the rostral level (+1.0 mm AP; relative to bregma and 
skull surface).  Scale bar represents 500 μm.  
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Assessment of cells remaining in the SNc and TH-positive fibres 
remaining in the striatum as a result of saline and ChABC treatment 
TH-positive cells of the SNc were counted in the lesioned and intact hemispheres of each 
animal (data not shown). These data were then used to produce values that represent the TH-
positive cells in the lesioned SNc as a percentage of the intact SNc. Unlike the previous study, 
the three levels of the SNc were not averaged as significance was found between them.  
When kept split into the three different levels of the SNc, a significant difference between the 
saline- (24.8 ± 6.1%) and ChABC-treated animals (51.6 ± 8.5%) was found at the rostral level 
(p=0.022; Student t-test; figure 38C). Both the caudal and medial levels of the SNc saw a 
consistent partial lesion equivalent to the degree of severity seen in Pilot Study 2 (Percentage 
TH-positive cells remaining: Saline: 44.6 ± 4%, ChABC: 49 ± 6% and Saline: 37 ± 6%, ChABC: 43 ± 
6%, respectively). However, no difference was found between the saline- and ChABC-treated 
groups at either level (figure 38A + B). Despite this, these data indicate that the ideal lesion size 
(~50 - 60%) was obtained. 
Similarly, when kept split into the three different levels of the striatum, a significant difference 
in TH-positivity between the saline- and ChABC-treated animals was found in the dorsal half 
(averaged DM and DL quadrants) of the rostral striatum (Saline: 15.3 ± 3.5%; ChABC: 36.3 ± 
6.5%; p=0.014; Two-Way ANOVA with Bonferroni post hoc test; figure 38F). As with the SNc, 
neither the caudal or medial levels presented any significance in ChABC-mediated cell terminal 
survival (figure 38D + E). However, the size and consistency of the lesion in these areas do 

































































































































































































































































































































































































Figure 39: Effects of ChABC on cell and terminal pathology in the partial lesion model. 
(A - C) Percentage of TH-positive SNc cells remaining in the lesioned hemisphere as compared 
to the intact for both saline- and ChABC-treated groups. Panels represent the percentage at 
the caudal (A), medial (B) and rostral (C) levels of the SNc. (D-F) Percentage TH-positive 
dopaminergic terminals in the lesioned striatum as compared to the intact for both the saline- 
and ChABC-treated groups. Panels represent the percentage at the caudal (D), medial (E) and 
rostral (F) levels of the striatum analysed. Data are split into the dorsal (Average of the DM and 
DL quadrants) and ventral regions (Average of the VM and VL quadrants). Panels A-C: Student's 
t-test; * denotes p<0.05; Panels D-F: Two-way ANOVA with Bonferroni post hoc test # denotes 
p<0.05 between the dorsal striata of the saline- and ChABC-treated groups. Saline: n=17 and 
ChABC: n=17. Data are mean ± S.E.M. 
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 Assessment of behavioural outcomes as a result of saline and ChABC 
 treatment 
In order to determine whether ChABC improves behavioural outcomes, two tests were 
enforced. These were the cylinder and the amphetamine-induced rotation tests. The 
apomorphine-induced rotations test was not used as it only induces rotations in fully lesioned 
animals (i.e. ~85% SNc cell loss). 
No significant differences between treatment groups were seen in asymmetry score on any day 
(figure 39A). Both groups presented similar average base line asymmetry scores (mean scores 
for days -3 and -1; Saline: 41.2 ± 1.2%; ChABC: 48.2 ± 1.4%). Scores declined from day 14 until 
the end of experimentation for both the groups (scores on day 35; Saline: 28.1 ± 4.6%; ChABC: 
36.5 ± 3.9%; ns; Two-Way repeat measures ANOVA with Bonferroni post hoc test).  
Amphetamine did not induce a difference in net ipsiversive rotations between saline- and 
ChABC-treated animals (figure 39B). Both groups peaked at ~70 minutes where mean scores of 
33.1 ± 8.1% and 28.6 ± 5.9 for saline and ChABC treatment, respectively. A similar number of 

































































































































































































































































































































































































































































Figure 40: Effects of ChABC on behavioural outcomes in a partial lesion hemiparkinsonian 
model of PD. 
(A) Asymmetry scores of animals in the saline and ChABC groups determined by the cylinder 
test. Animals were tested prior to lesioning and weekly for 35 days post lesion. (B) 
Amphetamine-induced net ipsiversive rotations of animals in the saline or ChABC groups. Mice 




The two main studies within this chapter set out to test two hypotheses. These were, firstly, 
whether ChABC administration would act as a strategy of increasing cell survival in the full 
hemiparkinsonian mouse model of PD. Secondly, whether ChABC administration would act as a 
strategy of increasing cell survival in the partial hemiparkinsonian mouse model of PD. 
3.5.1. Characterising the 6-OHDA full and partial lesion models 
In order to establish the model, a range of 6-OHDA neurotoxin doses was used to characterise 
the full lesion 6-OHDA model. Doses of 4, 6 and 8 μg 6-OHDA, chosen on the basis of similar 
previous mouse lesioning studies (Francardo et al., 2011; Glajch et al., 2012; Heuer et al., 2012; 
Iancu et al., 2005), were administered locally to the SNc. Both the 6 and 8 μg doses of 6-OHDA 
could have been chosen to ablate the SNc as both produced the desired size lesion. The 4 μg 
dose induced a near partial lesion and so was not taken into consideration. A significant 
weakness of this pilot study was the absence of striatal TH-positive dopaminergic terminal 
analysis. Due to a misfortunate loss of striatal tissue, this analysis was not possible. 
Nevertheless, the SNc pathology and behavioural analyses were conclusive enough for the 8 μg 
6-OHDA dose to be used for the full lesion model. 
Similar to the characterisation of the full lesion model, a range of 6-OHDA doses were chosen 
based on previously published mouse lesioning studies (Francardo et al., 2011; Heuer et al., 
2012; Iancu et al., 2005). Of the concentrations chosen, the 4 μg 6-OHDA dose induced a 
consistent partial lesion across all levels of the SNc and striatum; a comparable size to that 
found by others (Francardo et al., 2011; Heuer et al., 2012). Unfortunately, behaviour was not 
conducted in this pilot due to time constriants. However, the pathology the dose induced was 
ideal for the partial lesion study and so behavioural data was not essential for reaching this 
decision.  
3.5.2. ChABC digestion patterns  
As the use of ChABC in the parkinsonian BG was novel, the mechanism behind any beneficial 
effects were not known. To induce any restorative effect it was not known whether CSPG 
digestion would be required at the injured cell bodies (SNc), at their terminals (striatum) or 
between the two (MFB region). Therefore, it was logical to digest the entire NS in order to 
explore for any effect before focusing on one of three of the stated areas. When injected 
directly to the two sites (striatum and SNc), ChABC did not digest CSPGs along the entire NS, 
with ventral regions of the brain not being digested. The two relocated injection sites (caudal 
striatum and rostral SNc) were found to cause the full digestion required for the two lesion 
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model studies. This digestion was evident by the exposure of the C4S stub epitopes following 
ChABC treatment. This method of C4S staining has been frequently used in the spinal cord 
injury field as a method of detecting digested CS-GAGs. Although other epitopes can be 
detected (e.g. 2B6), they all produce the same pattern correlating to CS-GAG digestion.  
It is important to stress the significance of a single bolus injection being able to maintain 
digestion of CSPGs after a month. In the spinal cord field, ChABC's efficacy is considerably 
lower in long term studies and therefore methods of prolonging ChABC exposure have been 
investigated. Here we present data showing single administrations of ChABC providing the 
desired effect. Discussion regarding ChABC's efficacy and stability is further mentioned in 
section 3.5.7. 
3.5.3. ChABC does not improve cell survival or behavioural outcomes in a 
fully lesioned model of Parkinson's disease 
Despite the entire and sustained digestion of the NS (as shown in Pilot Study 3), ChABC did not 
provide a cell survival effect to either the state of cellular pathology or behavioural outcomes; 
disproving our first hypothesis. This lack of effect may be attributed to the severity and speed 
of the developed full lesion. Although ChABC-mediated digestion of the CSPGs occurs rapidly 
(within 24 hours; data not shown), it seems that no degree of NTF liberation or barrier removal 
can counter the effects of the cell death. Although a negative result, this does however 
highlight an important point behind the mechanism of ChABC’s beneficial nature. Any cellular 
repair or protection, if present, would most likely occur to slowly degenerating neurones rather 
than quickly ablated ones as seen in this model. This therefore highlights the importance of 
analysing the effects of ChABC within the partial lesion model where this slower degeneration 
occurs. 
3.5.4. ChABC successfully improves cell survival but not behavioural 
outcomes in a partially lesioned model of Parkinson's disease 
Digestion of the CSPGs along the entire NS proved to be beneficial to the rostral regions of the 
SNc and dorsal striatum, where cell number and TH-positive terminals were preserved 
respectively; adding support to our second hypothesis. However, these effects did not translate 
to an improved behavioural outcome. This is most likely due to the behavioural tests not being 
sensitive enough to detect such a subtle phenotype. To counter this, other behavioural tests 
would have to be investigated or a further promotion of detectable ChABC-mediated cell 
survival would be required. To note, the cell loss seen in the rostral SNc of the saline-treated 
animals was greater than the desired ~50% lesion. This was believed to be an effect of the 
close proximity between the rostral level analysed and the injection site of the ChABC. Despite 
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this, ChABC still demonstrated an increase in cellular protection against cell degeneration. 
Unfortunately, due to the preparation of the tissue from these studies (formalin fixed and 
embedded in paraffin wax) we could not test for increases in NTF or other potentially liberated 
factors that would help elucidate the beneficial mechanism behind CSPG digestion. Although 
this was not the main aim behind this study, it would have been of interest to investigate this 
further in this model of disease. Thus while we have evidence for some improvement, we 
cannot deduce whether this is down to the liberation of NTFs and other 
chemorepellents/attractants (i.e. semaphorin 3A) or through physical barrier degradation and 
the formation of cellular contacts (i.e. receptor protein tyrosine phosphatase sigma).  
3.5.5. Dissecting the mechanism of ChABC-mediated cell survival 
Throughout this chapter, ChABC has been discussed as an agent of improving cell survival. This 
is a loose term that has been used to describe either SNc cell neuroprotection or neurorepair. 
As was not clear whether ChABC was inducing one or the other, the term cell survival was 
used. Nevertheless, by altering the timing of the ChABC we may be able to dissect the 
neuroprotection potential from the neurorepair. As our current design administers ChABC 
during the same lesioning surgery, cell protection can occur during the early stages of lesion 
development and neurorepair can occur once the partial lesion has been established. This 
could be avoided by instead injecting ChABC in a separate surgery after the lesion has 
stabilised. Any increase in cell survival would then therefore be a result of neurorepair of the 







Figure 41: ChABC treatment timing could highlight whether neuroprotection or neurorepair 
is elicited. 
(A) Current design of ChABC administration. As ChABC is given to the NS whilst undergoing 
lesioning, it is unclear whether the enzyme is providing a protective effect during this stage or  
a repair effect once the lesion has established. (B) The proposed design of ChABC 
administration. This alters the time of ChABC treatment to when the lesion has developed. Any 





Chondroitin sulphate A CS-A
Chondroitin sulphate C CS-C
Chondroitin sulphate D CS-D
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GalNAc, sixth carbon; GlcA second carbon
GalNAc, fourth and sixth carbon
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3.5.6. Issues regarding pan-CS-GAG digestion 
Although CSPGs have their own separate subtypes, so do the CS-GAG side-chains. As previously 
mentioned, the CS-GAGs are formed by the disaccharide subunits comprised of GlcA and 
GalNAc. These moieties are sulphated by sulphotransferase enzymes at different carbon sites 
resulting in altered structures (see Table 5). By slightly altering the CS-GAG’s structure, and thus 
molecule binding affinities, the subtypes of CS-GAGs can bind to either beneficial or inhibitory 
growth molecules. The CS-GAG subtype most associated with inhibition is CS-E. CS-E has been 
shown to have high affinity for the axon-repulsive guidance molecule semaphorin 3A, and is 
therefore thought to account for the inhibitory nature of the PNN (Dick et al., 2013; Gilbert et 
al., 2005; Vo et al., 2013). In addition, neurotrophins (BDNF, NGF and NT-3 -4/5) have showed 
preferential binding for CS-E (Gama et al., 2005; Rogers et al., 2011) and therefore potentially 
trap growth promoting compounds to inhibit axonal growth. Other CS-GAG isotypes such as 
CS-A have been shown to be growth inhibitory (Wang et al., 2008), presumably due to 
inhibitors and guidance molecules being bound to that subtype.  
Fourth-carbon sulphated CS-GAGs (i.e. CS-E, CS-A) are considered inhibitory, whereas 
conversely, sixth-carbon sulphated CS-GAGs (i.e. CS-D, CS-C) are seen as growth permissive 
(Clement et al., 1998; Lin et al., 2011). It has been suggested that CSPGs with a higher ratio of 
sixth-carbon to fourth-carbon sulphated CS-GAGs give rise to a pro-plastic environment; lower 
ratios were associated with the inhibition of plasticity and the closure of the critical period 
(Miyata et al., 2012). It seems likely that this sulphation code may determine the fate of axonal 
regeneration following injury.   
 
With this in mind, a significant drawback to the use of ChABC has been its pan-CS-GAG 
digestive property. Pan ChABC-digestion removes not only the inhibitory CS-GAGs, such as CS-
E, but also the proposed growth permissive ones, namely CS-D. To promote the ChABC effect 
seen in the partial lesion study, it may be possible to selectively digest or block the inhibitory 
CS-GAGs whilst leaving the beneficial isoforms in order to maximise ChABC's effect. Genetic 
Table 5: Differing CS-GAG sulphation patterns give rise to different isoforms. 
Four CS-GAG subtypes exist within the mammalian brain. These are dependent on the location 
of the sulphate groups. CS-B is not included as it is dermatan sulphate and not of the 




approaches, pharmacological agents and inhibitory antibodies selective for certain sulphated 
CS-GAGs would be the next stage in manipulating the ECM for axonal recovery. To date, such a 
strategy is not yet possible at least in terms of pharmacological agents or blocking antibodies. 
3.5.7. Further considerations concerning ChABC  
Concern regarding ChABC’s proposed short-lived efficacy has been raised (a proposed 8 day 
half life (Mountney et al., 2013)). Studies in the spinal cord injury field have questioned the 
stability of ChABC over long periods (Tester et al., 2007). The enzyme is believed to become 
denatured/inactive quickly under physiological conditions and that prolonged exposure of the 
enzyme requires frequently repeated intrathecal administration (two week intervals) (Huang et 
al., 2006), gene therapy (Curinga et al., 2007) or trehalose-thermostabilising (Lee et al., 2010). 
Despite these concerns, the studies within this chapter have shown C4S immunoreactivity to 
be evident after a month, an extended timeframe to the aforementioned spinal cord injury 
investigations that saw CSPG turnover after two weeks. It is quite possible that the expression 
of CSPGs and their de novo synthesis following digestion is different in the brain to that of the 
spinal cord. The efficacy of a single bolus treatment of ChABC is of great importance to these 
studies, so investigating the degree of CSPG digestion following an additional month or two of 
recovery should be considered. This would indicate whether further administrations of ChABC 
would be required to maintain an increased effect of cell survival in a more chronic model of 
recovery. 
3.5.8. Chapter conclusions 
Overall, the studies in the Chapter have revealed for the first time that ChABC has cell survival 
benefits in a toxin model of PD. Although ChABC elicited no pathological recovery in the full 
lesion model, the lesion was believed to be too severe and fast acting for the benefits of ChABC 
to initiate. Thus, ChABC's benefits were only present in the slower and less severe partial lesion 
model. As of yet, no improved behavioural outcomes have been caused by ChABC 
administration. However, this may be due to the sensitivity of the tests used and the small 
increase in cell survival induced.  
ChABC has proven to be a worthwhile venture in the discovery of new therapeutic agents. 
Identifying methods of increasing ChABC's potency in cell survival would be a logical next step. 












BDNF, NT-3, -4, NGF
GDNF, neurturin, artemin, persephin
CNTF, LIF, IL-6, IL-11, CT-1, CLC, OSM
CDNF, MANF
NTFs
4. Enhancing the cell survival effects of ChABC with selegiline 
treatment 
4.1. Introduction 
As shown in Chapter 3, ChABC presents potential as a therapeutic agent in promoting 
neuroprotection or repair in the partial 6-OHDA lesion model. However as the degree of 
increased cell survival was modest, no changes in behavioural outcomes were observed. We 
propose that in order to achieve better behavioural phenotypes we must increase the degree 
of ChABC-mediated neuroprotection or repair. One of the main theories of why CSPG digestion 
leads to axonal regrowth and repair is that CS-GAG digestion causes the liberation of 
neurotrophic factors (NTFs) which then bind to neighbouring neurones. Therefore, in addition 
to ChABC administration we wish to promote NTFs within the injured NS; primarily GDNF and 
BDNF due to their significance in PD. This would test whether it is possible to enhance the level 
of cell survival previously shown in Chapter 3 to a degree that is detectable by behavioural 
tests. 
4.1.1. The Neurotrophic factor families 
NTFs were mentioned briefly in Chapter 1 as potential agents to improve cell survival in 
neurodegenerative diseases such as PD. Although only two NTFs were previously mentioned 
(GDNF and BDNF), there are many more which belong to four distinct families. These families 
are the GDNF family of ligands (GFLs), neurotrophins, neurokines and the mesencephalic 
astrocyte-derived neurotrophic factor/cerebral DA neurotrophic factor (MANF/CDNF) family 










NTFs are required for both neuronal development and maintenance in particular systems of 
the CNS. But only the NTFs that affect the midbrain DA neurones of the SNc are of importance 
to our work. Although studies have shown promise for the more recently discovered MANF 
(Petrova et al., 2003) and CDNF (Lindholm et al., 2010) NTFs in protecting dopaminergic cells, 
for the purpose of this chapter we shall focus on the two most well-described NTFs in relation 
Table 6: The four families of NTFs. 
There are four families of NTFs within the CNS, the neurotrophins, GFLs, 
neurokines and the CDNF/MANF family. The former two are most referred to 
in this thesis. 
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to PD – the GDNF and BDNF molecules.  
4.1.2. Signalling mechanisms of GDNF and BDNF 
GDNF 
The signalling cascades for GDNF are illustrated in figure 41. GDNF, like other members of the 
GFL family, initiate dopaminegic cell signalling through the activation of the transmembrane 
receptor tyrosine kinase known as Ret. Unlike other tyrosine kinases, GDNF does not bind to 
Ret directly. Instead GDNF binds to the membrane bound co-receptor GDNF-family receptor 
alpha 1 (GFRα1) before it then complexes with Ret. Four subtypes of this co-receptor exist, 
each with varying affinities for GFL molecules; GFRα1 possesses the highest affinity for GDNF. 
Ret phosphorylation occurs following the binding of the ligand to GFRα1, whereby several 
downstream pro-survival cascades are activated, such as the MAPK/ERK and PI3K/Akt pathways 
(d'Anglemont de Tassigny et al., 2015; Onyango et al., 2005; Ugarte et al., 2003).  
Interestingly, transgenic models displaying the heterozygous loss or a conditional knockout of 
the GFRα1 gene displayed degeneration of dopaminergic SNc cells and striatal dopaminergic 
terminals. Additionally, the heterogenous mouse was seen to possess an increased sensitivity 
to MPTP (Boger et al., 2008), whereas the conditional knockout saw pronounced glial 
activation within the SNc and striatum (Kramer et al., 2007). These data reinforce the notion 
that GDNF has a key supportive and protective role in the BG and in PD. 
In addition to the phosphorylation of Ret inducing pro-survival pathways (e.g. MAPK/ERK), 
GDNF has been shown to inhibit apoptosis by activating bcl-2 and bcl-xl whilst also inhibiting 
caspase-3 (Sawada et al., 2000). Addtionally, GDNF has shown to increase levels of the 
antioxidants glutathione peroxidise, SOD and catalase that are instrumental in countering ROS 
activity (Chao et al., 1999) (figure 41). Moreover, there is evidence suggesting that the anti-
apoptotic signalling pathway involving casein kinase 2 contributes to the protective effect of 
GDNF (Chao et al., 2006). Casein kinase 2 has been found to protect proteins from caspase-







































Figure 42: Pro-survival intracellular signalling of GDNF and BDNF. 
The pro-survival and anti-apoptotic pathways involved in GDNF and BDNF signalling overlap 
significantly. Upon binding of GDNF and BDNF, the GFRα1/Ret complex and TrkB receptors 
autophosphorylate and activate common pathways. Shc has high affinity for the 
phosphorylated tyrosine sites found on the Ret and TrkB intracellular domains. The binding of 
Src to the adapter protein growth factor receptor-bound protein 2 (Grb2) leads to the 
activation of Ras. Ras then activates both the MAPK/ERK cascade (through the activation of the 
Raf kinase) and the PI3K/Akt pathway (though SOS binding to PI3K); PI3K can also be activated 
through the Grb2 associated binder 1 (Gab1). The PI3K/Akt pathway leads the inhibition of the 
pro-apoptotic proteins p38 and c-Jun N-terminal kinases (JNK), it is also known to activate the 
transcription factor NF-κB that has a role in cell survival and the inflammatory response. 
Activated Ret is known to cause the activation of the B-cell lymphoma 2 oncoprotein (Bcl-2) 
and the inhibition of caspase 3 and other downstream effects that lead to the reduction in 






Being a member of the neurotrophins, BDNF binds and activates TrkB; a tyrosine kinase 
receptor of the tropomysin-related kinase (Trk) family (Barbacid, 1994). Upon the binding of 
BDNF, the TrkB receptor dimerises which causes the autophosphorylation of its intracellular 
domain and the exposure of docking sites for phospholipase C-γ (PLC-γ) and src homology 2 
domain containing adapter protein (Shc). These proteins are integral to the pro-survival and 
anti-apoptotic intracellular cascades such as MAPK/ERK, PI3K/Akt and PLC-γ (Kaplan et al., 
1997; Yamada et al., 1997b); a similar signalling transduction pattern to that of GDNF. 
Addtionally, BDNF has affinity for the p75 neurotrophin receptor (p75NTR)(Dougherty et al., 
1999), a receptor essential in aiding Trk binding affinities (Segal, 2003) but also the activation 
of nuclear factor κB (NF-κB); a key transcription factor which has a multitude of effects 




Both GFRα1/Ret and TrkB receptors are located at the terminals of dopaminergic cells. GDNF 
and BDNF, which are both secreted by neurones and glia (Chiu et al., 2009; Liu et al., 2001), 
signal primarily in a retrograde fashion whereby signal transduction starts at the cell terminal 
and proceeds down the axon to the cell soma. It is well established that axonal transection of 
neurones greatly inhibits cell growth and initiates cell degeneration (Hendry, 1975). This can be 
in part due to the cessation of this retrograde NTF signalling that is essential for cell survival 
and maintenance (Rich, 1992).  
Unfortunately, for many degenerative diseases axonopathy precedes neuronal death. It is 
thought that axonopathy results in NTF signalling not being able to reach the cell soma in order 
to promote pro-survival gene transcription; leading to a degenerative cycle. When discussing 
the application of NTFs as a therapeutic target this highlights the importance of timing 
(ensuring some cells undergoing axonopathy are alive and can respond to NTFs) and location of 
NTF delivery (NTF infusion at the cell terminals is more effective than at the cell soma (Ito et 
al., 2016)). In the case of the partial 6-OHDA lesion established in Chapter 3, the timing of NTF 
application would be throughout the development of the lesion and after it has been 
stabilised; causing both neuroprotection and neurorepair of the injured neurones. The location 
of NTF application would be the striatum as this is where the terminals of the injured SNc 
neurones reside. 
4.1.3. Promoting brain GDNF and BDNF levels with MAO-B Inhibitors 
The importance of GDNF and BDNF presence within the CNS is clear. Although the evidence 
supporting BDNF’s therapeutic capabilities is far less than that of GDNF, it is apparent that 
many of the downstream signalling cascades overlap. Therefore, BDNF may act in a very similar 
manner in lesion models of disease. As a result, these NTFs have been the target of many 
preclinical and clinical investigations to help promote neuronal repair. As described in Chapter 
1, both BDNF and GDNF have been researched in preclinical models of PD as agents of 
increased SNc cell survival (Martin et al., 1996; Singh et al., 2006; Winkler et al., 1996). Unlike 
BDNF, GDNF has reached the clinic multiple times with varying results (Gill et al., 2003; Patel et 
al., 2005) (see Chapter 1 section 1.11.3. for further details). Although promising in increasing 
SNc cell survival and potentially improving UPDRS scores, both BDNF and GDNF cannot 
penetrate the BBB. Alongside the direct intraputamenal GDNF infusions seen in the Gill et al 
clinical trial, multiple methods of delivering these NTFs have been suggested to counter their 
BBB-impenetrable nature. A recent study investigated the in vivo application of the synthetic 
BBB-penetrable GDNF-derived 11 amino acid neuropeptide, DA neuron stimulating peptide-11 
(DNSP-11), on the pathological and behavioural responses of hemiparkinsonian rodents. DNSP-
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11 elicited both the sparing of TH-positive cells and striatal dopaminergic terminals (Stenslik et 
al., 2015). Others have utilised nanoparticles to deliver NTFs across the BBB with some effect in 
increasing the striatal exposure to GDNF (Fletcher et al., 2011). These studies indicate the 
promise GDNF and its derivatives have on neuroprotection. Viral delivery of both BDNF and 
GDNF has shown success in PD models. Adeno-associated virus and herpes simplex virus 
delivery of GDNF and BDNF presented modest improvements in rat models of PD (Klein et al., 
1999; Sun et al., 2005). Herpes simplex virus delivery of BDNF and GDNF in the unilaterally 
lesioned 6-OHDA rat, as shown by Sun et al., increased the number of cells in the 6-OHDA 
lesioned SNc as a percentage of the intact from 22% in the lesion control to 34% and 54%, for 
BDNF and GDNF respectively. Although successful in promoting cell survival, these methods of 
NTF delivery have not been ideal. Methods of increasing intrinsic levels of NTFs through means 
other than exogenous administration have therefore been of interest. 
When exploring ways of potentially enhancing the degree of survival offered by ChABC 
treatment we have been keen to explore more translatable mechanisms to boost BDNF and 
GDNF levels. To date the one with most promise has been the treatment of MAO-B inhibitors. 
The MAO-B inhibitors rasagiline and selegiline have been suggested to promote the synthesis 
of neurotrophins and GFLs, such as GDNF and BDNF (Maruyama et al., 2013; Maruyama et al., 
2004; Mizuta et al., 2000) and also MAPK/ERK-mediated neuroprotective effects (Bar-Am et al., 
2010; Naoi et al., 2010; Riederer et al., 2011; Weinreb et al., 2009). Evidence has shown that 
the systemic administration of selegiline enhanced the levels of GDNF and BDNF in the 
striatum and ventral midbrain of MPTP-treated mice. These increased levels were suggested to 
reduce the MPTP-induced loss of SNc cells and TH-positive striatal fibres whilst also improving 
gait dysfunction (Zhao et al., 2013).  
As both MAO-B inhibitors are approved by the Food and Drug Administration, the drug 
repositioning potential of rasagiline and selegiline is attractive. With all of these 
aforementioned factors in mind, utilising a MAO-B inhibitor as a systemic inducer of GDNF and 







4.1.4. Study rationale 
We have previously shown that ChABC digestion of the CSPGs within the hemiparkinsonian BG 
produces an increase in cell survival. Although not yet proven, we theorise that this digestion 
leads to the liberation of NTFs from the ECM resulting in cell survival. If true, this could 
highlight the importance of intrinsic NTF release in providing restorative benefits within the 
damaged BG. Ultimately, the mechanism in which digestion works is not of importance other 
than that it results in the increased survival of SNc cells and dopaminergic nerve terminals. 
However, ChABC treatment does not give rise to a better behavioural phenotype when 
compared to controls; arguably an effect of the minor increase in cell survival.  
In this study, we investigated whether administration of the MAO-B inhibitor, selegiline, would 
increase NTF presence, namely GDNF and BDNF, within the mouse BG. Furthermore, we 
believe that this increase would enhance the cell survival induced by CSPG digestion in the 
partial 6-OHDA lesion mouse model to a degree beyond what was found in our previous study. 
This would result in an improved and detectable behavioural phenotype. Due to the 
aforementioned studies indicating NTF signalling being retrogradely transmitted, we believe 
that the primary region of enhanced GDNF and BDNF levels should be the dopaminergic nerve 
terminals within the dorsal striatum. Therefore, we focused our attention of GDNF and BDNF 




4.2. Aims and Hypotheses 
This chapter incorporates two studies. The first, to identify whether systemic treatment of the 
MAO-B inhibitor, selegiline, would increase GDNF and BDNF levels within the mouse BG. The 
second, investigate whether the incorporation of selegiline treatment in the previously 
established ChABC model would potentiate the cell survival effect seen by the digestion of the 
CSPGs in the lesioned murine BG. The main aims and hypotheses for this chapter are described 
below. 
Study aims: 
1. Identify whether the systemic treatment of selegiline increases GDNF and BDNF 
concentrations in the ventral midbrain and striatum of naive mice  
 
2. Investigate whether selegiline increases the cell survival promoted by ChABC through 
enhancing BDNF and GDNF levels in the 6-OHDA partial lesion mouse model  
Study hypotheses: 
1. Selegiline will increase the levels of both GDNF and BDNF within the ventral midbrain 
and striatum of naive mice 
 
2. Selegiline-enhanced concentrations of GDNF and BDNF will enhance the cell survival 




d1: Necropsy d3: Necropsy d7: Necropsy d14: Necropsy
Selegiline: n=3 Selegiline: n=3 Selegiline: n=3 Selegiline: n=3
Saline: n=3
Habituation period
8 week old; n =1 5
1 mg/kg Selegiline or saline; PO; midday dosing
d-7 - d-1 d0 - d14
4.3. Materials and Methods 
4.3.1. Pilot study: Investigating the effects of systemic selegiline on GDNF and 
BDNF levels within the SNc and striatum of naive mice 
 4.3.1.1. Animal subjects 
15 eight-week-old male C57Bl/6 mice (Harlan, UK) were maintained on a 12:12 hour light/dark 
cycle (07:00am lights on) with food and water ad libitum. Room temperature and humidity 
were kept at 22 ± 2°C and 55 ± 2% respectively. All surgical, behavioural and histological 
procedures were performed whilst blinded to the experimental groups. 
 4.3.1.2. Experimental design 
The study timeline is described below in figure 42. A week prior to the initiation of selegiline 
treatment, a 7 day habituation period was implemented to ensure animals were non-
responsive to non-biologically relevant stimuli. On day 0, selegiline (n=12) or saline (n=3) was 
orally gavaged daily at midday for the remaining 2 weeks. On days 1, 3, 7 and 14 following the 
initiation of selegiline treatment, three animals were culled to assess GDNF and BDNF levels in 
the striatum. On day 14 the three saline control animals were also killed. Animals were killed 
by cervical dislocation and brains were removed for biochemical analysis. 
 
 
 4.3.1.3. Selegiline treatment 
Mice were dosed either selegiline (n=12; 1 mg/kg; per os (p.o.); Sigma-Aldrich) or saline (n=3; 
PO) daily for 2 weeks. Dosing sessions were conducted every day at midday and directly before 
any culls on days 1, 3, 7 and 14. 
  
  
Figure 43: Experimental design for Pilot Study: Investigating the effects of systemic selegiline 
on GDNF and BDNF levels within the SNc and striatum of naive mice. 
All procedures of the study were conducted on certain days pre- and post- selegiline treatment 






50 mM Tris HCl Sigma
150 mM NaCl Sigma
1% NP-40 Sigma
0.1% SDS Sigma
0.5% Na Deoxycholate Sigma
0.1 mM EDTA Sigma
1 tablet per 10 ml Protease cocktail inhibitor Roche
1 tablet per 10 ml Phosphatase  cocktail inhibitor Merck
RIPA buffer recipe (for 1L)
pH to 7.4
 4.3.1.4. Western blotting procedure   
 Tissue extraction and preparation 
Upon the designated day of necropsy, mice were killed by dislocation of the neck and heads 
were removed. The ventral midbrain and striata, from both the left and right hemispheres, 
were dissected from the rest of the brain and individually stored on dry ice until homogenised. 
The ventral midbrain was removed instead of the SNc as it was difficult to accurately dissect 
the SNc from the rest of the ventral midbrain; previous studies had done the same (Zhao et al., 
2013). Four samples from each animal were thus obtained. Each sample was homogenised in 
500 µl RIPA buffer (see table 7 for recipe) on ice at pH 7.4 using a Ultra-Turrax tissue 
homogeniser (KIA Werke, Germany) to provide crude homogenates. The homogenates were 













 Protein quantification assay 
In order to determine the concentration of total protein within each sample the bicinchoninic 
acid assay was conducted. Firstly, a set of standards were prepared using BSA (Sigma-Aldrich, 
USA) in RIPA buffer. These standards were serially diluted to the following concentrations: 2, 
1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.0625 mg/ml and the crude homogenates to sample dilutions of 
1:2, 1:4, 1:8 and 1:16 in RIPA. 5 µl of either standard or samples was added to a well of a 96-
well plate (Nunc A/S, Denmark) in triplicate. Bicinchoninic acid reagents A (5 ml) and B (100 µl) 
were well mixed before 100 µl of the solution was added to each of the 96-wells. Any bubbles 
were popped with a fine sterile needle. Using a plate reader (Molecular Devices, Spectramax 
340PC), the absorbance readings for the standards (read at 562 nm) were used to create a 
standard curve. The standard curve was used to determine the concentration of the diluted 
unknown sample by comparing absorbance values.  
Table 7: RIPA homogenisation buffer recipe.  
In order to homogenise striatal and SNc samples the tissue was mixed in a solution of salts, 




Type Host Dilution Supplier
Primary Rabbit; polyclonal 1 in 5000 AB152; Millipore
Primary Rabbit; polyclonal 1 in 5000 ab18956; Abcam
Primary Rabbit; polyclonal 1 in 5000 ab108319; Abcam
Primary Rabbit; polyclonal 1 in 10000 ab6046; Abcam







 Western blotting 
With the concentration of the samples determined, appropriate volumes of crude sample, 5x 
Laemmli sample buffer (GenScript, USA) and dH2O were added to receive a final volume of 100 
µl with a final sample protein concentration of 1 µg/µl. Samples were then boiled at 95°C for 5 
minutes. Samples were stored at -20°C once cooled. 
24-well 10% SDS-polyacrylamide gels were used to run the samples. A cortex control standard 
(20 µg) was always run in the first lane and full-range molecular weight marker (2.5 µl; 
RPN800E; Amersham) in the second and centre lanes. 20 µg of total protein (thus 20 µl) was 
loaded into the remaining lanes, one for each sample. Gels were run at 160 volts until the 
molecular weight marker was visualised at the bottom of the gel.  
Individual gels were then sandwiched between a nitrocellulose membrane (Amersham 
Biosciences), blotting paper and fibre pads. Gels were transferred at 60 volts for 90 minutes. 
Post transfer, nitrocellulose membranes were blocked with 5% powdered milk in 0.1% tween-
20/PBS (PBST-milk) to ensure non-specific binding was kept to a minimum. After the blocking 
stage, the membranes were incubated in the desired primary antibody in PBST-milk overnight 
at 4°C (see table 8 for specific primary antibody concentrations). The following day, PBST 
washes (3x 5 minutes) were performed to remove excess antibody. The appropriate secondary 
antibodies (Table 8) were then incubated in PBST-milk for 1 hour. Final PBS washes (3x 5 
minutes) were then performed to remove excess secondary antibody. To ensure that the 
results were consistent, a total of three gels (3 results for each sample) were performed to 








Table 8: Antibodies used for Western blotting.  





15 g Glycine Sigma
1 g SDS Sigma
10 ml Tween20 Sigma
Mild stripping buffer (for 1 L)
pH to 2.2; bring to 1 L with dH20
Re-probing nitrocellulose membranes  
The nitrocellulose membranes were reprobed for different markers after use. Due to the 
molecular weight of GDNF and BDNF being similar, a membrane stripping process was required 
to remove the first round of antibodies. A mild stripping buffer (see Table 9 for formulation) 
was used to cover the membrane for 5 - 10 minutes at room temperature. The buffer was 
discarded before fresh mild stripping buffer was again applied to the membrane for a further 5 
- 10 minutes. The buffer was then discarded before PBS washes were performed (2x 10 
minutes). PBS-T washes were then finally performed (2x 5 minutes) to ready the membrane for 








Membrane image analysis 
Membranes were imaged using the Odyssey infrared scanner (Li-cor; version 3.0.16). 
Wavelength selection (i.e. 800 nm to be used), size of scan and scan intensity were tailored to 
the antibodies used within the Western blot. The intensity of the rat cortex control was 
calculated and used to express all other band intensities against it as a standardised ratio. The 
standardised values for the samples were then compared to the standardised samples from 
control mice (i.e. mice which received no selegiline) in order to determine whether NTF protein 
levels had been significantly increased following selegiline treatment. ImageJ was used to 
determine band intensities. 
  
Table 9: Mild stripping buffer recipe. 





4.3.2. Investigating the effect of selegiline in the established ChABC-treated 6-
OHDA partial lesion mouse model 
 4.3.2.1. Animal subjects 
40 eight-week-old male C57Bl/6 mice (Harlan, UK) were used and treated according to 
conditions in section 4.3.1.1. 
 4.3.2.2. Experimental design 
The time line for the study is described below in figure 43. A week prior to the initiation of 
selegiline treatment, a 7 day habituation period was implemented to ensure animals were non-
responsive to non-biologically relevant stimuli. Selegiline (n=20) or saline (n=20) was 
administered daily for a week before surgery (the required time for significant increases in 
GDNF and BDNF levels as discovered by the pilot study [see figure 44]) and up until necropsy. 
During the habituation period, baseline recordings for the cylinder test were conducted on 
days -3 and -1. All animals received 4 µg of intrastriatal 6-OHDA and either ChABC or saline 
(rostral SNc and caudal striatum) on day 0 in a randomised block design whilst blind to the 
treatment. A recovery period of 35 days was enforced whereby daily rehydration and health 
checks were conducted until the animals had returned to pre-surgical weight. During this 
period the cylinder test was conducted on all animals at weekly intervals (days 14, 21, 28 and 
35). On day 39 post-lesion animals were killed by anaesthetic overdose and brains were 
removed for biochemical and histological analysis. 
 
 4.3.2.3. Selegiline treatment 
Mice were dosed either selegiline (n=20; 1 mg/kg in saline; p.o.; Sigma-Aldrich) or saline (n=20; 
p.o.) daily for the entirety of the study. An 18 G stainless steel bent feeding needle (Harvard 
Apparatus) was used to administer selegiline or saline. A week of treatment was provided 
before lesioning to ensure significant increases in GDNF and BDNF were present, as discovered 
by the pilot study. Dosing sessions were conducted every day at midday and directly before any 
cylinder testing or culls. 
Figure 44: Experimental design for the study: Investigating the effect of selegiline in the 
established ChABC-treated 6-OHDA partial lesion mouse model. 
All procedures of the study were conducted on certain days pre- and post- ChABC and 6-OHDA 




 4.3.2.3. Surgery 
All surgical and post-operative care techniques were identical to the partial lesion study; 
described in sections 3.3.1.3. and 3.3.1.5. of Chapter 3, respectively.  
 4.3.2.4. Stereotaxic 6-OHDA and ChABC injections 
One week after the initiation of selegiline or vehicle treatment, all 40 mice underwent partial 4 
μg 6-OHDA lesioning, as described in Chapter 3 section 3.3.2.4. Five minutes post 6-OHDA 
injection mice received two single 1 μl injections of 10U/ml ChABC (n=19) or saline (n=19) at 
the two sites previously described in Chapter 3 section 3.3.3.5. These were in the rostral SNc: 
AP: -2.3 mm, ML: ± 1.0 mm and DV: -4.2 mm (relative to bregma and skull surface) and the 
caudal striatum: AP: +0.02 mm, ML: ±2.2 mm and DV: -3.5 mm (relative to bregma and skull 
surface).  
Two animals were culled during the recovery period due to ill health. This resulted in four 
experimental groups: Saline/Saline (n=10), Saline/Selegiline (n=9), ChABC/Selegiline (n=9) and 
ChABC/Saline (n=10).  
 4.3.2.5. Behavioural assessment of parkinsonian phenotype 
The cylinder test was performed on pre- or post-lesion days -3, -1, 14, 21, 28 and 35. The 
cylinder test was conducted as described in sections 3.3.4.6. of Chapter 3.  
 4.3.2.6. Striatum and SNc extraction 
On day 39, mice were killed by dislocation of the neck and heads were removed. The whole 
brain was coronally bisected leaving the striatal and nigral regions separate. The striata from 
both the lesioned (left) and intact (right) hemispheres were removed from the brain and 
separately stored on dry ice ready for Western blotting. The remainder of the brain containing 






 4.3.2.7. Western blotting procedure   
Striatal samples were prepped for Western Blotting as described in section 4.3.1.4. In addition 
to using antibodies directed against GDNF and BDNF, these samples were also probed for 
striatal TH levels (dilutions of antibodies found in Table 8). This was because all of the striatal 
tissue had been used for Western blotting and none for paraffin wax embedding and 
immunohistochemistry. 
Membrane image analysis  
As described in section 4.3.1.4., membranes were scanned at 800 nm. Size of scan and scan 
intensity were tailored to the antibodies used within the Western blot. The intensity of the rat 
cortex control was calculated and used to express all other band intensities against it as a 
standardised ratio. The standardised values for the samples were then compared to the 
standardised samples from saline/saline control mice (i.e. mice which received saline instead of 
selegiline and saline instead of ChABC) in order to determine whether protein levels had been 
significantly increased following selegiline or ChABC treatment. ImageJ was used to determine 
band intensities. 
4.3.2.8. Immunohistochemical assessment of lesion size 
Once the tissues containing the SNc had been post-fixed, they were embedded in paraffin wax 
and then sectioned (7 μm thick sections) with a microtome (Thermo Scientific) at three 
rostrocaudal levels of the SNc (rostral: -2.92 mm, medial: -3.16 mm and caudal: -3.52 AP mm; 
relative to bregma). Slide mounted sections were then stained for TH-positive SNc cells as 
described in Chapter 2 section 2.3.2.2. Cell counts were then conducted on imaged tissue to 
give the number of TH-positive cells in both the lesioned and intact SNc, as per Chapter 2 
section 2.3.2.5.  
4.3.3. Statistical analysis 
All statistical analyses were conducted with the Graphpad Prism 5; statistical tests used are 
displayed within the figure legends. Graphpad Prism 5 was used to plot all graphs. GPower 3.1 





4.4.1. Pilot study: Daily treatment of selegiline enhances striatal GDNF and 
BDNF levels in naive mice 
Work by Zhao et al., has previously shown that administration of the MAO-B inhibitor selegiline 
promotes the endogenous release of both BDNF and GDNF within the BG of MPTP-lesioned 
mice. As we wished to finally use this finding as a method of enhancing GDNF and BDNF levels 
beyond what was seen with our ChABC model (see Chapter 3), we wanted to first validate the 
results seen by Zhao et al.  
A time dependent increase in GDNF and BDNF levels was observed in the Western blot analysis 
following 14 days of daily selegiline administration (figure 44A). This reached significance after 
7 days of selegiline treatment (GDNF: 1.9 ± 0.06 and BDNF: 2.3 ± 0.24 compared to saline 
control; Two-Way ANOVA with Bonferroni post hoc test; P<0.001) and maintained for another 
week when the study finished (GDNF: 1.3 ± 0.14; p<0.01 and BDNF: 1.8  ± 0.21; p<0.05 
compared to saline controls; Two-Way ANOVA with Bonferroni post hoc test). Interestingly this 
significant increase was only apparent in the striatal tissue (figure 44B + C). Although the 
ventral midbrain tissue saw a similar dose dependent increase in BDNF and GDNF, neither NTFs 
were significantly raised beyond the saline control. 
A decline was apparent in both GDNF and BDNF levels on day 14 when compared to day 7 of 
daily selegiline treatment. This was observed in both the striatal and ventral midbrain tissue. 





















































































































































































































Figure 45: Semi-quantitative Western blot analysis of GDNF and BDNF levels within the BG 
following selegiline treatment. 
(A) Representative immunoreactive bands for GDNF, BDNF and βIII-Tubulin loading control. 
Each band represents one of three animals culled at that specific day (D1, D3, D7 or D14). 
Control (saline-treated) mice were culled on day 14 (D14). (B + C) Percentage intensity of 
control indicates the degree of GDNF and BDNF presence relative to the saline control animals. 
Two-way ANOVA with Bonferroni post hoc test. ***, ** and * denote p<0.001, p<0.01 and 
p<0.05, respectively, between experimental day and saline control. Each experimental group 














4.4.2. Investigating the effect of selegiline in the established ChABC-treated 6-
OHDA partial lesion mouse model 
As daily treatment of selegiline was considered successful in enhancing striatal GDNF and BDNF 
levels in naive mice, we wished to test whether this increase would further the beneficial 
effects seen by ChABC in the previous chapter. As the results in section 4.4.1. indicated that a 
week of selegiline treatment was required to maintain increased levels of GDNF and BDNF, a 
week of dosing was conducted before lesioning and ChABC administration. 
 Confirmation of CSPG digestion along the NS  
To validate the study in regards to CSPG digestion, the pattern of C4S immunoreactivity was 
firstly investigated. This study study used the coordinates determined by Pilot Study 3 in 
Chapter 3. As before, unilateral ChABC administration brought about the full digestion of the 
entire NS in the lesioned left hemisphere (figure 45). The ChABC digested the CSPGs 
surrounding the SNc, striatum and NS regions. Although not shown below, vehicle 
administration presented no C4S-positivity and thus no digestion. The degree of CSPG digestion 




Figure 46: Two bolus injections of ChABC digest the entire NS. 
Photomicrographs of four levels of the NS highlighting the regions of C4S-positivity and thus 
CSPG digestion (brown). ChABC was administered unilaterally into the 6-OHDA lesioned 











































 TH immunohistochemistry of the SNc and striatum  
To assess the therapeutic benefit of both selegiline and ChABC on cell survival, images of the 
SNc were obtained. Photomicrographs, shown in figure 46, depict only an increase in cell 
survival in the ChABC-only experimental group (bottom panel). No TH-positive striatal fibre 




Figure 47: Photomicrographs highlighting the TH-positive SNc cells remaining following 
selegiline or saline and ChABC or saline treatments. 
Coronal TH-positive SNc cell sections. Top to bottom: Saline/Saline control, Saline/ChABC, 
Selegiline/ChABC and Saline/ChABC. The unilaterally lesioned SNc is shown on the left of 
each section. All sections were cut at the rostral level (-2.92 mm AP; relative to bregma 















































































































































































Assessment of TH-positive cells remaining in the SNc as a result of 
ChABC and selegiline treatment 
 
Using the data obtained from the photomicrographs, TH-positive cells of the SNc were counted 
in the lesioned and intact hemispheres of each animal (data not shown). These data were then 
used to produce values that represent the TH-positive cells in the lesioned SNc as a percentage 
of the intact SNc. As with Chapter 3's study, the three levels of the SNc were not averaged as 
significance was found between them.  
There was no significant difference in the percentage of SNc cells remaining in the partially 
lesioned hemisphere between the saline- and selegiline-only treatment groups (blue versus 
white bars). This was consistent across all three levels of the SNc analysed. However, animals of 
the ChABC-only group displayed a higher percentage of cells remaining in the rostral SNc level 
to that of the saline control (Control: 23.5 ± 3.5% and ChABC only: 42.1 ± 10.5%; p=0.027; One-
Way ANOVA with Bonferroni post hoc test) (figure 47C; orange versus white bars). This increase 
in the rostral level was significantly higher than the combined treatment of selegiline and 
ChABC (selegiline/ChABC: 15.9 ± 2.9% and ChABC only: 42.1 ± 10.5%; p<0.05; One-Way ANOVA 
with Bonferroni post hoc test). Furthermore, the degree of cell survival ChABC-only induced 
matched the results from the ChABC partial lesion study in Chapter 3 (Chapter 3 rostral SNc: 








Figure 48: Analyses of SNc cells, striatal TH-positive fibres and striatal GDNF and BDNF levels 
following the treatment of ChABC and selegiline. 
(A - C) Percentage number of TH-positive SNc cells remaining in the lesioned hemisphere as 
compared to control of all four experimental groups. All three levels of the SNc were left 
separated. One-way ANOVA with Dunnett's post hoc test; * denotes p<0.05 between group 
and saline/saline control (white bar). Saline/saline (white bar): n=10, selegiline/saline (blue 
bar): n=9, selegiline/ChABC (green bar): n=10 and saline/ChABC (orange bar): n=9. Data are 
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 Semi-quantitative Western blot analysis of GDNF and BDNF levels 
 following ChABC and selegiline treatment  
Western blot analysis was conducted to identify whether striatal protein levels had been 
affected by ChABC or selegiline administration in an individual or synergistic manner. Although 
both the lesioned (ChABC/6-OHDA) and intact (control) striata were taken for GDNF and BDNF 
measurement, no difference was found between any experimental group. Results were 
therefore averaged for analysis. Western blotting revealed no statistical significance in GDNF 
and BDNF levels in the striatum between any groups at the end of the study (figure 48A - C).  
No improvements were found in the percentage of TH-positive fibres remaining in the lesioned 
striatum (as percentage of saline/saline control; ns; One-Way ANOVA with Bonferroni post hoc 
test).   
   
Figure 49: Analyses of striatal GDNF, BDNF and TH-positive fibre levels following the 
treatment of ChABC and selegiline. 
(A) Representative immunoreactive bands for GDNF, BDNF, TH and βIII-Tubulin loading 
control. (B + C) Western blot analysis of striatal GDNF and BDNF concentrations in both 
hemispheres, respectively. (D) Western blot analysis of striatal TH remaining in the lesioned 
hemisphere as a percentage of the intact. Saline/saline (white bar): n=10, Selegiline/Saline 
(blue bar): n=9, Selegiline/ChABC (green bar): n=10 and Saline/ChABC (orange bar): n=9. Data 






























 Assessment of behavioural outcomes as a result of ChABC and 
 selegiline treatment 
No significant differences between treatment groups were seen in asymmetry score on any day 
(figure 49). All four groups presented similar average base line asymmetry scores (averaged for 
days -3 and -1: Saline/saline: 49.8 ± 0.8%, selegiline/Saline: 48.9 ± 1.7%, selegiline/ChABC, 49.5 
± 0.9% and Saline/ChABC: 48.0 ± 1.5%; ns; Two-Way repeat measures ANOVA with Bonferroni 
post hoc test). A score of 50% represents an unbiased and therefore unlesioned phenotype. 
Following lesioning on day 0, scores declined from day 3 until the end of experimentation for 
all the groups (Score on day 35; Saline/saline: 34.5 ± 3.9%; selegiline/Saline: 40.2 ± 2.5%; 
selegiline/ChABC: 33.9 ± 3.5% and Saline/ChABC: 32.4 ± 2.3%; ns; Two-Way ANOVA with 
Bonferroni post hoc test). No significance was observed between any group receiving either 










Figure 50: Cylinder test. 
Asymmetry scores of animals from the four experimental groups (ChABC and selegiline 
treatment with saline controls). Mice were tested prior to lesioning and weekly for 35 days 
post lesion. Saline/saline: n=10, Selegiline/Saline: n=9, Selegiline/ChABC: n=10 and 





4.5.1. Systemically administered selegiline significantly enhanced GDNF and 
BDNF levels within the striatum of naive mice  
The studies in this chapter set out to test the hypothesis that the MAO-B inhibitor, selegiline, 
would enhance the degree of cell survival beyond what was discovered by ChABC alone in 
Chapter 3. This would ideally result in a favourable and detectable functional phenotype. 
Selegiline was theorised to enhance cell survival by increasing striatal GDNF and BDNF 
presence, a finding also found by others (Zhao et al., 2013).  
Initial studies sought to confirm that use of selegiline would be an effective way to boost GDNF 
and BDNF levels. Following 7 days of selegiline treatment it was found that both GDNF and 
BDNF protein levels were enhanced in the striatum of treated animals; supporting the use of 
selegiline as a pharmacological means to boost these NTF levels. Our results differed to those 
found in the Zhao study who not only found an increase in GDNF and BDNF within the striatum 
but also the ventral midbrain. However, due to the size of the dissected ventral midbrain, this 
difference could be attributed to an error in dissection. Being a small region to dissect, our 
ventral midbrain homogenates may have possessed different tissues not associated with the 
ventral midbrain, therefore diluting the results. However, variations in tissue content would be 
associated with a large degree of error, which was not found in our results.  
Although both the D7 and D14 time points saw the increased levels in GDNF and BDNF, the 
mean levels declined in concentration during the second week of daily selegiline treatment. 
Although we did not expand this pilot study beyond fourteen days, it may be wise in future to 
investigate whether an additional week of treatment would induce a significant fall in protein 
concentrations. If so, this may confound the outcome of chronic studies beyond fourteen days 
using daily selegiline treatment.  
4.5.2. Selegiline does not enhance the effect of ChABC treatment in the partial 
lesion mouse model 
This study was a success as not only were the NS CSPGs effectively digested by ChABC, but also 
because the CSPG-only group elicited an increase in survival of the rostral SNc cells. The degree 
of survival seen in the ChABC-only group was equivalent to that observed in Chapter 3's ChABC 
partial lesion investigation. However, contrary to our hypothesis, this survival was not further 
enhanced by selegiline and did not provide an improved and detectable behavioural 
phenotype. While disappointing, this study did however replicate our previous results obtained 




At the end of the study, Western blot analysis indicated selegiline to be ineffective at increasing 
GDNF and BDNF protein levels within the mouse striatum. This is despite the promising effects 
seen in the previous 14 day pilot study which saw a robust increase in striatal GDNF and BDNF 
after 7 and 14 days. It is likely that the trend in GDNF and BDNF decline has continued to a 
significantly lower level in the additional weeks this study ran. As we do not know the specific 
mechanism in which selegiline promotes GDNF and BDNF release, it is difficult to understand 
whether some form of desensitisation is occurring between the inhibitor and its target or 
through other means. It may be worth while exploring how frequently selegiline has to be 
administered to maintain heightened GDNF and BDNF levels once peak concentration at D7 
has been reached. This may halt the possibility of desensitisation to the compound. 
Although we are confident that GDNF and BDNF levels were elevated following 14 days of 
selegiline administration, the treatment of the MAO-B inhibitor did not enhance the levels of 
GDNF and BDNF after 39 days of daily treatment. This indicated that the 14 day window of 
increased striatal GDNF and BDNF content was not sufficient to enhance cell survival in this 2 
month study. This highlights a few points, firstly, that increased striatal levels of GDNF and 
BDNF (a result of selegiline treatment) within the neuroprotection window (initial 14 days post-
lesion) do not enhance neuroprotection. Secondly, as GDNF and BDNF levels were enhanced 
only within this early window of the study, we cannot conclude whether these increased NTF 




In addition, the co-treatment of selegiline and ChABC was, unexpectedly, equivalent to the 
saline control group and not the ChABC-only group. This result indicated a possible negating 
effect of selegiline on the ChABC-induced digestion of the CSPGs. Due to the unknown 
mechanisms underlying both CSPG digestion and selegiline's promotion of NTFs, it is difficult to 
pinpoint any conflicting protein interactions. Despite this, several studies have utilised both 
GDNF and ChABC treatment to promote recovery in spinal cord injury models with success 
(Tom et al., 2009; Zhang et al., 2013) or at least with no cancelling-out effect (Sivak et al., 
2014). Thus, any conflicting interactions between selegiline and ChABC must be either in a 
GDNF/BDNF-dependent pathway or directly between the two enzymes. This latter point has 
been resolved within this study, as the activity of ChABC was not inhibited by daily selegiline 
treatment; this was made evident by the digestion of CSPGs (C4S presence) within the NS. 
A significant flaw in this study was the use of selegiline during the 6-OHDA lesion induction 
stages of the study (D0-D14). The MAO inhibitor, pargyline, is commonly pre-treated before 6-
Figure 51: Time course of study following 6-OHDA lesioning. 
Single bolus treatment of ChABC induced cell survival when dosed alone (Chapter 3). This may 
have been attributed to either neuroprotection or repair as it was administered before 6-
OHDA lesioning. Selegiline increased GDNF and BDNF levels during 14 days of daily treatment 
(as described in pilot study, figure 44) but was not found to maintain these levels at the end of 
the study (d39). This indicated that, although GDNF and BDNF levels were enhanced during the 
early protection window, no significance was found. Therefore, selegiline's assumed beneficial 
effect is likely to not work via neuroprotection.   
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OHDA surgery to reduce the metabolism of the toxin and enhance its effects (Thiele et al., 
2012). With selegiline working in a similar fashion to pargyline, selegiline would have increased 
the efficacy of 6-OHDA in all the animals treated. This would have caused more severe lesions 
in mice receiving selegiline. In future studies it may be advisable to pre-treat all animals with 
pargyline to ensure all animals receive the same exposure to 6-OHDA with or without 
selegiline. Of course, direct infusion of GDNF and/or BDNF would have circumvented this 
problem, but we were keen to explore novel systemic strategies that have an easier translation 
to patients. 
Unfortunately, an improved behavioural phenotype was not found following ChABC and/or 
selegiline treatment. No significance was detected between the asymmetry scores in animals in 
any group. These are simply attributed to the lack of cellular and TH-positive fibre recovery 
provided by selegiline. The ChABC-only group did provide an increase in SNc cell survival, but 
as with the previous investigation in Chapter 3, the cylinder test was not sensitive enough to 
detect the modest improvement.   
4.5.3. Further considerations regarding selegiline  
Selegiline has shown in other works to be important in MAO-B inhibition but also in providing a 
degree of cell survival. We, and many others, believe that these two processes are mutually 
exclusive for the reasons below. As the inhibition of MAO-B is irreversible, the rate of MAO-B 
turnover is dependent on de novo synthesis. Studies have identified that the time taken for 
MAO-B levels to return back to basal activity following selegiline administration (0.25 mg/kg) to 
be 7 days in the rat (Timar, 1989). In humans, selegiline (5 mg/kg; twice daily) was found to 
have a persistent half life of 40 days (Fowler et al., 1994). However, in our studies and in other’s 
(Zhao et al., 2013), data suggest that daily administration of selegiline is required to promote 
and maintain the increase in GDNF and BDNF levels. This need for frequent treatment supports 
a non-MAO-B inhibition driven mechanism underlying this increase in GDNF and BDNF release.  
4.5.4. Future investigations 
Several areas of further investigation could be undertaken in regards of this study. In order to 
identify whether selegiline possesses any neuroreparative efficacy in this model of disease, 
alterations can be made to the dosing regimen. It is clear that selegiline has no neuroprotective 
role but it may possess effects of neurorepair. These effects were not apparent in this study as 
the increase in GDNF and BDNF levels would have declined after 2 weeks of daily 
administration and therefore selegiline would have been ineffective during this neurorepair 
window (i.e. after the lesion had developed). With this in mind, it may be of interest to 
administer selegiline 2 weeks post-lesion until the end of the investigation. Any increases in cell 
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survival would then be associated with neurorepair.  
Other NTFs to investigate would be neurturin, MANF and CDNF; candidates with promise in the 
dopaminergic system. Neurturin has been implemented in effective gene therapy strategies in 
both rodent and NHP models (Kordower et al., 2013) which have translated into the clinic. 
However, the efficacy of neurturin has yet to be proved in double-blinded trials (Domanskyi et 
al., 2015). Intranigral lentiviral expression of CDNF and MANF in the 6-OHDA lesioned mouse 
has proved beneficial. CDNF overexpression lowered the amphetamine-induced rotations and 
increased TH-positive terminals in the striatum, whilst MANF provided significant protection of 
the SNc neurones (Cordero-Llana et al., 2015). The same study saw the combined intranigral 
treatment of CDNF and MANF provide a synergistic combination of the two behavioural and 
pathological benefits (Lindahl et al., 2016). These investigations highlight the importance of 
detecting other NTFs that have proven to have neuroprotective results in both the human and 
animal models of PD.  
The expression of the GFRα1/Ret receptors, TrkB and p75NTR receptors on striatal 
dopaminergic terminals would be important to identify through both histological and 
biochemical means. Long-term exposure to selegiline may induce receptor plasticity that gives 
rise to more NTF receptors being trafficked to the cell membrane, ultimately increasing cell 
sensitivity to GDNF and BDNF. On the other hand, chronic exposure may cause receptor 
downregulation which may explain the dampening of any neuroprotective effect.  
It is possible that the increase in NTF release by selegiline is specific to only naive and MPTP 
lesioned mice (Zhao et al., 2013). Although highly unlikely, it is possible that the mechanism in 
which 6-OHDA causes toxicity inhibits the interaction between the MAO inhibitor and its 
target. To confirm whether this were true, a small pilot analysing the striatal NTF content and 
SNc cell pathology within MPTP- and 6-OHDA-lesioned mice treated with selegiline would be 
suggested. This study would follow the same protocol as described in section 4.3.2. but would 
also include MPTP treatment as a method of lesioning for an additional group. No ChABC 
would be administered, as this is purely an investigation into selegiline's ability to enhance NTF 




4.5.5. Chapter conclusions 
Overall, the studies in this chapter have revealed that the daily administration of selegiline 
does not enhance the degree of ChABC-mediated cell survival but it may in fact inhibit it. The 
reasons for this are unknown, but we assume it to be due to interactions between their two 
pathways rather than directly between the proteins. Surprisingly, the selegiline-only group did 
not promote the levels of striatal GDNF and BDNF as seen in the 2 week pilot study. This 
indicated that selegiline can only promote these levels for ~2 weeks before they return to 
baseline and that an altered dosing regimen may be required for longer studies such as this 
one. We suggest that, as selegiline does not induce neuroprotection during the initial 2 weeks, 





5. Identifying striatal changes in a rodent model of L-DOPA-
induced dyskinesia   
5.1. Introduction  
As mentioned in Chapter 1, L-DOPA-induced dyskinesia (LID) is one of the greatest drawbacks 
to L-DOPA use in the treatment of PD. Arising following the long-term pulsatile exposure to L-
DOPA, LID brings about abnormal involuntary movements (AIMs) that drastically lower quality 
of life. LID therefore remains a key unmet clinical need for people with PD. In the absence of a 
complication-free effective anti-dyskinetic treatment, further understanding of the 
mechanisms that underlie LID is required to unveil new therapeutic targets.  
5.1.1. Mechanisms underlying L-DOPA-induced diskinesia 
The pulsatile stimulation of the postsynaptic dopaminergic receptors in the striatum alongside 
severe SNc denervation gives rise to LID. However, the mechanisms behind its manifestation 
have not been fully elucidated.  
The pathogenesis of LID is thought to combine several pre- and post-synaptic alterations within 
the many pathways of the BG. Therefore, the phenomenon is likely not to be confined to a 
single mechanism. A previously accepted theory of LID states that L-DOPA exposure leads to a 
hyperactive direct pathway and a hypoactive indirect pathway through D1 and D2 receptor 
agonism (Jenner 2008). The culmination of the two leads to the lowered activity of the GPi/SNr 
complex that in turn causes the aberrant disinhibition of the thalamocortical feedback loop 
and the induction of involuntary movements. Although nicely simplistic and somewhat true, 
this theory is outdated. Contradictory evidence, such as an unaffected indirect pathway in NHP 
models of LID (Herrero et al., 1996) and pallidotomies reducing LID (not increasing LID as 
suggested by the theory) (Parkin et al., 2002) indicates a far more complex mechanism, or 
combination of mechanisms, at work. 
On balance, it would appear that stimulation of D1 and D2 receptors have a significant role in 
the induction of dyskinesia. Studies utilising genetic knockout mice demonstrated that the 
deletion of D1 receptors led to a lowered expression of dyskinetic associated markers, such as 
FosB and dynorphin, whilst also inhibiting the manifestation of LID. Furthermore, the same 
experimenters saw persistence of the typical manifestation of LID and the associated molecular 
markers in D2 receptor deficient mice (Darmopil et al., 2009). This suggested that D1 receptors, 
but not D2, were an absolute requirement for LID manifestation. D2 on the other hand may 
play a more modulatory role.  
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Interestingly, studies show a role for the D2-like D3 receptor in the modulation of LID (Bezard et 
al., 2003). Mainly expressed within the nucleus accumbens and other ventral striatum regions 
(Xu et al., 1997), D3 receptors become overexpressed within the dorsal striatum after L-DOPA 
treatment in PD models (Guillin et al., 2001). Studies have produced conflicting results when 
using D3 antagonists as anti-dyskinetic agents (Kumar et al., 2009; Mela et al., 2010; Visanji et 
al., 2009). These varied results may be explained by the lack of selectivity the D3 antagonists 
may have for other receptors of the D2-like family. To investigate the role of D3 receptors in 
LID, recent studies utilised a knockout D3 receptor mouse and determined LID susceptibility. 
These transgenic mice presented lower dyskinesia scores whilst retaining the efficacy of L-
DOPA as a DA replacement therapy (Solis et al., 2015). D3 receptor antagonism may therefore 
be an interesting move in the treatment of LID. 
Increasing evidence suggests 5-HT has a significant role in the maintenance of LID. The DA from 
L-DOPA metabolism is not only formed, stored and released within the dopaminergic neuronal 
terminals but also in the serotonergic neurones (Maeda et al., 2005; Tanaka et al., 1999). In 
response to L-DOPA treatment and the insufficient DA regulation caused by the extensive 
dopaminergic denervation, 5-HT fibres release DA as a false NT (Carta et al., 2007). This is 
possible due to their similarity to dopaminergic terminals (i.e. VMAT2 and the DDC enzyme 
expression (Carta et al., 2008)). In support of this, 5-HT1A and 5-HT1B agonists have been shown 
to ameliorate LID (Gil et al., 2011), whereby, these agonists dampened the activity of the 
presynaptic 5-HT neurones that were releasing DA (Carlsson et al., 2007).  
Altered glutamatergic transmission within the corticostriatal pathway has long been associated 
with the manifestation of LID. Evidence suggests that this pathway is overactive within animal 
models of LID resulting from the enhanced expression and phosphorylation of glutamate 
receptors (Ba et al., 2011; Chase et al., 2000; Ouattara et al., 2010). The NMDA receptor, more 
specifically the striatal concentrated NR2B-subunit containing NMDA receptor (Calon et al., 
2003), has been pharmacologically investigated in LID. Selective NR2B NMDA receptor 
antagonists, such as dextromethorphan, have shown to reduce dyskinetic effects in both Man 
and NHPs, whereby abnormal movements were reduced (Morissette et al., 2006; Verhagen 
Metman et al., 1998). Further evidence suggests that in rodent and NHPs LID models 
antagonists of the glutamatergic amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) 
receptor also inhibit the progression of LID (Bibbiani et al., 2005). Alongside the already 
prescribed anti-dyskinetic NMDA antagonist amantadine (detailed in Chapter 1), these data 
further emphasise the importance of the glutamatergic corticostriatal pathway in LID 
pathogenesis and also the complexity of the mechanisms underpinning LID.  
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This putative aberrant plasticity in the corticostriatal pathway (e.g. altered transmission, false 
transmitter release) has been researched extensively. However, CSPGs have not yet been 
investigated as potential mediators of this plasticity. We understand that throughout 
development and into adulthood, CSPGs shape axonal sprouting and growth through 
controlling cellular plasticity. It is because of this strong relationship with cellular plasticity that 
we were interested in identifying whether CSPGs played a role in LID. 
5.1.2. CSPGs in L-DOPA-induced diskinesia 
To date, there has been no direct link between the CSPGs of the ECM and LID. CSPG-related 
plasticity has been associated with the early development of the corticostriatal pathway and 
other striatal connections (Lee et al., 2008). Therefore, CSPGs may play a role in striatal 
alterations found later in life or in disease states such as LID.  
The CSPG neurocan was expressed within the rat neostriatum during early development. 
Within the first postnatal week dopaminergic terminals increase within the striatum, 
correlating to a rise in neurocan expression in the same striatal compartments (Charvet et al., 
1998). Similarly, PNN development occurs a week later (second postnatal week) within the 
striatum, whereby their presence is associated with the closing of the critical period and the 
dampening of neuroplasticity (Pizzorusso et al., 2002). It is therefore clear that CSPGs and 
PNNs are involved in the development and wiring of dopaminergic systems, but their 
involvement in the aberrant plasticity of LID manifestation is yet to be revealed. 
5.1.3. Preclinical models of L-DOPA-induced diskinesia 
Two well established models of LID are the hemiparkinsonian 6-OHDA rodent and the MPTP 
NHP. After varying durations of daily L-DOPA and DDC inhibitor (e.g. benserazide) 
administration, hemiparkinsonian rodents develop AIMs. In rodents, these AIMs are described 
as aberrant axial (trunk twisting), limb (dystonic or ballistic movements) and orolingual 
(repetitive tongue protrusions, chewing) (ALO) movements; AIMs are the rodent equivalent of 
human dyskinesias. Although AIMs do not resemble true dyskinetic movements, they are 
countered by anti-dyskinetic agents. This presents good predictive validity of this LID model. As 
with the 6-OHDA lesion model, the key advantage of using a hemiparkinsonian model of LID is 
its ability to compare between the lesioned and intact hemispheres of the dyskinetic animals. 
However this leads to a major flaw when analysing the results (as seen within this chapter’s 
study), as effects from L-DOPA treatment cannot be separated from the potential effects 
caused by dyskinesia. This is as AIMs will usually manifest in denervated animals following L-
DOPA treatment. The inability to create non-dyskinetic L-DOPA-treated hemiparkinsonian 




The NHP dyskinesia model more closely replicates human dyskinesia. The MPTP-driven 
dopaminergic denervation primes the brain for quick-onset dyskinesias following L-DOPA 
treatment. As with the hemiparkinsonian rodent, the same anti-dyskinetic agents (i.e. 
amantadine) also reduce the dyskinesia found in the NHP model. Unfortunately, the same 
problem exists regarding an effective control group, whereby MPTP lesioned NHPs will exhibit 
dyskinesia to a degree following L-DOPA treatment and so no non-dyskinetic control can be 
replicated.  
In recent years there has been a current interest in developing a genetic model of LID which 
presents slow dopaminergic degeneration. Initial strategies of using known genetic models of 
PD to induce LID were unsuccessful due to the low denervation caused by the mutation 
(Francardo et al., 2014). The most successful genetic model of LID has been the unconventional 
pentraxin 3 knockout, otherwise known as the aphakia mouse (Francardo et al., 2014). 
Pentraxin 3 is a transcription factor required for dopaminergic cell differentiation. Aphakia mice 
have been shown to have an age-degenerative decline in dopaminergic cells alongside LID 
manifestation following L-DOPA treatment. Although possessing differing AIMs (known as three 
paw dyskinesias) to those of the 6-OHDA LID model, the aphakia mouse presents 
pharmacologically reversible involuntary movements together with increased levels of 
dyskinetic associated markers such as ΔFosB/FosB (Ding et al., 2007; Ding et al., 2011). Despite 
this promise, the aphakia mouse also suffers from the same inability to create non-dyskinetic 
controls. 
As the hemiparkinsonian rodent is the most accessible, most economical and less ethically 
impacting model, it is frequently chosen for LID investigations. Unlike other models in this 
thesis, the rat model was used. This was because of the accessibility for neuroimaging (a key 
part of this chapter) and for the previously described reasons. 
5.1.4. Structural and functional assessments of the striatum in a dyskinetic 
rat 
In order to unravel the complexities underlying LID, methods of detecting alterations within key 
BG regions of patients have been explored extensively using neuroimaging techniques such as 
magnetic resonance imaging (MRI) and positron emission tomography (PET). To date, 
functional MRI (fMRI) investigations have highlighted brain network and metabolic activity 
changes relating to dyskinesia and its pathophysiology (Brooks et al., 2000; Cerasa et al., 2012). 
However, the link between these biological mechanisms and known correlates of brain 
functional activity such as the structure and volume of the basal ganglia and other areas of 
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grey matter (Fauvel et al., 2014; Ilg et al., 2008), have yet to be extensively investigated. 
Therefore, investigating potential neuroanatomical correlates with LID in the dyskinetic 6-
OHDA rodent model would be of great scientific interest. 
5.1.5. Study rationale 
As there is a gap in our understanding of LID and any associated neuroanatomical changes, this 
chapter attempted to identify any alterations in the striatum of the dyskinetic rat. By 
combining the well-established rodent model of LID with structural neuroimaging, specifically 
structural MRI, it was thought possible to elucidate any potential underlying structural changes 
within the striatum associated with LID. As the corticostriatal pathway is considered one of the 
key signalling pathways involved in the pathophysiology of LID, the striatum was targeted for 
neuroimaging.  
Investigations were then undertaken to identify whether CSPGs, known modulators of 
plasticity, were altered within the striatum of the dyskinetic rat. Alterations in CSPG expression 
were thought to underlie the changes found within the striatum that lead to LID. As aggrecan 
and versican had been successful in previous immunohistochemical studies (Chapter 2), these 
were chosen for this chapter. 
Finally, changes in striatal volume were correlated to CSPG expression along with cellular 
markers (e.g. vasculature, microglia). Finding correlates of striatal shape and volumetric 
alterations may highlight new aspects not yet investigated in LID research. Each marker is 
described below. 
Aggrecan and versican 
As CSPGs are associated with the plasticity and rewiring of the striatum during development, 
aggrecan and versican were theorised to affect LID manifestation. Furthermore, it was believed 
that their decreased expression could give rise to an increased ECM volume and therefore may 
explain the expansion of the dorsal striatum.  
GFAP 
Astrocytes (GFAP) were stained for within the striatum due to the believed association of 
neuroinflammation existing within patients experiencing LID (Bartels et al., 2007). 






Endothelial cells (RECA1) were stained for within the striatum due to its believed association 
with dyskinesia, in which angiogenesis and BBB permeability are potential hallmarks of LID 
(Faucheux et al., 1999; Ohlin et al., 2011). Angiogenesis in particular may explain any increases 




5.2. Aims and Hypotheses 
This study was a collaborative effort between the laboratories of Dr Susan Duty and Dr 
Anthony Vernon. The former was responsible for establishing the rodent model of LID, scoring 
AIM severity and conducting immunohistochemistry, whereas the latter was responsible for 
the neuroimaging. Reference to individuals responsible for any results included herein will be 
made. The aims and hypotheses for the study are described below. 
Study aims: 
1. Using T2-weighted MRI, investigate any structural alterations that correlate with 
dyskinesia in a rodent model of LID  
 
2. Analyse aggrecan and versican expression within the striatum of dyskinetic and non-
dyskinetic animals to identify whether CSPGs underlie LID manifestation 
 
3. If any MRI alterations have been detected, identify any changes in cellular (GFAP, 
RECA1 and Iba1) and extracellular markers (versican and aggrecan) that could account 
for these structural changes 
Study hypotheses: 
1. T2-weighted MRI will detect significant alterations in striatal volume and structure of 
dyskinetic animals 
 
2. Aggrecan and versican expression will alter within the striatum of dyskinetic animals  
 
3. Immunohistochemical techniques will detect changes in extracellular and cellular 
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L-DOPA treatment and AIMs testing
d21 - d42
L-DOPA (or saline) treatment  and 
5.3. Materials and Methods 
5.3.1. Animals 
20 adult male Sprague-Dawley rats (270-300g, Harlan Laboratories, UK) maintained on a 12:12 
hour light/dark cycle (07:00am lights on) with food and water ad libitum. Room temperature 
and humidity were kept at 22 ± 2°C and 55 ± 2% respectively. All AIMs testing, MRI and 
histological procedures were performed whilst blinded to the treatment groups. 
5.3.2. Experimental design 
The timeline for the study is described below in figure 51 and fuller destails given in 
subsequent materials and methods sections. A week prior to lesioning (d-7) a 7 day habituation 
period was implemented to ensure animals were non-responsive to non-biologically relevant 
stimuli. During this habituation period, baseline recordings for the cylinder test were 
conducted on day -1. On day 0, all animals received a full 6-OHDA lesion of the MFB. A recovery 
period of 13 days was then given post-lesion whereby daily rehydration and health checks were 
conducted until the animals had returned to pre-surgical weight. On day 14 following the 
recovery period, baseline cylinder tests were conducted. The LID priming phase was then 
conducted between days 21 and 42, whereby L-DOPA (n=9) or saline (n=10) was administered 
(whilst blind to the treatment group) alongside AIMs testing on alternate days. The AIMS 
reversal test was conducted on day 56. On day 63, animals were killed by anaesthetic overdose 
and brains were left in their heads ready for MRI scanning. A month later, the brains were 
removed from the heads and stored at 4°C for immunohistochemistry. 
All procedures up to and including the removal of the heads (sections 5.3.3. to 5.3.10.) were 
conducted by Dr Clare Finlay, Duty laboratory.  
  
Figure 52: Experimental design for the dyskinesia study. 
All procedures of the study were conducted on certain days pre- and post-lesioning as 




5.3.3. Pargyline and desipramine pretreatment 
30 minutes before MFB lesioning, all 20 rats were pre-treated with 5 mg/kg pargyline (i.p.) to 
inhibit the MAO-B-mediated peripheral metabolism of 6-OHDA and also 25 mg/kg desipramine 
(i.p.) to block the noradrenaline transporter and increase selectivity of 6-OHDA for 
dopaminergic cells.  
5.3.4. Surgery  
Even though this study utilised rats instead of mice, surgical (apart from the lesioning protocol) 
and post-operative care techniques were identical to sections 3.3.1.3. and 3.3.1.5., 
respectively, of Chapter 3.  
5.3.5. Full 6-OHDA lesioning of the rat median forebrain bundle  
Unlike previous lesioning studies described, this study induced a full lesion by injecting 6-OHDA 
into the MFB. 
Fine-bore holes (Ø 1 mm) were drilled at coordinates AP: -2.6 mm and ML: ±2.0 mm (relative to 
intraural line and skull surface). A blunt-ended 30 G needle was then inserted above the MFB 
to DV: -8.8 mm (relative to intraural line and skull surface) before all animals were infused with 
12.5 μg 6-OHDA.HBr (Sigma-Aldrich) in 2.5 μl ice-cold 0.02% ascorbate/saline. The injection 
needle was left in place for 5 minutes after toxin administration to ensure the full diffusion of 
the compound.  
5.3.6. Behavioural assessment of parkinsonian phenotype 
To ensure that all the animals entering the LID priming phase had a complete lesion, the 
cylinder and apomorphine-induced rotation tests were conducted.  
5.3.7. Cylinder test  
The cylinder test, as described in section 3.3.4.6. of Chapter 3, was conducted to assess 
whether animals had attained the fully ablated SNc and parkinsonian phenotype required for 
LID induction post-lesioning. As rats were utilised within this chapter, the only difference in 
testing to other chapters was that the testing environment was a Perspex cylinder 21 cm in 
diameter and 34 cm in height. Cylinder tests were conducted during the habituation period on 




5.3.8. Apomorphine-induced rotations 
On day 14, the apomorphine-induced rotation test was conducted to ensure a full lesion had 
developed. Following 30 min acclimatisation in rotometers, rats were injected with 
apomorphine (0.5 mg/kg, s.c.) and the total net contraversive rotations were then recorded 
over 90 minutes using Rotorat software (MedAssociates Inc.). Rats bearing a successful full 
lesion (19 of the 20; one failed to produce any rotations and so was removed from the study 
for not having a full lesion) were then randomly assigned to saline or L-DOPA treatment groups.    
5.3.9. Induction, measurement and confirmation of L-DOPA-induced 
abnormal involuntary movements 
Starting three weeks post lesioning (d21), successfully lesioned animals were injected daily for 
a further 21 days with either L-DOPA (6.25 mg/kg; s.c.) and benserazide (15 mg/kg; s.c.) (n=9) 
or saline (s.c.; n=10). The severity and durations of axial, forelimb and orolingual AIMs were 
assessed on days 21, 23, 25, 27, 29, 31, 33, 37 and 41 of post-lesion using the established 
scoring criteria (Cenci et al., 1998; Winkler et al., 2002). 
Rats were placed in a 40 cm diameter clear acrylic cylinder for 30 minutes acclimatisation and 
scored for baseline AIMs. Following injection of L-DOPA or saline, rats were scored for a one 
minute period every 20 minutes for up to 180 minutes (or until baseline was finally reached). 
Each animal was scored for severity and duration of individual ALO AIMs.  
On day 56 to confirm that dyskinesia was established, rats were treated with the known anti-
dyskinetic compound, amantadine HCl (Sigma Aldrich; 40 mg/kg; s.c.), or saline 30 minutes 
prior to L-DOPA-treatment (or saline-treatment in control rats). This was conducted in a 
randomised, crossover design allowing a wash out between treatments. AIMs were scored as 
above by an experimenter blinded to the treatment received. 
5.3.10. Animal necropsy 
On day 63 rats were terminally anaesthetised with sodium pentobarbital (600 mg/kg; i.p.) and 
transcardially perfused with saline then 10% formalin. The heads were removed and, with the 
brain left in situ, were placed in 10% formalin for a further 24 hours. Residual 10% formalin was 
then removed by immersing the heads in PBS with 0.05% sodium azide at 4°C for four weeks to 





The following neuroimaging techniques and procedures were carried out by the Vernon 
laboratory based at the Institute of Psychiatry, Psychology and Neuroscience (King's College 
London) based at Denmark Hill, London. The methods are included here for completeness. 
  5.3.11.1. Magnetic resonance imaging 
A 7T small-bore horizontal magnet MRI scanner (Agilent Technologies Inc. Santa Clara, USA) 
equipped with a custom-made quadrature volume radiofrequency coil (43 mm inner diameter, 
Magnetic Resonance Laboratory, Oxford) was used for all ex vivo MR acquisition. Anatomical 
MRI were acquired using a Fast Spin Echo sequence: repetition time/effective echo time = 
4000/60 ms, averages=8, field of view = 30 x 30 mm, matrix size 128 x 128, 45 contiguous 
coronal slices, 0.6 mm thick, giving an in-plane resolution of 125 µm. Scans were acquired 
blinded to treatment status in a random order, interspersed with phantoms to ensure 
consistent operation of the magnet. Post-acquisition, anatomical MR images were converted 
offline to NIFTI file format and visually inspected for motion or intensity artifacts prior to 
analysis. No scans were excluded on this basis. 
The volume of the corpus striatum in each hemisphere was calculated by multiplying the sum 
of the striatum surface area on all slices measured by the slice thickness (0.5 mm). Intra-rater 
and inter-rater reliability were assessed following repeated measurements using the intraclass 
correlation coefficient as previously described with values <0.9 rejected (Wolf et al., 2002). An 
index of striatal asymmetry was also computed by calculating the ratio of the volume of the 
striatum in the left (ipsilateral) and right (contralateral) hemispheres for each animal in each 
treatment group.  
 5.3.11.2. Tensor based morphometry MRI 
A mean image of the entire dataset (n=19 scans) was generated using rigid-body registration (6 
degrees of freedom) using a population-based registration method based on FSL-FLIRT (Crum 
et al., 2013; Jenkinson et al., 2002; Jenkinson et al., 2001). Using this mean image, the external 
and internal borders of the left and right corpus striatum from approximately X to Y mm from 
bregma based on the rat stereotaxic atlas (Watson 2007 atlas) were manually defined using the 
polygon tool in ITK-SNAP (http://www.itksnap.org) (Yushkevich et al., 2006) by two expert 
raters (Miss Ana Lopez and Dr Anthony Vernon, IoPPN, KCL) using previously published criteria 
(Vernon et al., 2011; Wolf et al., 2002). Segmentation performance was assessed using intra-
class correlation co-efficient with values <0.95 rejected. This segmentation was used to create 
a binary mask for implementation in our tensor based morphometry (TBM) pipeline to assess 
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anatomical differences related to L-DOPA treatment in the striatum. Maps of localized volume 
difference at each voxel relative to the reference brain for the striatum were computed from 
the log of the Jacobian determinant of this non-rigid transformation for each scan. In addition, 
we then performed an exploratory brain-wide TBM analysis to identify potential anatomical 
changes beyond our a priori driven interest in the striatum. Data are shown at both an 
exploratory uncorrected threshold (p<0.01 uncorrected) and corrected for multiple 
comparisons using the false discovery rate (q=0.1; 10%) (Genovese et al., 2002).  
5.3.12. Tissue preparation and immunohistochemistry for aggrecan, 
versican, GFAP, Iba1 and RECA1 
The following procedures were all performed by me as part of this thesis work. One month 
following MRI analysis, brains were removed from the skulls and submerged in 30% 
sucrose/PBS with 0.05% sodium azide for three days then post-fixed in 10% formalin for a 
further 24 hours. Brains were then embedded in 10% porcine gelatin and again post-fixed in 
10% formalin for 24 hours before a final immersion in 30% sucrose/PBS with 0.05% sodium 
azide. 40µm thick coronal sections were cut through the striatum (AP: +1.70 mm to -2.50 mm 
relative to bregma; Paxinos and Watson 2007) using a freezing sledge microtome and stored as 
free-floating sections in PBS with 0.05% sodium azide.  
Sections were incubated for 10 minutes with 3% H2O2 and 10% methanol in dH2O, washed 
thrice in TBS (pH 7.4) and then incubated for 60 minutes in 0.2% triton-X100 in TBS (TXTBS) 
containing 3% normal goat serum (NGS) or, in the case of anti-Iba1, 1% BSA. Next, sections 
were incubated overnight at room temperature in rabbit polyclonal anti-TH (1:2500; Millipore 
AB152), rabbit polyclonal anti-GFAP (1:10000; Abcam ab7260), goat polyclonal anti-Iba1 
(1:2000; Abcam ab5076) or mouse polyclonal anti-RECA1 (1:2000; Abcam ab9774). Sections 
were then washed in TBS before a one hour incubation in 1% BSA or 3% NGS containing the 
appropriate biotinylated secondary antibody - goat anti-rabbit (1:1000; Vector BA-1000), horse 
anti-goat (1:1000; Vector BA-9500) or horse anti-mouse (1:1000; Vector BA-2001). Next, 
sections were incubated in streptavidin horseradish peroxidise binding complex (Vector Labs; 
SA-5004) for 30 minutes before a final TBS wash and immersion in developing solution (0.05% 
DAB in TBS with 0.01% H2O2) for 10 minutes. Sections were mounted onto Superfrost plus® 
slides (VWR International) and left to dry overnight and dehydrated in industrialised 
methylated spirit before being coverslipped with DPX mountant.   
5.3.13. Image analysis 
Densitometry images for the aggrecan and versican markers were acquired with a Canon DSLR 
camera with a macro lens. High magnification images used for Iba1-positive, GFAP-positive and 
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RECA1-positive analysis were obtained using a Zeiss Axioskop brightfield microscope and a 20X 
objective (Zeiss). A 63X oil immersion objective (Zeiss) was also adopted for further detailed 
images of Iba1-positive microglia. Axiovision 4.6 software (Zeiss) was used to capture the 
images.  
Digital TIFF format images from all treatment groups were equilibrated in Adobe Photoshop 
CS5 in order to create the background uniform in terms of brightness and contrast. ImageJ was 
used to measure the optical densities of each striatum. To correct for background staining the 
density of the medial corpus callosum, a region not known to be associated with dyskinesia, 
was subtracted from the striatal density measurements.  
Aggrecan, versican, RECA1, GFAP and Iba1 background corrected density measurements were 
obtained from both the dorsal and ventral striatum of the lesioned and intact hemispheres. An 
average of nine sections across the rostrocaudal axis was obtained per animal. For Iba1 cell 
number, counts were obtained from dorsal striatum alone, in the lesioned and intact 
hemispheres. For all markers, three sections (section 3: AP: +0.26 mm, section 5: AP: -0.7 mm 
and section 7 AP: -1.66 mm; relative to bregma) of each nine-section rostrocaudal series were 
taken. 
For measures of Iba1 density per soma, density was obtained from microglia resident to the 
dorsal striatum in lesioned and intact hemispheres. An average of 3 sections per rat (sections 3, 
5 and 7 as above) were taken. To calculate the grey mean density of just the soma, the 
freehand selection tool was used to mask density calculations to just the cell bodies. 
All densitometry and microglial cell count figures present data averaged across the three 
sections of the rostrocaudal axis. This was to obtain an average of the entirety of the striatum. 
5.3.14. Statistical analyses 
All statistical analyses within this chapter were conducted with the SigmaPlot 12 package; 
statistical tests used are displayed within the figure legends. Graphpad Prism 5 was used to plot 





5.4.1. Medial forebrain lesioning induced a full ablation of the SNc in all 
animals as determined by behavioural testing 
In order for effective LID development, behavioural tests were conducted to ensure that a 
parkinsonian phenotype was present in all animals. As animals were to be kept alive on this 
experimental day (d14), SNc cell counts were not possible and so the use of the cylinder and 
apomorphine-induce rotation test was required.  
A day before lesioning (d-1), all animals conducted the cylinder test to establish baseline 
readings. A typical asymmetry score of ~50% (indicative of no paw preference) was detected 
for the to-be 6-OHDA lesioned animals (48.9 ± 0.99%; baseline value). This highlighted that the 
animal cohort was not naturally biased to preferring one paw. Post-lesion (d14) (figure 52A), 
unilaterally lesioned animals produced asymmetry scores of 6.0 ± 1.5% (p<0.001 versus 
baseline; Student’s t-test) indicating that the animal cohort had been significantly unilaterally 
lesioned since contralateral paw use had markedly fell. 
To confirm that the unilateral lesion expressed was not partial but full (as required for sufficient 
LID development), animals conducted the apomorphine-induced rotation test. A test, as 
previously described to induce rotations only in fully unilaterally lesioned animals. 
On day 14 post-lesion, the apomorphine-induced rotation test was conducted (figure 52B).  
Animals assigned to the saline- or L-DOPA-treatment groups were separated post hoc to assess 
whether each group had equally lesioned animals. When dosed with apomorphine, to-be 
saline-treated animals produced high counts of contraversive rotations (386 ± 44). These 
counts were similar to those of the to-be L-DOPA-treated animals, which displayed 377 ± 50 
rotations; no significance was found between the groups (Student t-test). Due to the large 
number of contraversive rotations, both groups were considered to have fully lesioned NS. One 
animal was removed from the study as it produced no net contraversive rotations, it was 







































































































Figure 53: Cylinder test and apomorphine-induced rotation assessment of parkinsonian 
phenotype on day 14 post-lesion.  
(A) At baseline, to-be lesioned rats presented no bias in asymmetry score. These same animals 
post-lesion, presented a significant decrease in asymmetry score indicating a loss in 
contralateral paw use. (B) Lesioned animals administered with apomorphine produced high 
counts of contraversive rotations, representative of a fully ablated SNc. Both the to-be saline 
treated and to-be L-DOPA treated rats displayed a similar level of net contraversive rotations. 
Panel A: Student’s t-test; *** denotes p<0.001. 6-OHDA-lesioned n=20. Panel B: to-be saline 
treated: n=10; to-be L-DOPA treated: n=9. Data are mean ± SEM. Graphs were produced by 
myself from data obtained by Dr Clare Finlay. 
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5.4.2. Administration of L-DOPA induced significant, pharmacologically 
reversible dyskinesias in fully lesioned rats 
To analyse the striatum for markers of dyskinesia, a sufficient degree of LID was first needed. 
Animals were therefore tested for their scale of dyskinesia severity in the 180 mins following 
administration of L-DOPA or saline (depending on their experimental group).  
 
Using the aforementioned rodent ALO AIMs scale (Cenci et al., 1998; Winkler et al., 2002), 
scores for each treatment day during the three week dyskinesia priming period (days 21 - 42 
post-lesion) were obtained for every animal (figure 53A). The L-DOPA-treated animals 
presented an instant increase in AIMs score that then balanced out after 11 days of treatment 
(day 31 post-lesion; 182 ± 13). The scores of the L-DOPA-treated animals were significantly 
higher (p<0.001; Two-Way repeat measures ANOVA with Bonferroni post hoc) at every time 
point when compared to the saline-treated controls. Saline-treated animals presented no AIMs 
score (0) on any day of treatment. When all of these data were averaged within their 
respective groups (figure 53B), L-DOPA-treated animals displayed significantly higher AIMs 
scores (160 ± 17.44; p<0.001; Student’s t-test) to those of the saline group, which did not 
produce any AIMs whatsoever (0).  
 
Of the 9 L-DOPA treated animals 2 were considered moderately dyskinetic (boxed points) 
whereas the remaining 7 were classed as severely dyskinetic. However, all animals were 
included in the analysis, as all were considered dyskinetic. 
 
To confirm that the AIMs measured in figures 53A + B were representative of LID, an AIMs 
reversal test was conducted using the known anti-dyskinetic agent amantadine (figure 53C). 
The saline-treated animals did not express any reduction in AIMs with either saline- or 
amantadine-treatment as no AIMs had been previously established. This confirmed that 
amantadine did not induce any AIMs following a single dose. L-DOPA-treated animals 
presented a significant decline in AIMs score when administered with amantadine rather than 
saline (saline: 167 ± 17, L-DOPA: 113 ± 19; p=0.04; Two-Way ANOVA with Bonferroni post hoc). 
This indicated that the AIMs induced by L-DOPA represented a rodent correlate of dyskinesia as 







































































































































































































































































































   
Figure 54: Assessment of L-DOPA administration in rats presenting a full 6-OHDA lesion. 
(A) L-DOPA-treated animals displayed significantly higher AIMs scores on every day of 
treatment when compared to the saline-treated control group. (B) Every L-DOPA-treated 
animal displayed significantly higher AIMs scores on the final day of treatment (d41) when 
compared to the animals of the saline-treated control group. Blue rectangle: rats with 
moderate LID scores, still dyskinetic however. (C) Only the L-DOPA-treated animals presented 
a significant decrease in AIMs score when administered amantadine. Saline controls did not 
respond to amantadine. Panel A: Two-Way repeat measures ANOVA with Bonferroni post hoc, 
*** denotes p<0.001: between saline- and L-DOPA-treated animals on that day. Panel B: 
Student’s t-test; *** denotes p<0.001. Panel C: Two-Way ANOVA with Bonferroni post hoc, ### 
denotes p<0.001: between AIMs scored following saline- and amantadine-treatment. Saline: 
n=10, L-DOPA n=9. Data are mean ± SEM. Graphs were produced by me from data obtained by 
Dr Clare Finlay. 
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5.4.3. Tensor-based morphometry MRI detected an increase in volume of the 
dorsal injured striatum in dyskinetic animals 
To assess whether striatal volume changes had occurred within the dyskinetic striatum, 
structural tensor-based morphometry (TBM) MRI was conducted. A mean template image was 
created from the entire animal cohort (n=19), against which the L-DOPA-treated dyskinetic 
animals were compared. A heat map of voxel expansion or retraction of the L-DOPA-treated rat 
compared to the cohort template is shown in figure 54; this highlighted regions of increased or 
decreased volume. Figure 54 depicts 7 representative images of the striatum along the 
rostrocaudal axis of a L-DOPA-treated animal; the left hand hemisphere is the 6-OHDA-lesioned 
striatum whereas the right is the intact control hemisphere. The L-DOPA-treated animals 
present an increased volume of the dorsal striatum only in the lesioned hemisphere when 
compared to the template.  
All data handling and analysis was performed by members of the Vernon laboratory based at 
the Institute of Psychiatry, Psychology and Neuroscience (King's College London) based at 
Denmark Hill, London. 
  
Figure 55: Tensor-based morphometry MRI highlighted an increase in striatal volume in the 
L-DOPA-treated parkinsonian striatum when compared to the parkinsonian hemisphere of 
the saline controls. 
Orange region depicts a region of voxel expansion and thus increased volume. The 
parkinsonian 6-OHDA-lesioned striatum for both the L-DOPA and saline group was the left 




5.4.4. Aggrecan optical densities were not altered in either the intact or 
lesioned striatum of dyskinetic rats 
Using antibodies against aggrecan and versican, which have shown to stain well within the 
rodent striatum in Chapter 2, we assessed the CSPGs’ optical densities for any alterations in the 
dorsal injured striatum of the dyskinetic striatum. These alterations may correlate with the 
volume increase detected in the MRI. 
The optical densities of aggrecan were uniform across the striata of the dyskinetic and non-
dyskinetic animals as previously seen in Chapter 2 (figure 55A). Aggrecan optical densities of 
the dorsal intact and dorsal lesioned striata of the non-dyskinetic (saline-treated) (Intact: 0.086 
± 0.004, Lesion: 0.077 ± 0.004) and of the dyskinetic (L-DOPA-treated) animals (Intact: 0.076 ± 
0.004, Lesion: 0.077 ± 0.004) were not statistically significant (figure 55B). This lack of 
significance was also detected in the ventral intact and ventral lesioned striata optical densities 
(figure 55C) of the non-dyskinetic (saline-treated) (Intact: 0.114 ± 0.004, Lesion: 0.103 ± 0.004) 
and of the dyskinetic (L-DOPA-treated) animals (Intact: 0.104 ± 0.004, Lesion: 0.103 ± 0.004). 










































































































































































































































































































































































































    
Figure 56: Aggrecan marker optical densities measured within the dorsal and ventral 
striatum of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A) Photomicrographs (5X magnification) of aggrecan optical density within the medial-level 
intact and lesioned hemispheres of non-dyskinetic and dyskinetic rat striatum. Dashed lines 
divide the striatum into the dorsal and ventral regions taken for optical densities (B + C) No 
changes in aggrecan optical densities were detected within the dorsal or ventral striatum in 
either hemisphere or between experimental groups. Saline: n=10, L-DOPA n=9. Data are mean 
± SEM. Data are averaged across all three levels of the rostrocaudal axis. Scale bar: 500 µm. 
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5.4.5. Versican optical densities were not increased in either the intact or 
lesioned striatum of dyskinetic rats 
The optical densities of versican were uniform across the striata of the dyskinetic and non-
dyskinetic animals as previously seen in Chapter 2 (figure 56A). Versican optical densities of the 
dorsal intact and dorsal lesioned striata of the non-dyskinetic (saline-treated) (Intact: 0.211 ± 
0.006, Lesion: 0.197 ± 0.006) and of the dyskinetic (L-DOPA-treated) animals (Intact: 0.21 ± 
0.004, Lesion: 0.208 ± 0.004) were not statistically significant (figure 56B). This lack of 
significance was also the case for the ventral intact and lesioned striata optical densities (figure 
56C); non-dyskinetic (saline-treated) (Intact: 0.218 ± 0.006, Lesion: 0.206 ± 0.006) and of the 
dyskinetic (L-DOPA-treated) animals (Intact: 0.211 ± 0.004, Lesion: 0.214 ± 0.004). All data 











































































































































































































































































































































































































Figure 57: Versican marker optical densities measured within the dorsal and ventral striatum 
of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A) Photomicrographs (5X magnification) of versican optical density within the medial-level 
intact and lesioned hemispheres of non-dyskinetic and dyskinetic rat striatum. Dashed lines 
divide the striatum into the dorsal and ventral regions taken for optical densities (B + C) No 
changes in versican optical densities were detected within the dorsal or ventral striatum 
between hemispheres or between experimental groups. Saline: n=10, L-DOPA n=9. Data are 





5.4.6. GFAP optical densities increased in the dorsal and ventral lesioned 
striata of both non-dyskinetic and dyskinetic rats 
Representative photomicrographs of the GFAP-positive astrocytes within the dorsal striatum 
are displayed in figure 57A (magnification 20X; dorsal striatum). There was a significant 
difference between the optical densities of the dorsal intact and dorsal lesioned striata of the 
non-dyskinetic (saline-treated) animals (Intact: 0.249 ± 0.004, Lesion: 0.297 ± 0.007; p<0.001; 
Two-Way ANOVA with Bonferroni post hoc; figure 57B) and also the dorsal intact and dorsal 
lesioned striata of the dyskinetic (L-DOPA-treated) animals (Intact: 0.247 ± 0.005, Lesion: 0.302 
± 0.007; p<0.001; Two-Way ANOVA with Bonferroni post hoc). 
As with the dorsal striatum, the ventral intact and ventral lesioned hemispheres of the non-
dyskinetic (Intact: 0.225 ± 0.004, Lesion: 0.252 ± 0.004; p<0.001; Two-Way ANOVA with 
Bonferroni post hoc test) and of the dyskinetic animals (Intact: 0.226 ± 0.005, Lesion: 0.259 ± 
0.005; p<0.001; Two-Way ANOVA with Bonferroni post hoc test; figure 57C) were significantly 
different.  
Importantly, there was no difference in GFAP expression between dyskinetic and non-









































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 58: Astrocytic marker optical densities measured within the dorsal and ventral 
striatum of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A) High magnification (20X) photomicrographs of GFAP optical density within the medial-level 
dorsal intact and lesioned hemispheres of non-dyskinetic and dyskinetic rat striatum. (B + C) A 
significant increase in GFAP optical density was detected between the intact and lesioned 
striata in both the dorsal and ventral regions of both the non-dyskinetic and dyskinetic groups. 
Panels B + C: Two-way ANOVA with Bonferroni post hoc; *** denotes p<0.001. Data are mean ± 
SEM. Data are averaged across all three levels of the rostrocaudal axis. Saline: n=10, L-DOPA 




5.4.7. RECA1 optical density did not increase in the lesioned hemisphere of 
the dorsal and ventral striatum in either treatment group 
Representative photomicrographs of the RECA1-positive endothelial cells within the dorsal 
striatum are displayed in figure 58A (magnification 20X; dorsal striatum). RECA1 optical 
densities of the dorsal intact and dorsal lesioned striata of the non-dyskinetic (saline-treated) 
(Intact: 0.039 ± 0.003, Lesion: 0.048 ± 0.003) and of the dyskinetic (L-DOPA-treated) animals 
(Intact: 0.043 ± 0.002, Lesion: 0.043 ± 0.004) were not significantly different (figure 58B). This 
lack of significance was also the case for the ventral intact and lesioned striata optical densities 
(figure 58C); non-dyskinetic (saline-treated) (Intact: 0.048 ± 0.005, Lesion: 0.063 ± 0.006) and 
of the dyskinetic (L-DOPA-treated) animals (Intact: 0.058 ± 0.003, Lesion: 0.06 ± 0.006). All data 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 59: Endothelial cell marker optical densities measured within the dorsal and ventral 
striatum of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A) High magnification (20X) photomicrographs of RECA1 optical density within the medial-
level dorsal intact and dorsal lesioned hemispheres of non-dyskinetic and dyskinetic rat 
striatum. (B + C) No changes in versican optical densities were detected within the dorsal or 
ventral striatum in either hemisphere or between experimental groups. Saline: n=10, L-DOPA 
n=9. Data are mean ± SEM. Data are averaged across all three levels of the rostrocaudal axis. 




5.4.8. Striatal Iba1-positive optical densities are significantly increased 
within the lesioned hemisphere of L-DOPA treated animals 
Representative photomicrographs of the Iba1-positive mciroglia within the dorsal striatum are 
displayed in figure 59A (magnification 20X; dorsal striatum). There was a significant difference 
between the optical densities of the dorsal intact and dorsal lesioned striata of the non-
dyskinetic (saline-treated) animals (Intact: 0.016 ± 0.003, Lesion: 0.034 ± 0.003; p<0.001; Two-
Way ANOVA with Bonferroni post hoc; figure 59B). Significance was also detected between the 
optical densities of the dorsal intact and dorsal lesioned striata of the dyskinetic (L-DOPA-
treated) animals (Intact: 0.024 ± 0.008, Lesion: 0.051 ± 0.004; p<0.001; Two-Way ANOVA with 
Bonferroni post). 
Most importantly, a further increase in Iba1 optical density was detected between the two 
lesioned dorsal hemispheres of the non-dyskinetic and dyskinetic animals (p=0.014; Two-Way 
ANOVA with Bonferroni post hoc tests). This indicated a L-DOPA treatment effect. 
The ventral striatum also presented significance but only between the intact and lesioned 
hemispheres of the non-dyskinetic (Intact: 0.026 ± 0.003, Lesion: 0.044 ± 0.004; p<0.001; Two-
Way ANOVA with Bonferroni post hoc) and dyskinetic animals (Intact: 0.024 ± 0.003, Lesion: 
0.057 ± 0.004; p<0.001; Two-Way ANOVA with Bonferroni post hoc; figure 59C). No significance 





























































































































































































































































































































































Figure 60: Microglial marker optical densities measured within the dorsal and ventral 
striatum of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A) High magnification (20X) photomicrographs of Iba1 optical density within the medial-
level dorsal intact and lesioned hemispheres of non-dyskinetic and dyskinetic rat 
striatum. (B) A significant increase in Iba1 optical density was detected between the 
intact and lesioned striata in both the dorsal and ventral regions of both the non-
dyskinetic and dyskinetic groups. A further increase in Iba1 optical density was detected 
within the lesioned hemisphere of the dyskinetic animals compared to non-dyskinetic. 
(C) A significant increase in Iba1 optical density was detected between the intact and 
lesioned striata in both the dorsal and ventral regions of both the non-dyskinetic and 
dyskinetic groups. Panels B + C: Two-way ANOVA with Bonferroni post hoc; ***p<0.001: 
between intra-group hemispheres, #P<0.05: specific hemisphere between treatment 
groups. Data are mean ± SEM. Data are averaged across all three levels of the 
rostrocaudal axis. Saline: n=10, L-DOPA n=9. Iba1, ionized calcium-binding adapter 





































































































































































































































5.4.9. L-DOPA treatment does not affect the total microglial cell number 
within the lesioned striatum 
To investigate the increased optical density of Iba1 within the dorsal lesioned dyskinetic 
striatum, counted the number of Iba1-positive microglia within the dorsal striatum.  
Using the photomicrographs presented in figure 59A, the mean number of Iba1-positive 
microglia within the optical view was obtained. There was a significant difference between the 
number of Iba1-positive microglia in the dorsal intact and dorsal lesioned striata of the non-
dyskinetic (saline-treated) animals (Intact: 82 ± 3 cells, Lesion: 104 ± 3 cells; P<0.001; Two-Way 
ANOVA with Bonferroni post hoc tests; figure 60A) and the dorsal intact and dorsal lesioned 
striata of the dyskinetic (L-DOPA-treated) animals (Intact: 87 ± 3 cells, Lesion: 106 ± 5 cells; 
p<0.001; Two-Way ANOVA with Bonferroni post hoc tests). 
As with the dorsal striatum, the ventral striatum also presented significance between the intact 
and lesioned hemispheres of the non-dyskinetic (Intact: 83 ± 3, Lesion: 98 ± 5; p<0.001; Two-
Way ANOVA with Bonferroni post hoc test) and dyskinetic animals (Intact: 81 ± 2, Lesion: 96 ± 
3; p<0.001; Two-Way ANOVA with Bonferroni post hoc; figure 60B). 
There was no significant effect of L-DOPA or dyskinesia enhancing Iba1-positive microglial 
proliferation in either the dorsal or ventral dyskinetic striatum. 
  
Figure 61: Manually quantified Iba1-positive microglial cell counts within the dorsal and 
ventral striatum of non-dyskinetic saline-treated and dyskinetic L-DOPA-treated rats. 
(A + B) A significant increase in Iba1-positive microglia was detected between the intact and 
lesioned striata in both the dorsal and ventral regions of both the non-dyskinetic and 
dyskinetic groups. Two-way ANOVA with Bonferroni post hoc; *** denotes p<0.001. Data are 
mean ± SEM. Data are averaged across all three levels of the rostrocaudal axis. Saline: n=10, L-




5.4.10. Iba-positive microglia of the dyskinetic lesioned striatum present a 
higher Iba1 intensity 
Utilising higher magnification photomicrographs (63X oil immersion), Iba1 intensity of the 
microglial cell somas were analysed (figure 61A, dorsal stiatum).  
There was a significant difference between the Iba1 intensity of the cell somas in the dorsal 
intact and dorsal lesioned striata of the non-dyskinetic (saline-treated) animals (Intact 0.153 ± 
0.004, Lesion: 0.167 ± 0.004; p<0.001; Two-Way ANOVA with Bonferroni post hoc; figure 61B) 
and the dorsal intact and dorsal lesioned striata of the dyskinetic (L-DOPA-treated) animals 
(Intact: 0.15 ± 0.007, Lesion: 0.179 ± 0.004; p<0.001; Two-Way ANOVA with Bonferroni post 
hoc). 
Furthermore, a further increase in Iba1 intensity of the cell somas were detected between the 
two lesioned dorsal hemispheres of the non-dyskinetic and dyskinetic animals (p=0.014; Two-
Way ANOVA with Bonferroni post hoc tests). 
The ventral striatum also presented significance between the intact and lesioned hemispheres 
of the non-dyskinetic animals (Intact: 0.144 ± 0.007, Lesion: 0.16 ± 0.008; p<0.001; Two-Way 
ANOVA with Bonferroni post hoc) and the dyskinetic animals (Intact: 0.142 ± 0.005, Lesion: 
0.159 ± 0.007; p<0.001; Two-Way ANOVA with Bonferroni post hoc tests; figure 61C).  
However, no significant difference between dyskinetic and non-dyskinetic animals was noted in 




















































































































































































































































































































































































Figure 62: Iba1 intensity per microglial cell soma measured within the dorsal and ventral 
striatum of non-dyskinetic saline-treated and dysk netic L-DOPA-treated rats. 
(A) High magnification (63X, oil immersion) photomicrographs of Iba1 intensity per cell soma 
within the edial-level dorsal intact and lesioned hemispheres of non-dyskinetic and 
dyskinetic rat striatum. (B) A significant increase in Iba1 intensity per cell soma was detected 
between the dorsal intact and dorsal lesioned striata of both the non-dyskinetic and dyskinetic 
groups. A further increase in Iba1 intensity per cell soma was detected within the lesioned 
hemisphere of the dyskinetic animals compared to non-dyskinetic. (C) A significant increase in 
Iba1 optical density per cell soma was detected between the ventral intact and ventral 
lesioned striata of both the non-dyskinetic and dyskinetic groups. Panels B + C: Two-way 
ANOVA with Bonferroni post hoc; ***p<0.001: between intra-group hemispheres, #P<0.05: 
specific hemisphere between treatment groups. Iba1, ionized calcium-binding adapter 
molecule 1. Data are mean ± SEM. Two-Way ANOVA with Bonferroni post hoc. Saline: n=10, L-




This study examined whether, firstly, there were any structural or volumetric alterations found 
within the stratum of the rat 6-OHDA model of dyskinesia using T2-weighted MRI. Secondly, if 
the expression of aggrecan and versican had been altered in the striatum of the dyskinetic rat. 
Finally, if any structural changes could be correlated to cellular and extracellular modulators of 
plasticity (e.g. astrocytes, microglia). This was of particular interest due to the known 
correlation between brain functional activity and grey matter volume and shape (Fauvel et al., 
2014; Takeuchi et al., 2010; Zatorre et al., 2012).  
5.5.1. MRI detected an increase in the volume of the dorsal striatum in 
dyskinetic rats   
L-DOPA-treatment induced a high degree of AIMs in the unilaterally lesioned rats that were 
pharmacologically reversed by amantadine, the only known anti-dyskinetic agent in clinical use. 
Pharmacological reversal proved the validity of the rat model used and justified their use in the 
MRI investigations.  
Dyskinetic rats presented significant volume expansions within the lesioned dorsal striatum 
when compared to the equivalent striatum in the non-dyskinetic parkinsonian animal. This 
volume increase therefore supports our first hypothesis that states that we would find 
structural changes in the striatum of the dyskinetic rats. This increase in dorsal striatum volume 
was potentially caused by a few factors, these being cell proliferation and expansion of the 
ECM. The most likely cells to contribute to enhanced proliferation would be the inflammatory 
cells (i.e. inflammatory astrocytes and microglia) and endothelial cells (i.e. markers of 
angiogenesis), both of which have been previously described as influential to dyskinesia 
(Bartels et al., 2007; Bortolanza et al., 2015a; Ohlin et al., 2011). The most likely cause of ECM 
expansion would be the CSPGs, whereby increased CSPG expression would expand the 
interstitial space between neurones. Although not yet correlated with LID, CSPGs are known to 
increase in expression during CNS injury (Burnside et al., 2014) therefore we believe they are a 
likely candidate of this expansion. On the other hand, if the CSPGs were found lowered within 
the dyskinetic striatum this could suggest that the lack of inhibition is promoting the sprouting 
of other cells. Perhaps measuring the optical density of dopaminergic terminals and GABAergic 





5.5.2. CSPGs are not upregulated in the striatum of dyskinetic rats and do not 
correlate with the increase in dorsal striatum volume 
CSPGs are key regulators of plasticity in other CNS pathways and systems. Therefore, we 
examined whether their presence within the striatum was altered in the dyskinetic rats when 
compared to the non-dyskinetic. Although we know a wide range of CSPGs (primarily the 
lectican family) to be found within the mammalian striatum, only aggrecan and versican were 
found to be present within the adult brain (see Chapter 2). These were therefore the two 
CSPGs investigated. 
No alterations in aggrecan or versican expression were found in the striatum of the dyskinetic 
animals. This was rather disappointing, as the previous two chapters of this thesis have 
identified CSPGs as a promising therapeutic target in PD. It is likely that these CSPGs do retain a 
significant function in the corticostriatal pathway but only during early development, as with 
neurocan (Charvet et al., 1998). It may be worth applying ChABC to the same dyskinetic model 
as established within this chapter (during the same surgery as the MFB lesioning) to see 
whether CSPGs and PNNs have a say in LID manifestation. Unfortunately, due to the 
immunohistochemical embedding process, it was not possible to stain for PNNs within this 
study. This would have been of interest, as these structures surround the many GABAergic 
MSNs within the striatum that contribute to the corticostriatal pathway. Perhaps the removal 
of PNNs would lead to aberrant plasticity via the reopening of the critical period.  
Additionally, lectican CPSGs that are expressed only during development (i.e. neurocan (Milev 
et al., 1998)) may have been expressed within the dyskinetic rat striatum. These CSPGs would 
be wise to investigate in later studies as we know they have plastic effects within the 
corticostriatal pathway during development (Charvet et al., 1998). 
5.5.3. Only Iba1 was found to correlate with the expansion of the dorsal 
striatum. Neither RECA1 nor GFAP presented an increase. 
For the aforementioned reasons stated in section 5.5.2., we analysed the expression of certain 
cellular markers in order to try to explain the volume increase within the striatum. Astrocytic 
(GFAP) and microglial (Iba1) optical densities were both increased within the lesioned 
hemisphere of both the dyskinetic and non-dyskinetic animals. However, only the Iba1 optical 
density was further enhanced within only the dorsal striatum of the dyskinetic animals. This 
correlates with the expansion found in the MRI. It is worth noting, that the astrocytic response 
found in the lesioned hemisphere of both groups was most likely the effect of 6-OHDA-induced 
cell death.  
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Our data suggest that the increase in Iba1-positive optical density was due to cell soma Iba1-
positivity; indicating increased soma density or increased cell activity (i.e. an activated 
phenotype). To date there is no evidence that the Iba1 protein itself has any role in dyskinesia, 
therefore within this study we considered it merely a marker of microglial cells. 
It was surprising that there was not an increase in vasculature in the striatum of the dyskinetic 
rats. It has been documented that angiogenesis occurs within the brains of dyskinetic PD 
patients and animal models. Studies have discovered the proliferation of blood vessel 
endothelial cells (Faucheux et al., 1999; Ohlin et al., 2011) and alterations in BBB permeability 
(Westin et al., 2006) of the dyskinetic BG. These alterations are theorised to be due to 
enhanced energy consumption, altered neuronal firing and synaptic activity; factors that are 
present in regions of the striatum with the most prominent level of microvasculature (Westin 
et al., 2006). However, in this work BBB permeability was detected in animals treated with 
much higher doses of L-DOPA (25 mg/kg; 10 mg/kg) (Ohlin et al., 2011; Westin et al., 2006), 4-
fold and 2-fold higher than the dose used in this study. We argue that these alterations in 
striatal microvasculature are only observed in animals receiving higher doses of L-DOPA.  
5.5.4. Microglia may play a role in L-DOPA-induced dyskinesia manifestation 
Due to the subtlety of the detected histological change, it is most unlikely that the increased 
expression of Iba1-positive microglia account for the entirety of the increased dorsal striatum 
volume and, therefore, a direct cause of LID. However, these data do suggest that microglia 
play a role in the dyskinetic corticostriatal pathway. Be it a cause or effect, however, we do not 
know. 
It is understood that microglia have a significant role in neuronal synapse plasticity such as 
remodelling and pruning. These activities are integral to the development of the brain and 
potentially the progression of neurodegenerative disease (Hong et al., 2016; Paolicelli et al., 
2011a; Paolicelli et al., 2011b). If the increased activity of microglia follows a similar pattern in 
the dyskinetic human, it may be possible that downstream remodelling such as neuronal 
arborisation, a known candidate for maladaptive plasticity in LID (Linazasoro, 2005; Morgante 
et al., 2006), could have a role in the disorder. This theory becomes more pertinent with the 
recent discovery of inflammatory glia expressing DA receptors de novo following environmental 
stress. Studies have discovered reactive astrocytes expressing both D1 and D2 receptors (Kuric 
et al., 2013; Ruscher et al., 2012) whereas microglia were found expressing D2 (Huck et al., 
2015). In PD this could turn the striatum into a DA sensitive state, in which activated microglia 
may potentiate the effects of L-DOPA through direct DA agonism. Thus leading to a 
neuroinflammatory feedback mechanism, further activating more microglia and worsening the 
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effect of LID through increased plasticity and remodelling, or through the production of 
inflammatory mediators.  
It has been previously shown that the typical loss of SNc neurons found in PD can be associated 
with the increased microglial response in the BG (Niranjan, 2014; Przedborski, 2010). However, 
it is uncertain whether these responses are a cause or effect of the disease and whether they 
have a significant role in LID. Studies investigating levels the microglial-derived inflammatory 
molecule, NO, and its neuronal production enzyme, nNOS, have shown increased levels of both 
within the BG of PD patients (Eve et al., 1998; Gatto et al., 2000) and the striatum of 6-OHDA 
lesioned rats (Czarnecka et al., 2013; Padovan-Neto et al., 2011). Recently, targeted inhibitors 
of nNOS such as 7-nitroindazole (7-NI) have been administered to lesioned rats alongside L-
DOPA. These treatments saw no manifestation of AIMs, a result claimed to be associated with 
the inhibition of glial cell activation and the glial-expressed NOS, inducible nitric oxide synthase 
(iNOS) (Bortolanza et al., 2016; Bortolanza et al., 2015b; Del-Bel et al., 2015). This indicates an 
indirect role for microglia in the worsening of LID. However, selective iNOS inhibition studies 
have yet been conducted and so it may be worthwhile to investigate the assumed 
downregulation of iNOS through 7-NI-inhibited nNOS. 
Although our data suggest an increased density of microglia within the dyskinetic striatum, 
these data do not account for their activity phenotype. Activated microglia can adopt one of 
two phenotypes depending on environmental factors, the pro-inflammatory (M1) and pro-
repair (M2) phenotype (Sica et al., 2012). As opposed to the classical M1 macrophage, the M2 
is seen as beneficial to injury in which they initiate tissue repair and the de-activation of the 
M1 response (Fiorentino et al., 1989). Therefore, identifying levels of either the M1 or M2 
phenotype by cytokine expression would be of interest. Nevertheless, it must be understood 
that the release of inflammatory cytokines does not indicate a damaging pro-inflammatory 
response entirely. The release of striatal tumour necrosis factor-α has been shown to be an 
adaptive response to the disease state and as a way of returning homeostasis to striatal 
synaptic function (Lewitus et al., 2014).  
In recent years, imaging techniques have been used to analyse inflammatory responses within 
patients in vivo. Through means of PET scanning PD patients (but not specifically dyskinetic), 
researchers have indirectly measured microglial activity by the expression of 18 kDa 
translocator protein (TSPO), a receptor site found on the outer mitochondrial membrane of 
activated macrophages. Although initially promising, the use of radioligands such as [11C]-
PK11195, [18F]-FEPPA and [11C]-PBR28 (Gerhard, 2013; Jucaite et al., 2015; Koshimori et al., 
2015) to analyse microglial activity within the parkinsonian brain, have come under scrutiny 
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due to mixed results. While issues with radioligand sensitivity and binding are present, 
differences within the patient groups have most likely confused results. Despite these issues, 
TSPO PET scanning of the PD striatum between dyskinetic and non-dyskinetic patients could 
help identify mechanisms involved in LID development whilst avoiding the problems associated 
with post mortem tissue. 
5.5.5. Study validity and future studies 
As previously mentioned, a significant drawback to this study was the inability to reproduce 
dyskinetic controls, i.e. non-dyskinetic L-DOPA-treated 6-OHDA lesioned rats. As the 
prerequisites for LID development were met, dyskinesia was inevitable. The lack of this control 
made it impossible to distinguish the increases in dorsal striatal microglial optical density and 
volume as an effect of dyskinesia itself rather than purely L-DOPA treatment.  
However, if these changes were purely due to L-DOPA treatment in the dyskinetic rats, these 
effects may be transient and could decline following a drug wash out period. If so, in future 
studies a L-DOPA holiday would be enforced to help differentiate plastic changes in response to 
the drug treatment or the dyskinetic state. The caveat to this is that we assume the dyskinetic 
state is permanent. Additionally, in future studies it may be of interest to lower the dose of L-
DOPA to induce milder dyskinetic responses. A study with a cohort of rats with both mild and 
severe dyskinesia could help tease these volumetric and cellular changes from L-DOPA 
treatment and dyskinesia, whereby we would expect a higher striatal volume in the more 
severely dyskinetic rats. Interestingly in this study, two animals were considered moderately 
dyskinetic (section 5.4.2.). Although their striata were investigated, they were not significantly 
different to rats with more severe AIMs. However, as there were only two moderately 
dyskinetic animals we cannot use this data to support our hypothesis. 
In future studies it would be wise to investigate this enhanced neuroinflammatory response in 
more detail. Utilising several Western blotting and ELISA techniques to detect inflammatory 
mediators (e.g. interleukin-6, -10, tumour necrosis factor-α) could further identify the source of 
microglial activation. Certain inflammatory mediators could also highlight the phenotype of the 
microglia within the dorsal striatum of the dyskinetic animals. Could the microglia resident to 
the dyskinetic rat lesioned striatum be associated with positive plasticity and repair (i.e. M2 
microglia; expression of interleukin-4 and -13(Tang et al., 2016))?  
5.5.6. Chapter conclusions 
The studies in this chapter revealed novel findings in the mechanisms underpinning LID. 
Tensor-based morphometry MRI detected an increase in dorsal striatal volume within 
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dyskinetic rats. Although previous investigations have correlated functional neuroimaging with 
LID, this is the first time structural changes been associated with the dyskinetic brain. This is 
also the first time cellular changes have been mapped to these alterations as well.  
Aggrecan and versican expression was investigated in the dyskinetic rat striatum to identify 
whether CSPGs were potential mediators of LID and also whether they were the cause of the 
striatal volume increase (i.e. ECM expansion). However, neither CSPG was found up regulated 
in the dorsal or ventral striatum. This indicated that aggrecan and versican are unlikely to 
contribute to LID or indeed the volume change found in the dorsal striatum. As previously 
described, it may be of use to investigate other CSPGs not expressed in the adult rodent 
striatum. These CSPGs may be aberrantly expressed in the dyskinetic brain and so contribute to 
LID pathophysiology. 
Although endothelial and astrocytic cells were theorised to be accountable for the striatal 
volume increase in the dyskinetic rats (i.e. angiogenesis and astrogliosis), only Iba1-positive 
microglia were seen to increase within the dorsal striatum of the dyskinetic rats. From our 
data, the number of resident microglia was not the cause of the detected optical density; 
rather it was the cell soma Iba1-positivity that had increased. Correlating inflammatory 
alterations in the dorsal striatum has highlighted a novel therapeutic target in LID research. It 
has also highlighted the importance of investigating anti-inflammatory agents to counter LID, 
as others have before (Teema et al., 2016).  
To date there is no epidemiological evidence to suggest anti-inflammatory agents decrease the 
risk of LID. However, this would be worth investigating to shed light on the potential link 




6. General conclusions 
Investigating novel approaches to address the two unmet clinical needs of PD was the ultimate 
target of the work presented in this thesis. These needs were, firstly, to discover new strategies 
that halt disease progression by increasing SNc cell survival. Secondly, to elucidate the 
mechanisms underpinning LID to support the search for better anti-dyskinetic agents. 
It is nearly 200 years since PD was first discovered and yet there is still no effective way to 
tackle its associated cell pathology. Although treatments are available to counter the motor 
dysfunctions caused by SNc degeneration, they are not without their flaws. Perhaps the most 
successful therapeutic is L-DOPA but, as previously discussed, its chronic treatment induces 
dyskinesia.  
In this thesis, we examined whether the CSPGs of the extracellular matrix may act as novel 
targets for achieving cellular recovery and act as contributors to LID manifestation. Previous 
studies have identified the digestion of these CSPGs, via the bacterial enzyme ChABC, 
permitted axonal regeneration following brain injury (Bradbury et al., 2002; Moon et al., 2001). 
Although ChABC’s efficacy has been analysed as an agent to improve the success of homotopic 
dopaminergic cell grafting (Diaz-Martinez et al., 2013), no study has assessed its efficacy in 
promoting cell survival in a validated model of PD (e.g. 6-OHDA lesion model). Here for the first 
time, we investigated the potential of ChABC as a therapeutic strategy to aid cellular recovery 
in PD. 
The general aims of this thesis were therefore to firstly confirm the expression of CSPGs within 
the naive mouse BG, particularly the SNc, and to check whether this expression was still 
evident in the more PD-relevant aged brain. Next, we aimed to investigate the efficacy of 
ChABC as an agent of cell survival in a 6-OHDA mouse model of PD, and to explore whether 
promoting striatal NTF levels within the same model could enhance any effect caused by 
ChABC treatment. The final aim of this thesis was to investigate the mechanism underpinning 
LID; CSPGs were strong contenders in the manifestation and propagation of the dyskinetic state 




6.1. CSPG and PNN distributions in the mouse basal ganglia 
CSPGs as therapeutic targets are a novel venture in the field of PD. Because of this, the 
expression of various CSPGs in the mouse BG had not been well characterised. We believed 
that although CSPG presence had been detected within the mouse CNS, it was important to 
identify the level and pattern of expression of a select few lectican CSPGs within the BG. If we 
were to continue the investigation of CSPG manipulation in the mouse this characterisation 
would help identify which CSPGs were most expressed and thus integral to the ECM 
surrounding pertinent regions (i.e. the SNc).  
In Chapter 2, although we observed a moderate expression of the CSPGs aggrecan and versican 
within the SNc, NG2 was present in very low levels. Expression of brevican and neurocan was 
negligible, with imaging not being possible. In the case of brevican, this low expression was 
contrary to the works of Milev et al. We therefore focused on aggrecan and versican in our 
subsequent studies. While only mounted sections of the SNc were investigated in these 
studies, characterisation of CSPGs within the striatum would have been of great interest as 
particular CSPGs may have been expressed additionally within this region. This information 
would have widened the CSPG search beyond aggrecan and versican in the LID studies 
discussed later.  
We also assessed the distribution of PNNs within the mouse BG. As work by Bruckner et al. had 
already identified PNNs to be absent in almost all dopaminergic systems in the human BG, we 
had hypothesised that this pattern was reflected in the mouse. This was certainly the case, 
confirming our hypothesis. WFA-positive PNNs were absent from the SNc and appeared to be 
exclusive to the neighbouring GABAegic regions such as the SNr. In the future it would be 
interesting to examine whether these PNNs were indeed co-localised with GABAergic cells, as 
seen in other brain regions such as in the striatum (Bruckner et al 2008). Although not directly 
affecting our studies, our results raise an interesting point concerning the potential protective 
role for PNNs. As SNc cells are potentially more susceptible to cell death due to their increased 
metabolic rate and poor Ca2+ homeostasis (e.g. low calbindin levels, large influxes of Ca2+ (Chan 
et al., 2010; Liang et al., 1996)), the lack of PNN buffering in the SNc may therefore exacerbate 
cell susceptibility to excess Ca2+. Although difficult to imagine how it may be achieved, if it was 
possible to induce PNN deposition in the SNc this may enforce neuroprotection against the 
intrinsic sensitivity to excess Ca2+ ions. 
Our final investigative study of Chapter 2 analysed CSPG distributions in the aged and young 
adult mouse BG. Aggrecan and CS56 were used to assess the CSPG and CS-GAG presence, 
respectively. Aggrecan and CS56 both displayed enhanced expression within the aged SNc and 
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aggrecan was further elevated within the dorsal striatum. This enhanced degree of CSPG 
expression was consistent with the lectican expression plots described in Chapter 2 (Milev et 
al., 1998). As the aged mouse retained CSPG expression from the young adult, CSPG presence 
confirmed their use as therapeutic targets in age-related diseases such as PD. Although a small 
increase, this expression in the aged tissue suggested that young adult mice could be used to 
model PD. Additionally, this increase in aggrecan and CS56 expression indicated a potential role 
of these CSPGs in ageing. 
This alteration in expression between the aged mouse and the young adult (a typical age for 
experimentation) raised the point of model validity when researching age-related diseases. 
However, it is unlikely that research groups will adopt older animals due to the many monetary 
and ethical considerations.  
Within this investigation, we also assessed whether age was a factor in the number of SNc cells 
present and the density of TH-positive fibres within the striatum. The aged animals had far 
fewer TH-positive cells within the SNc than the young adult had but possessed significantly 
more TH-positive fibres in the striatum. Although the decline in cells was not surprising, as age 
correlates with lowered activity in several pro-survival systems and senescence (e.g. UPS (Tai et 
al., 2008)), the increase in TH-positive fibres was. This may be a form of compensatory terminal 
sprouting where the decline in SNc cells (~50% of the young adult) spurs plasticity in the 
striatum to counter the loss in DA release. Contrary to this theory, published evidence suggests 
that there is a loss in striatal dopaminergic markers in relation to age (Haycock et al., 2003). 
Therefore, further investigation is required to clarify the exact nature of changes within the 
striatum in aged mouse brain. 
Importantly, the studies in this chapter set the scene for subsequent Chapters by identifying at 
least two CSPGs present in the mouse BG and that the young adult mouse translates to the PD 






6.2. ChABC as a strategy for improving SNc cell survival 
With the knowledge that CSPGs were expressed within the mouse BG, we next proceeded to 
investigate the effects of their digestion via ChABC in the 6-OHDA unilateral lesion model of PD. 
Due to the novelty of the strategy, initial studies were conducted to examine the pattern of 
digestion of CSPGs along the NS. At this point, we were not sure whether the cell terminals or 
SNc cell bodies were to be the target of CSPG digestion for cell survival effects, therefore the 
entire NS was digested. After a failed attempt of digesting the entire NS, whereby the injection 
sites were too far away from each other, the coordinates for the intracerebral administration of 
ChABC were readjusted. This new protocol ensured the entire digestion of CSPGs along the 
entire NS; a digestion pattern consistently reproduced throughout these studies.  
ChABC did not provide any cell survival in the full lesion model. This was thought to be caused 
by the severity and speed at which this lesion developed. Perhaps the beneficial effects 
induced by ChABC were too slow to tackle the quick loss of SNc cells. In contrast, ChABC 
possessed a modest cell survival effect within the partial lesion model. Although we still do not 
know what underpins the efficacy of ChABC treatment post CSPG digestion, our work can 
argue in favour of either a neuroprotective or neuroreparative effect. However, this work 
cannot distinguish between these effects.  
Neuroprotective 
A neuroprotective mechanism would be one that occurs in tandem with SNc cell degeneration. 
ChABC treatment induces pro-survival effects (e.g. NTF liberation, removal of physical contacts 
as discussed in Chapter 3) that counter the slow decline in SNc cell number. Unlike the partial 
lesion that takes ~2 weeks to develop, the full lesion model would have taken only 2 to 3 days. 
This is perhaps far too rapid or severe for the beneficial events brought about by ChABC to take 
effect within the neuroprotective window. See figure 40 in Chapter 3 representing this window. 
Neuroreparative 
On the other hand, a neurorepair action is one that occurs after the initial damage to the SNc 
has occurred. Alternatively, ChABC-mediated digestion of the CSPGs requires some remaining 
cells for repair and plasticity. Therefore, in a fully ablated SNc no/very few cells remain to 
respond to the pro-repair events caused by ChABC treatment. In the partial lesion, the ~40-
50% cells remaining is enough to benefit from CSPG digestion during the repair period 




This debate of protection or repair has been discussed throughout this thesis. Although we did 
not set out to test whether ChABC had a neuroprotective or neuroreparative action, it is of 
importance to investigate this in the future. Fortunately, this can be conducted with relative 
ease. As described in Chapter 3, administering ChABC before lesioning would examine a 
protective effect and administrating ChABC after the lesion was stable (i.e. two weeks post 
lesion) would examine a repair effect. If we were to see beneficial effects from the protective 
examination, we could assign the effects to protection and repair. If the repair examination 
presented beneficial effects then this would be solely a result of a repair effect. Comparing cell 
survival between these two examinations may help dissect the protection from repair effects 
underlying CSPG digestion.    
Inducing cell survival in the partial lesion model was a success. However, the lack of 
behavioural phenotype was a disappointing shortfall. The overall aim of this novel strategy was 
to induce cell survival in order to better the motor function in the animal model and, 
ultimately, PD itself. We therefore next set out to improve this modest cell survival effect by 
promoting NTF release in the striatum. 
CSPGs have been previously described as reservoirs for growth factors (Bandtlow et al., 2000). 
Although we had not assessed the liberation of NTFs from CSPG digestion, being reservoirs, 
CSPG digestion would therefore be predicted to liberate harboured NTFs which would activate 
pro-survival pathways (Wang et al., 2012a). However, it was clear from data in Chapter 3 that 
the degree of increased survival was small, suggesting there was insufficient liberation of NTFs 
to have functional significance. Unfortunately, due to the preparation of the tissue (i.e. paraffin 
embedded fixed tissue) it was impossible to assess NTF levels following ChABC treatment.  
In Chapter 4 we set out to examine whether, by enhancing NTF levels by other means, we 
could enhance the beneficial effects of ChABC on SNc cell survival and thereby reveal a 
behavioural improvement. We were keen not to complicate matters by delivering NTFs directly 
into the striatum. Therefore, we chose a pharmacological approach to promote intrinsic NTF 
expression instead. Selegiline had been previously confirmed to promote striatal GDNF and 
BDNF levels in mice following two weeks of once-a-day daily administration (Zhao et al., 2013). 
We therefore wished to test selegiline's efficacy. Our pilot study found that once-a-day daily 
administration of selegiline for 7 days induced a significant increase in striatal GDNF and BDNF 
in naive mice. This level was then maintained until the end of the study (14 days). When a daily 
once-a-day treatment of selegiline was applied to our ChABC administered lesioned model 
from Chapter 3, no improved cell survival or even increases in NTF levels were found. 
Unexpectedly, selegiline rather negated the pro-survival effect of ChABC. The ChABC-only 
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group reproduced effects seen in Chapter 3, ChABC was concluded to still be in effect. We 
believe that these unaffected NTF levels may be due to selegiline desensitisation. This is due to 
the possible decline of GDNF and BDNF levels seen on day 14 following daily treatment in the 
selegiline pilot study, whereby there was a marked decrease in GDNF and BDNF levels 
compared to the levels seen at day 7 (NTF levels on day 14 were still significant however). 
Selegiline may therefore only induce an increase in the two NTFs over a small timeframe when 
daily dosed at 1 mg/kg. It may be worth investigating the levels of NTFs at regular time points 
following 1 to 2 months of daily selegiline treatment. If a clear maintained decrease in GDNF 
and BDNF were apparent at 2 weeks, a subsequent study investigating variations in selegiline 
treatment (e.g. lower dose, intermittent dosing times) may help establish a dosing regimen 
that would bypass the potential desensitisation to selegiline.  
6.3. L-DOPA-induced dyskinesia 
While Chapters 3 and 4 focussed on the unmet clinical need of improving SNc cell survival, 
Chapter 5 aimed to further our understanding of the mechanism behind LID in order to help 
tackle the need for improved anti-dyskinetic agents. LID is thought to involve several aberrant 
alterations within the striatum and the corticostriatal pathway that lead to a dysregulated BG. 
However, the exact nature of this corticostriatal plasticity remains unknown. We hypothesised 
that striatal plasticity may be reflected in structural changes within the striatum that may 
involve CSPG alterations. However, following the investigation of aggrecan and versican 
expression levels in the striatum of dyskinetic rats, no changes were found. We next 
investigated the structure and volume of the striatum in the dyskinetic rats. Using structural 
MRI, we detected an increase in volume within the dyskinetic animals’ dorsal striatum. Several 
candidates were suggested to cause this increase such as the CSPGs, inflammatory cells and 
vasculature endothelial cells. As previously mentioned, no changes in aggrecan and versican 
expression were found in the dorsal striatum. Similarly, no alterations in vasculature (RECA1) or 
astrocytes (GFAP) optical densities were either observed. The latter two have been associated 
with LID in previous studies whereby BBB permeability and astrogliosis go hand-in-hand within 
the pathophysiology of PD and LID (Cabezas et al., 2014; Ohlin et al., 2011). However, only Iba1 
optical density was found to increase within the dorsal striatum of the dyskinetic animals. This 
suggests an increased activation of Iba1-positive microglia in the dyskinetic state, a finding that 
raises several interesting points concerning the neuroinflammatory response in LID.  
Published studies have identified glia to express D1 and D2 receptors de novo under stressed 
conditions (Huck et al., 2015; Ruscher et al., 2012). This work suggests a de novo expression of 
DA receptors on glia in the stroke-stressed brain, a possibility that may also occur in the PD-
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stressed brain. If this were the case in PD, L-DOPA-metabolised DA may agonise and activate 
resident glia in the striatum furthering neuroinflammation and plasticity. In addition, other 
work has found the inhibition of NOS to halt the manifestation of dyskinesia, suggesting a 
significant role of microglial-derived NO in LID (Bortolanza et al., 2016; Bortolanza et al., 
2015a). Moreover, other work has highlighted the importance of the NO/cyclic GMP pathway 
in the regulation of striatal signalling (Calabresi et al., 1999) and in the release of glutamate 
(Neitz et al., 2011). Therefore, it may be possible that activated microglia of the striatum 
mediate LID through the production of NO. If the works by Huck et al. were to apply to PD, the 
presence of de novo expressed microglial-DA receptors may potentiate resident microglia 
activity resulting in the promotion of NO. This increase in NO could therefore explain the 
aberrant glutamatergic transmission of the corticostriatal pathway as depicted in the schematic 
below (figure 62). 
 
In subsequent studies, it would be of interest to test this theorised mechanism. A preliminary 
in-house immunofluorescent investigation (not shown) has suggested an increase in D1 
receptor and Iba1 in the 6-OHDA-stressed striatum. Further investigations identifying the 
location of these receptors would be a wise next step in an attempt to confirm the de novo 
Figure 63: Theorised mechanism of microglia in the manifestation of LID. 
(1) Under stressed conditions such as PD, striatal microglia express D1 receptors (DA receptor 
subtype known to modulate LID). (2) The increased level of L-DOPA-metabolised DA agonises 
the microglial D1 receptors. (3) Agonism increases activity of resident microglia that produce 
NO and citrulline as a result of L-arginine (L-arg) oxidation via the iNOS enzyme. (4) NO 
translocates to the glutamatergic afferents of the corticostriatal pathway. (5) NO stimulates 
the production of cyclic GMP (cGMP) via the binding to soluble guanylyl cyclase (sGC). (6) 
cGMP induces the increased release of glutamate transmission in the corticostriatal pathway. 
(7) Amantadine targets the post-synaptic NMDA receptors to reduce transmission. Red cell = 























microglial expression of DA receptors. If microglia were seen to express DA receptors in the 6-
OHDA model tissue, further in vivo testing would be required. Utilising iNOS inhibitors in the 
established rat model of LID would be of interest as only nNOS inhibitors (e.g. 7-NI) have been 
tested as anti-dyskinetics so far. 
6.4. Concluding remarks 
The work presented in this thesis represents entirely novel ventures within the PD field and 
although previous work had suggested ChABC may induce axonal repair (Moon et al., 2001), it 
was not guaranteed. Therefore, it was a significant discovery to find ChABC-treatment as a 
potential therapeutic strategy in the mouse model of PD. Although ChABC induced only a 
modest increase in SNc cell survival that did not provide a better behavioural phenotype, this 
discovery can be considered a starting point for further studies. Subsequent studies identifying 
ways to enhance ChABC-mediated cell survival will be invaluable, as behavioural benefits are 
desirable for PD therapeutics. However, in its current state, ChABC has potential use as an 
adjunct to L-DOPA where ChABC may halt disease progression whilst L-DOPA improves motor 
function. Despite this, ChABC’s efficacy as a bolus or a mini-pump treatment may be 
inadequate due to its limiting enzymatic properties (e.g. denaturing under certain conditions). 
Furthering its use as a virally expressed enzyme is most likely the future for ChABC; a venture 
already spearheaded by the spinal cord injury field (Bartus et al., 2014). 
In lieu of a PD cure, addressing the problematic dyskinesias patients experience from the 
treatment of L-DOPA is required. We have shown that structural changes occur in the striatum 
of dyskinetic rats and that they are accompanied by an increase in Iba1 expression. As this 
expression may be integral to LID, investigating the suggested LID manifestation mechanism 
(figure 62) would be an interesting venture to pursue. Although we identified an increase in 
Iba1-positive microglia optical density within the striatum of dyskinetic animals, we believe 
that this does not account for the volume increase detected by MRI. This is because there was 
no increase in microglial cell number, and only a slight enhancement in Iba1 optical density. 
Therefore, further investigations into the true cause of this striatal expansion in LID would be 
an interesting next step.  
In conclusion, whilst not producing any firm indication of how the unmet clinical needs in PD 
may be addressed, this work has paved the way for novel investigations in the use of ChABC as 
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